

**EPHMRA**  
**ANATOMICAL CLASSIFICATION**  
**GUIDELINES 2026**

"The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EPHMRA) and is therefore the intellectual property of this Association.

EPHMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EPHMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EPHMRA Copyright in publications etc.

Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria."

© EPHMRA 2026

## CONTENTS

## PAGE

### INTRODUCTION

<b>A ALIMENTARY TRACT AND METABOLISM</b>	<b>1</b>
<b>B BLOOD AND BLOOD FORMING ORGANS</b>	<b>28</b>
<b>C CARDIOVASCULAR SYSTEM</b>	<b>36</b>
<b>D DERMATOLOGICALS</b>	<b>52</b>
<b>G GENITO-URINARY SYSTEM AND SEX HORMONES</b>	<b>60</b>
<b>H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES)</b>	<b>71</b>
<b>J GENERAL ANTI-INFECTIVES SYSTEMIC</b>	<b>76</b>
<b>K HOSPITAL SOLUTIONS</b>	<b>93</b>
<b>L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	<b>101</b>
<b>M MUSCULO-SKELETAL SYSTEM</b>	<b>114</b>
<b>N NERVOUS SYSTEM</b>	<b>119</b>
<b>P PARASITOLOGY</b>	<b>129</b>
<b>R RESPIRATORY SYSTEM</b>	<b>131</b>
<b>S SENSORY ORGANS</b>	<b>144</b>
<b>T DIAGNOSTIC AGENTS</b>	<b>148</b>
<b>V VARIOUS</b>	<b>150</b>

## INTRODUCTION

The Anatomical Classification was initiated in 1971 by EPHMRA. It has been developed jointly by Intellus/PBIRG and EPHMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.

These notes are known as the Anatomical Classification Guidelines, and are intended to be used in conjunction with the classification. This **English** version of the Guidelines is the authorised, definitive version produced by EPHMRA.

Since the guidelines were originally prepared, various additions and amendments have been made in order to better explain which kinds of products are included in a particular group and the rules governing the allocation of products to a particular group.

Where it is felt that the heading is self-explanatory, no guideline was prepared eg N2C Anti-migraine preparations. In other cases, the guideline is clearly stated eg N5C Tranquillisers - "includes minor tranquillisers, eg benzodiazepines, hydroxyzine, meprobamate....

One or two words used in the guidelines sometimes cause confusion, in particular the terms plain and combination. A plain product can contain one or more active ingredients of a similar type, eg a topical steroid containing one or two corticosteroids. When another active ingredient is added eg an anti-infective agent, it becomes a combination product. Only the active ingredients are taken into consideration when determining whether a product is a plain product or a combination. Non-therapeutic ingredients, eg the propellant in bronchodilator aerosols, are ignored.

Whilst every effort has been made to eliminate anomalies in the text, and to make clear the definition of types of products included in any particular class, it is inevitable that there will still be guidelines which are not clear. If you feel there are specific improvements which could be made, please make your views known to the Chair of the Classification Committee.

There are certain codes used against a class entry in the Guidelines to indicate the status and date of change of that class.

From Jan 2008 a modification to the R status has been introduced. Upper case letter R is used for a major revision of a class – eg split of a third level to fourth levels. Lower case r is used for a minor revision eg clarification of explanation. Before Jan 2008 only upper case R has been used for a revision and so there is no distinction between minor or major revisions.

I = Introduction  
R = Revision (major)  
r = revision (minor)  
D = Deletion

For example:

I2006	This indicates a class was introduced from the beginning of 2006.
R2006	This indicates a class was revised in content or meaning from the beginning of 2006; this could be a major or a minor change.
R2008	This indicates a class was revised in a major way from the beginning of 2008.
r2008	This indicates a class was revised in a minor way from the beginning of 2008.
D2006	This indicates a class was deleted from the beginning of 2006.

## Use and Re-use of Classification Codes

1. The actual classification code does not have any meaning except at the first level (eg A). In addition, the letter X and the number 9 are usually used for the 'Other' classes.
2. The sequence of codes does not generally imply any priority or meaning.
3. In some cases a rule is created for a particular area where the order of the classes is important; however any code can be used for any description.
4. There can be gaps between codes in a sequence eg A10P can be followed by A10S, ie there are no A10Q or A10R classes. This may be because room is being left for classes that may come into operation later but not at the moment.
5. The letters I and O are avoided because of confusion with numbers 1 and 0.
6. If a code is deleted it is not used again for 3 years; this is to avoid confusion in describing classes by code and to ensure there is not mixed data in datasets created at the time of changeover to the new code structure. This code discontinuity can cause gaps to appear in a code sequence; there is no significance to this for the actual classification.
7. Codes should not be different to the WHO codes at the third level; in some cases this may exist for historical reasons before harmonisation work started.
8. The valid EPHMRA codes are from A to V7.



<b>A</b>	<b>ALIMENTARY TRACT AND METABOLISM</b>	
<b>A1</b>	<b>STOMATOLOGICALS, MOUTH PREPARATIONS, MEDICINAL DENTIFRICES ETC</b>	
<b>A1A</b>	<b>STOMATOLOGICALS</b>  Includes the pharmaceutical preparations for the anterior part of the mouth i.e. for teeth, gums etc. Products indicated both for the posterior part of the mouth and throat infections are classified in either R2A or A1A depending on the main indication. Pilocarpine used for dry mouth is classified here. Non-pharmaceutical products (especially non-medicated toothpastes and chewing gum, non-medicated gargles, non-medicinal dental products etc) are classified in V7A and all local anaesthetics for surgery and pain relief are classified in N1B. Systemic anti-infectives for the treatment of stomatological conditions are classified in J.  4th level used in France, French West Africa, FTO, and Italy.	R2007
<b>A1A1</b>	<b>Toothpastes</b>  Toothpastes as pastes, powders, liquids, chewing gum excluding the ones containing fluorine (see A1A4).	
<b>A1A2</b>	<b>Mouth antiseptics and anti-infectives</b>  Mouth antiseptics and anti-infectives for the anterior part of the mouth (teeth, gums, etc) such as mouthwashes, gargles, pastes, tinctures, oral gels etc. If they extend their activity to the posterior part of the mouth and throat they are classified in R2A, except if containing fluorine (see A1A4). Antifungal products in oral topical form are classified in A1B.	R1999
<b>A1A3</b>	<b>Mouth anti-inflammatories and mouth analgesics for topical use</b>  Mouth anti-inflammatories and mouth analgesics for topical use for the anterior part of the mouth (teeth, gums etc) including corticoids. Otherwise classify in R2A. For products containing fluorine see A1A4.	
<b>A1A4</b>	<b>Mouth preparations w/fluorine</b>  All preparations containing fluorine including toothpaste, chewing gum, liquids and powders.	
<b>A1A5</b>	<b>All other stomatologicals</b>  All preparations not classifiable in the preceding 4th level groups and particularly products against pyorrhea. Pilocarpine used for dry mouth is classified here.	R2001

<b>A1B</b>	<b>MOUTH ANTIFUNGALS</b>  Includes topical oral forms of products eg pastilles, gels for fungal infections of the mouth (oral cavity). Also includes other forms eg oral suspensions when these are mainly used for fungal infections of the mouth.	I1999
------------	---	-------



<b>A2</b>	<b>ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS</b>	
<b>A2A</b>	<b>ANTACIDS, ANTIFLATULENTS, CARMINATIVES</b>	
<b>A2A1</b>	<b>Plain antacids</b>  Includes combinations of two or more antacid substances as well as skimmed-milk powder and milk complexes with pure antacid combinations. Stomach teas are classified in A2X. Includes combinations with alginic acid. Alka Seltzer is classified in N2B when it contains an analgesic. If it contains only an antacid, it is classified here.	r2018
<b>A2A2</b>	<b>Plain antiflatulents and carminatives</b>  This group includes mainly dimethicone/simethicone (dimethylpolysiloxane, DMPS) preparations. Carminatives and herbal combinations are classified in A2A7 except carminatives with a choleric or cholagogue effect which are classified in A5A. Dimethicone/simethicone preparations with enzymes are classified in A9A.	R1994
<b>A2A3</b>	<b>Antacids with antispasmodics</b>  Distinguishing between antispasmodics and ulcer therapy is often difficult but products with a substance with known antispasmodic properties are included in this group.	
<b>A2A4</b>	<b>Antacids with antiflatulents or carminatives</b>  Includes combinations of plain antacids with antiflatulents or carminatives.	
<b>A2A5</b>	<b>Antacids with antiflatulents and/or carminatives and antispasmodics</b>  Products in this group should contain an antacid and an antispasmodic together with an antiflatulent or a carminative or both.	
<b>A2A6</b>	<b>Antacids with other drugs</b>  Includes antacid combinations other than those classified in A2A3, A2A4 and A2A5. Specific anti-ulcerants are classified in A2B. Alka-Seltzer is classified in N2B or A2A1. Combinations of low dose H2 antagonists with antacids are classified here.	R2002
<b>A2A7</b>	<b>Antiflatulents and/or carminatives with other drugs</b>  Includes all antiflatulents and/or carminative combinations not included in A2A4, A2A5, A9A. Combinations of antispasmodics with antiflatulents are classified in A3E.	r2011

<b>A2B</b>	<b>ANTIULCERANTS</b>  Combinations of specific antiulcerants with other substances, such as anti-infectives against <i>Helicobacter pylori</i> , antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1.	r2020
A2B1	<b>H2 antagonists</b>  Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6.	R2002
A2B2	<b>Proton pump inhibitors</b>  Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro-oesophageal disease or similar conditions are classified here. Includes potassium-competitive acid blockers (P-CABs) such as revaprazan, tegoprazan, vonoprazan, etc.	r2021
A2B3	<b>Prostaglandin antiulcerants</b>  Includes misoprostol, enprostil.	
A2B4	<b>Bismuth antiulcerants</b>  Includes combinations with antacids.	
A2B9	<b>All other antiulcerants</b>  Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to A2B4. Combinations of antiulcerants with antispasmodics are classified in A2B1 to A2B9 according to the type of antiulcerant. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2X.  In Japan, Korea and Taiwan only, sulpiride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9.  Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9.	r2020

<b>A2C</b>	Out of use	D2018
<b>A2X</b>	<b>OTHER STOMACH DISORDER PRODUCTS</b>  Includes herbal preparations and also plain alginic acid. Combinations of antacids with alginic acid are in A2A1.	I2018

<b>A3</b>	<b>FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS</b>	R2003
<b>A3A</b>	<b>PLAIN ANTISPASMODICS AND ANTICHOLINERGICS</b>	R1993
	Includes all plain synthetic and natural antispasmodics and anticholinergics.	
<b>A3B</b>	Out of use; can be reused.	
<b>A3C</b>	<b>ANTISPASMODIC/ATARACTIC COMBINATIONS</b>	
	This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4.	
<b>A3D</b>	<b>ANTISPASMODIC/ANALGESIC COMBINATIONS</b>	R1997
	This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1.	
<b>A3E</b>	<b>ANTISPASMODICS COMBINED WITH OTHER PRODUCTS</b>	r2020
	Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; combinations of antispasmodics with antiulcerants are classified in A2B1 to A2B9 according to the type of antiulcerant. Combinations of antispasmodics with antifatulents are classified here.	
<b>A3F</b>	<b>GASTROPROKINETICS</b>	r2020
	This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9.	
	Combinations of gastroprokinetics with other substances are classified here if used for dyspepsia or gastro-oesophageal reflux. Combinations of gastroprokinetics with antiulcerants for ulcers, gastro-oesophageal disease or similar conditions are classified in A2B.	

<b>A3G</b>	<b>GASTRO-INTESTINAL SENSORIMOTOR MODULATORS</b>  Products which are specifically developed to modulate the multiple symptoms of irritable bowel syndrome (IBS). Includes alosetron, tegaserod.  Linaclotide (290mcg) indicated for IBS-C (irritable bowel syndrome with constipation) is classified here; linaclotide (145mcg) indicated for chronic constipation is classified in A6A9. Products containing linaclotide for both chronic constipation and for IBS-C are classified here when there is no distinction by strength. Lubiprostone (8mcg) indicated for IBS-C is classified here; lubiprostone (24mcg) indicated for chronic constipation is classified in A6A9. Products containing plecanatide indicated for chronic constipation and IBS-C are classified here. Other drugs for constipation, including laxatives, are classified in A6A.	r2019
------------	--	-------

<b>A4</b>	<b>ANTIEMETICS AND ANTINAUSEANTS</b>	
<b>A4A</b>	<b>ANTIEMETICS AND ANTINAUSEANTS</b>  Products indicated for vertigo and Meniere's disease are classified in N7C. Gastroprokinetics are classified in A3F.	R1996
<b>A4A1</b>	<b>Serotonin antagonist antiemetics/antinauseants</b>  This class includes granisetron, ondansetron, palonosetron, tropisetron. Combinations of serotonin antagonists with NK1 antagonists are classified in A4A2.	r2016
<b>A4A2</b>	<b>NK1 antagonist antiemetics/antinauseants</b>  Includes products containing eg aprepitant, fosaprepitant, netupitant, rolapitant. Combinations of NK1 antagonists with serotonin antagonists are classified here.	I2016
<b>A4A9</b>	<b>Other antiemetics and antinauseants</b>  Includes eg cerium oxalate, metopimazine, scopolamine.	I1996

<b>A5</b>	<b>BILIARY TRACT AND LIVER DISORDER PRODUCTS</b>	r2023
<b>A5A</b>	<b>BILIARY TRACT DISORDER PRODUCTS</b>	r2023
<b>A5A1</b>	<b>Cholagogues</b>  Includes products, plain and in combination, indicated as choleretics and cholekinetics.	r2023
<b>A5A2</b>	<b>Bile stone therapy</b>  Includes products indicated for biliary conditions such as stone dissolvers eg chenodesoxycholic acid, ursodesoxycholic acid. Products containing ursodesoxycholic acid for primary biliary cholangitis are classified here.	r2018
<b>A5A9</b>	<b>Biliary tract disorder products, other</b>  Includes products containing obeticholic acid for primary biliary cholangitis.	r2023
<b>A5B</b>	<b>LIVER DISORDER PRODUCTS, HEPATIC PROTECTORS AND LIPOTROPICS</b>  Includes products for liver disorders such as metabolic dysfunction-associated steatohepatitis (MASH), hepatic protectors and combinations, but excludes liver extracts indicated for the treatment of anaemia, which are classified in B3B.	r2026
<b>A5C</b>	<b>CHOLAGOGUE/LIPOTROPIC COMBINATIONS</b>	

<b>A6</b>	<b>DRUGS FOR CONSTIPATION AND BOWEL CLEANSERS</b>	r2014
	Includes laxatives and other products for constipation. Products that are both laxatives and bowel cleansers are classified in the appropriate laxative class. For the classification of products indicated for irritable bowel syndrome with constipation (IBS-C) see A3G.	
<b>A6A</b>	<b>DRUGS FOR CONSTIPATION</b>	r2014
<b>A6A1</b>	<b>Faecal softening laxatives</b>	r2015
	Includes products containing softening laxatives such as liquid paraffin or docusate sodium. Combinations of faecal softening laxatives with osmotic laxatives are classified here. Combinations with bulk-forming laxatives are classified in A6A3. Combinations with stimulant laxatives are classified in A6A2.	
	For castor oil products see A6A2. Glycerol suppositories are classified in A6A9.	
<b>A6A2</b>	<b>Stimulant laxatives</b>	r2013
	Includes products containing laxatives that have a stimulant effect on the intestinal membrane and peristalsis. Many of these are herbal, eg senna, or of herbal origin (anthraquinones, emodines, glycosides, etc). This group also includes phenolphthalein-derivatives, bisacodyl, and sodium picosulphate when used as a laxative. Products containing a stimulant laxative in combination with other laxative substances (except bulk-forming) are classified here.	
<b>A6A3</b>	<b>Bulk-forming laxatives</b>	r2013
	Includes products containing substances such as bran, ispaghula, methylcellulose, sterculia. Products containing a bulk-forming laxative in combination with other types of laxative are classified here.	
<b>A6A4</b>	<b>Enemas</b>	R2015
	Includes all products for constipation in enema form. Other rectal forms for constipation are classified as appropriate in the other constipation classes. Glycerol suppositories and effervescent suppositories are classified in A6A9.	
	Combination packs containing an enema and another form are classified according to the other form.	
<b>A6A5</b>	<b>Peripheral opioid antagonist laxatives</b>	I2024
	Includes products containing peripheral opioid receptor antagonist laxatives for the treatment of opioid-induced constipation (OIC). Substances include methylnaltrexone, naldemedine, naloxegol, etc.	
	Products containing naloxone for opioid dependence are classified in N7F.	

A6A6	<b>Osmotic laxatives</b>  Includes products containing osmotic laxatives. Substances include lactitol, lactulose, macrogols, magnesium citrate, magnesium hydroxide, magnesium sulphate, mannitol, sorbitol, etc. Combinations with other laxative substances are classified in A6A1, A6A2 and A6A3. Combinations with electrolytes that are present to ensure a neutral impact on electrolyte levels are classified in A6A7.	I2013
A6A7	<b>Osmotic laxatives with electrolytes</b>  Includes products containing osmotic laxatives in combination with electrolyte substances. These specific electrolytes are present to ensure a neutral impact on electrolyte levels.	I2013
A6A9	<b>Other drugs for constipation</b>  Includes other drugs for constipation and combinations of laxatives not classified in A6A1-A6A7. Combinations of laxatives with centrally acting anti-obesity substances are classified in A8A.  Glycerol suppositories and effervescent suppositories are classified here.  Prucalopride for chronic constipation is classified here. Linaclotide (145mcg) indicated for chronic constipation is classified here; linaclotide (290mcg) indicated for IBS-C (irritable bowel syndrome with constipation) is classified in A3G. Products containing linaclotide for both chronic constipation and for IBS-C are classified in A3G when there is no distinction by strength. Lubiprostone (24mcg) indicated for chronic constipation is classified here; lubiprostone (8mcg) indicated for IBS-C is classified in A3G. Products containing plecanatide and indicated for both chronic constipation and IBS-C are classified in A3G.	r2019



<b>A6B</b>	<b>BOWEL CLEANSERS</b>  Includes products specifically for bowel cleansing prior to surgery or an investigative procedure.	I2013
A6B1	<b>Osmotic bowel cleansers</b>  Includes products that contain osmotic laxatives and are for bowel cleansing prior to surgery or an investigative procedure. Combinations of an osmotic laxative with a stimulant, when used as a bowel preparation, are classified here.	I2013
A6B2	<b>Osmotic bowel cleansers with electrolytes</b>  Includes products that contain osmotic laxatives in combination with electrolyte substances and are for bowel cleansing prior to surgery or an investigative procedure. These specific electrolytes are present to ensure a neutral impact on electrolyte levels. Bowel cleansers with electrolytes and that contain both an osmotic laxative and a stimulant laxative are classified here.	I2013
A6B9	<b>Other bowel cleansers</b>  Includes other products for bowel cleansing prior to surgery or an investigative procedure.	I2013

<b>A7</b>	<b>INTESTINAL DISORDER PRODUCTS</b>  Products for functional gastro-intestinal disorders are in A3 and products for constipation and bowel cleansing are in A6.	r2019
<b>A7A</b>	<b>INTESTINAL ANTI-INFECTIVES</b>  Includes all products containing one or more intestinal anti-infectives with or without other substances that are used for diarrhoea and/or hepatic encephalopathy. Sulphonamides and special antibacterials such as polymyxin, neomycin, vancomycin or colistin in oral form, when mainly indicated as antidiarrhoeals are included in this group. Combinations with motility inhibitors, intestinal adsorbants and micro-organisms are also included.  Products containing rifaximin for either diarrhoea or hepatic encephalopathy are classified here. Products containing fidaxomicin for <i>Clostridium difficile</i> intestinal infections are classified here.	r2019
<b>A7B</b>	<b>INTESTINAL ADSORBENT ANTIDIARRHOEALS</b>  Includes products such as kaolin and pectin. Combinations with micro-organisms are also included.	r2011
<b>A7C</b>	Out of use; can be reused.	
<b>A7D</b>	Out of use; can be reused.	
<b>A7E</b>	<b>INFLAMMATORY BOWEL DISORDER PRODUCTS</b>  Includes products for inflammatory bowel disorders. Immunosuppressant products used for inflammatory bowel disorders as well as other conditions are classified in L4, for example in L4B (anti-TNF products).	r2025
<b>A7E1</b>	<b>Intestinal aminosalicylate products</b>  Includes products containing balsalazide, mesalazine, olsalazine, sulfasalazine and similar aminosalicylates for inflammatory bowel disorders. Products containing aminosalicylates and indicated for rheumatoid arthritis are classified in M1C.	I2017
<b>A7E2</b>	<b>Intestinal corticosteroid products</b>  Includes products containing corticosteroids for inflammatory bowel disorders and for eosinophilic oesophagitis.	r2023

<b>A7E9</b>	<b>Inflammatory bowel disorder products, other</b>  Includes other products for inflammatory bowel disorders. Products containing vedolizumab and indicated for inflammatory bowel disease only are classified here.  Products containing disodium cromoglicate and indicated for food allergy are classified here.  Darvadstrocel (allogenic stem cells) for perianal fistulae in Crohn's disease are classified here.  Products containing sphingosine-1-phosphate (S1P) receptor modulators, eg etrasimod, ozanimod etc, for inflammatory bowel disease only, eg ulcerative colitis, Crohn's disease etc, are classified here. Products containing S1P receptor modulators and indicated for both inflammatory bowel disease and multiple sclerosis are classified in N7A.	r2025
<b>A7F</b>	<b>ANTIDIARRHOEAL MICRO-ORGANISMS</b>  Includes micro-organisms such as lactobacillus acidophilus which are indicated for the treatment of diarrhoeal disease. Excluded are combinations with other antidiarrhoeals such as anti-infectives, motility inhibitors, and intestinal adsorbents. Products containing racecadotril are classified in A7X.	r2020
<b>A7G</b>	<b>ORAL ELECTROLYTE REPLACERS</b>  Oral electrolyte replacers are included in this group where diarrhoeal disease has been indicated. Intravenous preparations are included in K.	I1993
<b>A7H</b>	<b>MOTILITY INHIBITORS</b>  Includes narcotic derivatives such as loperamide, diphenoxylate and paregoric. Combinations with intestinal adsorbents and micro-organisms are also included.	I1993
<b>A7X</b>	<b>INTESTINAL DISORDER PRODUCTS, OTHER</b>  Includes other products for intestinal disorders, including antidiarrhoeal products. Products containing racecadotril only, or in combination with micro-organisms, are classified here.	r2020

<b>A8</b>	<b>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</b>	
<b>A8A</b>	<b>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</b>  Includes all centrally- and peripherally-acting substances indicated for obesity, eg amphetamines, cannabinoid receptor antagonists (CB1), and lipase inhibitors. Combinations of these substances with laxatives or dietetics are included in A8A when the specific indication is obesity. Herbal products are also included. This class excludes dietary products (nutrients) used to aid in weight reduction (see V6A). Chitin-based products are classified in V6A when used in weight reduction.  Combinations of anti-obesity drugs with antidiabetics where the aim is to treat both the diabetes and the obesity are classified in A10X1.  Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for weight management only are classified here. Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for diabetes, or for both diabetes and weight management, are classified in A10S.	r2024

<b>A9</b>	<b>DIGESTIVES, INCLUDING ENZYMES</b>	r2017
<b>A9A</b>	<b>DIGESTIVES, INCLUDING ENZYMES</b>  Includes only those enzymes acting on the digestive tract. Combinations of dimethicone/simethicone (dimethylpolysiloxane, DMPS) with an enzyme, with or without other active substances, and specifically indicated as digestives are included in this group. Specific cholagogues are classified in A5A. Trypsin products for enzymatic wound treatment are classified in D3A and X-chymotrypsin products for ophthalmic use are classified in S1S9. Enzymes with various fields of application are classified in V3H.	R1994

<b>A10</b>	<b>DRUGS USED IN DIABETES</b>	R1993
<b>A10A</b>	Out of use; can be reused from 2001.	D1998
<b>A10B</b>	Out of use; can be reused from 2012.	D2009
<b>A10C</b>	<b>HUMAN INSULINS AND ANALOGUES</b>	I1998
A10C1	<b>Human insulins and analogues, fast-acting</b>  Includes human soluble insulin (neutral insulin) and insulin lispro. Includes inhaled forms of insulin.	R2007
A10C2	<b>Human insulins and analogues, intermediate-acting</b>  Includes human isophane insulin (NPH) and human amorphous insulin zinc suspension (semi-lente).	I1998
A10C3	<b>Human insulins and analogues, intermediate- or long-acting, combined with fast-acting</b>  Includes combinations of human isophane with human soluble insulins (biphasic isophane insulin). Includes combinations of insulin degludec with insulin aspart.	R2016
A10C4	<b>Human insulins and analogues, intermediate-acting combined with long-acting</b>  Includes fixed combinations of human crystalline insulin suspension 70% with human amorphous insulin zinc suspension 30% (lente).	I1998
A10C5	<b>Human insulins and analogues, long-acting</b>  Includes human crystalline insulin zinc suspension (ultra-lente) and insulin degludec.	r2013
A10C9	<b>Other human insulins and analogues</b>  Combinations of human insulins or analogues with GLP-1 agonist antidiabetics are classified here.	r2016
<b>A10D</b>	<b>ANIMAL INSULINS</b>	I1998
<b>A10E</b>	<b>INSULIN DEVICES</b>  Only those products which do not contain any active ingredients but are used to administer insulin, are classified in this group.	I1998

<b>A10H</b>	<b>SULPHONYLUREA ANTIDIABETICS</b>  Includes plain products containing chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, tolbutamide, etc. For combinations of sulphonylureas with other antidiabetics, use the most appropriate specific combination class. For combinations with vitamins only, classify as plain sulphonylureas.	I2009
<b>A10J</b>	<b>BIGUANIDE ANTIDIABETICS</b>	I2009
A10J1	<b>Biguanide antidiabetics, plain</b>  Includes plain products containing buformin, metformin, phenformin, etc.	I2009
A10J2	<b>Biguanide and sulphonylurea antidiabetic combinations</b>  Includes combinations of biguanides with sulphonylureas.	I2009
A10J9	<b>Biguanide antidiabetic combinations, other</b>  Includes combinations of biguanides with other antidiabetics where there is no other appropriate class. For combinations with vitamins only, classify as plain biguanides.	I2009
<b>A10K</b>	<b>GLITAZONE ANTIDIABETICS</b>  Products containing glitazars, eg carfloglitazar, saroglitazar etc, are classified in A10X9.	r2024
A10K1	<b>Glitazone antidiabetics, plain</b>  Includes plain products containing pioglitazone, rosiglitazone, troglitazone, etc.	I2009
A10K2	<b>Glitazone and sulphonylurea antidiabetic combinations</b>  Includes combinations of glitazones with sulphonylureas.	I2009
A10K3	<b>Glitazone and biguanide antidiabetic combinations</b>  Includes combinations of glitazones with biguanides.	I2009
A10K9	<b>Glitazone antidiabetic combinations, other</b>  Includes combinations of glitazones with other antidiabetics where there is no other appropriate class. Combinations of a glitazone with a biguanide and also a sulphonylurea are classified in A10K9. Combinations of a glitazone with a biguanide and also a DPP-IV inhibitor are classified in A10N9.	I2009

<b>A10L</b>	<b>ALPHA-GLUCOSIDASE INHIBITOR ANTIDIABETICS</b>  Includes plain products containing acarbose, miglitol, voglibose, etc.	I2009
<b>A10M</b>	<b>GLINIDE ANTIDIABETICS</b>	I2009
A10M1	<b>Glinide antidiabetics, plain</b>  Includes plain products containing repaglinide, nataglinide, mitiglinide, etc.	I2009
A10M3	<b>Glinide and biguanide antidiabetic combinations</b>  Includes combinations of glinide antidiabetics with biguanides.	I2009
A10M9	<b>Glinide antidiabetic combinations, other</b>  Includes combinations of glinide antidiabetics with other antidiabetics where there is no other appropriate class.	I2009
<b>A10N</b>	<b>DPP-IV INHIBITOR ANTIDIABETICS</b>	I2009
A10N1	<b>DPP-IV inhibitor antidiabetics, plain</b>  Includes plain products containing denagliptin, saxagliptin, sitagliptin, vildagliptin, etc.	I2009
A10N3	<b>DPP-IV inhibitor and biguanide antidiabetic combinations</b>  Includes combinations of DPP-IV inhibitors with biguanides.	I2009
A10N9	<b>DPP-IV inhibitor antidiabetic combinations, other</b>  Includes combinations of DPP-IV inhibitors with other antidiabetics where there is no other appropriate class. Combinations of a DPP-IV with a glitazone and a biguanide are classified in A10N9. Combinations of a DPP-IV inhibitor with an SGLT2 inhibitor and a biguanide are classified in A10P9.	r2020

<b>A10P</b>	<b>SGLT2 INHIBITOR ANTIDIABETICS</b>	R2016
A10P1	<b>SGLT2 inhibitor antidiabetics, plain</b>  Includes plain products containing SGLT2 inhibitors, eg canagliflozin, dapagliflozin, empagliflozin, etc. Products containing SGLT2 inhibitors for diabetes and also for heart failure and/or chronic kidney disease are classified here. Products containing SGLT2 inhibitors for diabetes and/or cardiovascular risk are classified here.	r2024
A10P3	<b>SGLT2 inhibitor and biguanide antidiabetic combinations</b>  Includes combinations of SGLT2 inhibitors with biguanides.	I2016
A10P5	<b>SGLT2 inhibitor and DPP-IV inhibitor antidiabetic combinations</b>  Includes combinations of SGLT2 inhibitors with DPP-IV inhibitors.	I2017
A10P9	<b>SGLT2 inhibitor antidiabetic combinations, other</b>  Includes combinations of SGLT2 inhibitors with other oral antidiabetics where there is no other appropriate class. Combinations of an SGLT2 inhibitor with a DPP-IV inhibitor and a biguanide are classified here.	r2020
<b>A10S</b>	<b>GLP-1 AGONIST ANTIDIABETICS</b>  Includes glucagon-like peptide 1 receptor agonist antidiabetics, eg exenatide, liraglutide, lixisenatide. Combinations of GLP-1 agonist antidiabetics with human insulins or analogues are classified in A10C9.  Products containing oral forms of GLP-1 agonists for diabetes are classified here.  Products containing dual GIP and GLP-1 agonists for diabetes are classified here.  Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for weight management only are classified in A8A.  Products containing GLP-1 agonists, or dual GIP/GLP-1 agonists, for both diabetes and weight management are classified here.	r2024



<b>A10X</b>	<b>OTHER DRUGS USED IN DIABETES</b>	<b>R2010</b>
<b>A10X1</b>	<b>Antidiabetic multitherapy combination products</b>  Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. For example, rosiglitazone in combination with simvastatin. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity. For example, metformin in combination with sibutramine.	<b>I2010</b>
<b>A10X9</b>	<b>Other drugs used in diabetes</b>  Includes products used for the treatment of diabetes, as well as adjuvant therapy in the treatment and prevention of conditions associated with or developing from diabetes.  Includes aldose reductase inhibitors (eg epalrestat, tolrestat), guar gum and glucose products specifically intended for the treatment of hypoglycaemic shock.  Includes products containing glucokinase activator antidiabetics, eg dorzagliatin.  Includes products containing glitazars, eg carfloglitazar, saroglitazar etc.  Teas and other herbal extracts used as adjuvant therapy are classified here.  Products containing teplizumab or cell-based therapies (eg donislecel) for type 1 diabetes, are classified here.  Products containing gabapentinoids for diabetic neuropathy are classified in N2D.	<b>r2025</b>

<b>A11</b>	<b>VITAMINS</b> <p>Multivitamins are combinations of three or more vitamins and must contain vitamin A and/or vitamin D.</p> <p>Multivitamins for parenteral infusion are classified in K4D (less than 100ml).</p> <p>Products containing vitamins which are specifically for eye conditions are classified in S1M.</p>	r2026
<b>A11A</b>	<b>MULTIVITAMINS WITH MINERALS</b> <p>Includes products containing more than two vitamins in combination (and not specified elsewhere) with one or more minerals, eg calcium, potassium, magnesium, iron, copper, manganese and zinc etc. Potassium and magnesium aspartate are not considered as minerals (see A12 and C6X). Excluded are all oral preparations containing procaine where procaine is one of the major components (see A13A1).</p>	r2017
A11A1	<b>Prenatal</b> <p>Includes those products specifically indicated for vitamin supplementation during pre-conception, pregnancy or lactation (eg containing fluoride as mineral).</p>	r2023
A11A2	<b>Paediatric</b> <p>Includes products with halibut liver oil or vitamin D which are indicated only for paediatric conditions. Products with malt extracts are classified in A13A.</p>	
A11A3	<b>Geriatric</b> <p>Includes vitamin preparations with hormones for geriatric patients. The term "ger" often forms part of the name of products in this group (see also A14A2).</p>	
A11A4	<b>Other multivitamins with minerals</b> <p>Includes all other multivitamin products not specified in A11A1, A11A2 or A11A3. Calcium-containing products promoted for osteoporosis or calcium deficiency are classified in A12A. Vitamin C combinations, eg promoted for hypovitaminose C, are classified in A11G2. When in doubt the calcium component takes precedence over the other ingredients. Products based on lecithin or glutamic acid used as tonics are classified in A13A.</p>	

<b>A11B</b>	<b>MULTIVITAMINS WITHOUT MINERALS</b>	R2003
	Includes all multivitamin combinations as defined under A11A but without minerals, except all oral preparations containing procaine (see A13A1). Products for general well-being are classified in A13A.	
A11B1	<b>Prenatal</b>	r2023
	Includes those products specifically indicated for vitamin supplementation during pre-conception, pregnancy or lactation.	
A11B2	<b>Paediatric</b>	
	Analogous to A11A2 but without minerals.	
A11B3	<b>Geriatric</b>	
	Analogous to A11A3 but without minerals (see also A14A2).	
A11B4	<b>Other multivitamins without minerals</b>	
<b>A11C</b>	<b>VITAMIN A AND D, INCLUDING COMBINATIONS OF THE TWO</b>	
A11C1	<b>Vitamin A</b>	
	Includes combinations of vitamin A with vitamin E, but excludes combinations of vitamin A with vitamin D (see A11C3).	
A11C2	<b>Vitamin D</b>	r2021
	Excludes combinations of vitamin D with vitamin A (see A11C3).	
	Products containing vitamin D or its analogues with multiple indications are classified here. Products only for secondary hyperparathyroidism are classified in H4F. Cinacalcet is classified in H4F.	
	Products containing vitamin D that are mainly for vitamin D deficiency but also contain minerals (for example, magnesium) are classified here. Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.	
	Products containing vitamin D with vitamin E (with and without minerals) are classified here. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.	

A11C3	<b>Combinations of vitamin A with vitamin D</b>  Products containing halibut or cod liver oil are included in this group. Combinations of vitamin A and/or vitamin D with other vitamins are classified as multivitamins in A11A or A11B.	R2003
A11D	<b>VITAMIN B1 AND COMBINATIONS</b>  For vitamin B complex, see A11E.	R2003
A11D1	Out of use; can be reused from 2006.	D2003
A11D2	Out of use; can be reused from 2006.	D2003
A11D3	<b>Vitamin B1 plain</b>  Includes products containing only vitamin B1 (thiamine) or analogues (eg cocarboxylase). Products of this type containing eg lidocaine, glucose, are also classified here.	I2003
A11D4	<b>Vitamin B1 combinations with vitamin B6 and/or vitamin B12</b>  Includes vitamin B1 in combination with vitamin B6, vitamin B1 in combination with vitamin B12, and vitamin B1 in combination with both vitamins B6 and vitamin B12. Products of this type containing lidocaine are also classified here.	I2003
A11D9	<b>Other vitamin B1 combinations</b>  Includes vitamin B1 products (with or without B6 and/or B12) in combination with other vitamins or substances (excluding vitamin A, or vitamin D). Combinations of B1 and/or B6 and/or B12 with analgesics and mainly indicated for analgesia are usually classified in N2B. Combinations of B1 and/or B6 and/or B12 with anti-inflammatories are usually classified in M1A2. Combinations of B1 and/or B2 and/or B12 with corticosteroids are classified in H2B.	I2003
A11E	<b>VITAMIN B COMPLEX</b>  Vitamin B complex contains Vitamin B1 (thiamine), B2 (riboflavine), B6 (pyridoxine) and B12 (cyanocobalamin). In addition, B5 (pantothenic acid), B7 (biotin), B3 (niacinamide) and folic acid can be included. Included are products containing liver extracts, but not those indicated for anaemia (see also B3B).  Vitamin B complex with vitamin A or vitamin D is classified in A11A or A11B.  For other vitamin B1 products, see A11D.	R2003
A11E1	<b>Plain vitamin B complex</b>  Includes dried yeast.	R2004

A11E2	<b>Vitamin B complex with vitamin C</b>  Includes vitamin B complex combinations with vitamin C only, except when they contain other drugs as well (see A11E3).	R2003
A11E3	<b>Vitamin B complex with other drugs</b>  Includes products containing vitamin B complex and other components, with or without vitamin C.	R1998
A11F	<b>PLAIN VITAMIN B12</b>  This group contains plain vitamin B12 (cyanocobalamin, hydroxocobalamin) products, with or without lidocaine. Combinations with other substances are classified in either A11A, A11B, A11D, A11E, A11X9, B3B or B3X.	R2003
A11G	<b>VITAMIN C, INCLUDING COMBINATIONS WITH MINERALS</b>	
A11G1	<b>Plain vitamin C (including vitamin C salts)</b>	
A11G2	<b>Vitamin C combinations</b>  Products of this group include vitamin C with other components, but products with calcium salts for the therapy of calcium deficiency or osteoporosis are classified in A12A. When in doubt, the calcium component takes precedence over the other ingredients.  Specific vitamin C combinations are classified as follows; with vitamin B1 in A11D9; with vitamin B complex in A11E2; with vitamin A only, or vitamin D only, are classified in A11X9. Multivitamin combinations containing vitamin C are classified in A11A or A11B.  For other vitamin C combinations with only one vitamin, and possibly other substances, A11X9 is appropriate.	r2026
A11H	Out of use; can be reused.	
A11J	Out of use; can be reused from 2005.	D2002
A11X	<b>OTHER VITAMINS</b>	I2002
A11X1	<b>Nicotinamide (vitamin B3), plain</b>  Includes products containing nicotinamide (vitamin PP).	R2003
A11X2	<b>Vitamin B6 (pyridoxine), plain</b>  Pyrithioxine products are included in N6D.	I2002

A11X3	<p><b>Vitamin E, plain</b></p> <p>Combinations with vitamin A are in A11C1. Vitamin E products with wheatgerm are classified here.</p>	I2002
A11X9	<p><b>All other vitamins, plain and in combination</b></p> <p>Includes all other vitamin products such as pantothenic acid, riboflavine (vitamin B2) and para-aminobenzoic acid (PABA). Vitamin K is classified in B2B, and vitamin P in C5C.</p> <p>Includes all vitamin B combinations without vitamin B1 when they do not contain vitamin A or vitamin D.</p> <p>Vitamin B2 with vitamin B6 is classified here.</p> <p>Vitamin B1 with vitamin B2 is classified in A11D9.</p> <p>Products containing vitamin D that are mainly for vitamin D deficiency but also contain minerals (for example, magnesium) are classified in A11C2. Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</p> <p>Products containing vitamin D in combination with vitamin E (with and without minerals) are classified in A11C2. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</p>	r2021

<b>A12</b>	<b>MINERAL SUPPLEMENTS</b>	
<b>A12A</b>	<b>CALCIUM PRODUCTS</b>  Includes single and combination products promoted for osteoporosis or calcium deficiency, even when indicated for other diseases as well (see A11G2 and A11A4). See also M5B.  Products containing both calcium and magnesium to treat deficiency of these minerals are classified here.  Products containing calcium and indicated for both hyperphosphataemia and calcium deficiency are classified in V3G2.  Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified here. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified here.	r2021
<b>A12B</b>	<b>POTASSIUM PRODUCTS</b>  Potassium diuretic combinations are classified in C3 (see note under A12C regarding potassium aspartate).	
<b>A12C</b>	<b>OTHER MINERAL SUPPLEMENTS</b>  Includes magnesium and/or fluoride products used as alimentary supplements. Potassium and magnesium aspartate are usually indicated in the treatment of cardiac disease and should be classified in C6X. In certain cases, however, when these compounds are indicated as mineral supplements, they should be classified in A12.  Products containing both calcium and magnesium to treat deficiency of these minerals are classified in A12A.	r2017
A12C1	<b>Magnesium supplements</b>	R1993
A12C2	<b>Other mineral supplements</b>	

<b>A13</b>	<b>TONICS</b>	R2003
<b>A13A</b>	<b>TONICS</b>	
	Products for general well-being are classified here.	
<b>A13A1</b>	<b>Preparations containing procaine</b>	
	This group includes all oral preparations containing procaine which are indicated for geriatrics.	
<b>A13A2</b>	<b>All other tonics</b>	
	Herbal tonics are included in this class. Anti-anaemics are classified in B3.	

<b>A14</b>	<b>ANABOLICS, SYSTEMIC</b>	
<b>A14A</b>	<b>ANABOLIC HORMONES, SYSTEMIC</b>	
<b>A14A1</b>	<b>Plain anabolic hormones, systemic</b>	
	This group does not include anti-cancer products (L1).	
<b>A14A2</b>	<b>Anabolic hormone combinations</b>	
	Vitamin and mineral combinations with anabolic hormones, predominant in the geriatric field, are classified in A11A3 or A11B3 (see comment in those groups).	
<b>A14B</b>	<b>OTHER ANABOLIC AGENTS, SYSTEMIC</b>	
	Includes all other anabolic agents.	

<b>A15</b>	<b>APPETITE STIMULANTS</b>	R2003
<b>A15A</b>	<b>APPETITE STIMULANTS</b>	
	Includes products of the cyproheptadine group, buclizine, and pizotifen when indicated as appetite stimulants.	



<b>A16</b>	<b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b>	
<b>A16A</b>	<b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b>  Includes all alimentary tract and metabolism products not classified elsewhere. Oral preparations containing procaine are classified in A13A1.  Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1.  Products containing teduglutide for short bowel syndrome are classified here.  Products containing prebiotic fibre for gut health and/or immune support are classified here. Products containing prebiotic fibre in combination with probiotic micro-organisms for gut health and/or immune support are classified here.  Products containing lumasiran for primary hyperoxaluria type 1 are classified in G4X.  Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified in L3A9.	r2025

<b>B</b>	<b>BLOOD AND BLOOD FORMING ORGANS</b>	
<b>B1</b>	<b>ANTITHROMBOTIC AGENTS</b>	R1994
<b>B1A</b>	<b>VITAMIN K ANTAGONISTS</b>	R2004
	Includes coumarin and indanedione derivatives.	
<b>B1B</b>	<b>HEPARINS</b>	R2004
<b>B1B1</b>	<b>Unfractionated heparins</b>	
	Includes injectable high molecular weight (unfractionated) heparin (pure and in combination with other substances) with an average molecular weight from 5000 up to 30000 Dalton. The molecules are unfractionated.	
<b>B1B2</b>	<b>Fractionated heparins</b>	R2003
	Includes injectable low molecular weight (fractionated) heparin (pure and in combination with other substances) with an average molecular weight from 2000 up to 18000 Dalton. The molecules are fractionated (fragments). Included are, eg bemiparin, enoxaparin, tedelparin and tinzaparin.	
<b>B1B3</b>	<b>Heparins for flushing</b>	r2025
	Includes heparin products for use with catheters eg Hepflush etc.	
	Catheter lock solution products that contain heparin, eg Heplock etc, are classified here. Catheter lock solution products without heparin are classified in K7A.	
<b>B1B9</b>	<b>Other heparins</b>	R2004
<b>B1C</b>	<b>PLATELET AGGREGATION INHIBITORS</b>	r2017
	Includes all products claiming platelet aggregation inhibition as the main indication eg ticlopidine. Also included are those products which have specific packs or presentations which are mainly indicated for platelet aggregation inhibition. These products, such as sulphinpyrazone, ditazole, dipyridamole, aspirin and non-steroidal anti-inflammatories are also prescribed for other conditions.	
<b>B1C1</b>	<b>Cyclo-oxygenase inhibitor platelet aggregation inhibitors</b>	R2010
	Includes specific presentations of eg acetylsalicylic acid (aspirin), indobufen, picotamide, sulfinpyrazone, which are mainly indicated for platelet aggregation inhibition.	
	All oral solid low-dose aspirin products (162mg and below) are classified in B1C1 worldwide.	

B1C2	<b>ADP (adenosine diphosphate) receptor antagonist platelet aggregation inhibitors</b>  Includes clopidogrel and ticlopidine.	I2000
B1C3	<b>GP IIb/IIIa (glycoprotein) antagonist platelet aggregation inhibitors</b>  Includes abciximab, eptifibatide and tirofiban.	I2000
B1C4	<b>Platelet cAMP enhancing platelet aggregation inhibitors</b>  Includes prostacyclin derivatives eg beraprost, iloprost, limaprost and also phosphodiesterase (PDE) inhibitors eg anagrelide, dipyridamole when mainly indicated for platelet aggregation inhibition. Products containing epoprostenol are classified in C6B3. Products containing prostacyclin derivatives and only indicated for PAH are classified in C6B3. Products containing prostacyclin derivatives and indicated for both PAH and other conditions are classified here.	R2017
B1C5	<b>Platelet aggregation inhibitors, combinations</b>  Includes combinations of two of more platelet aggregation inhibitors, eg a cyclo-oxygenase inhibitor with an ADP receptor antagonist, or a cyclo-oxygenase inhibitor with a PDE inhibitor.  Products containing a combination of a platelet aggregation inhibitor together with another substance and for use as antithrombotics are classified here.	R2004
B1C9	<b>Other platelet aggregation inhibitors</b>  Includes eicosapentanoic acid, nifedipine, ozagrel, vorapaxar.	r2015
B1D	<b>FIBRINOLYTICS</b>  Includes endogenous proteins (eg urokinase), exogenous proteins (eg streptokinase) as well as anistreplase, plasmin, plasminogen, tissue plasminogen activator (TPA), an anisoylated plasminogen-streptokinase activator complex (APSAC) and pro-urokinase (a precursor form of urokinase).	R2004
B1E	<b>DIRECT THROMBIN INHIBITORS</b>  Includes argatroban, bivalirudin, desirudin, lepirudin, melagatran, ximelagatran.	I2004
B1F	<b>DIRECT FACTOR XA INHIBITORS</b>  Includes products containing direct factor Xa inhibitors, eg apixaban, betrixaban, edoxaban, rivaroxaban.	r2019

<b>B1X</b>	<b>OTHER ANTITHROMBOTIC AGENTS</b> <p>Includes danaparoid, dermatan sulphate, activated protein C (drotrecogin alpha, activated), fondaparinux, <i>Ligustrum lucidum</i>, pentosan polysulphate sodium, poloxalkol, protein C. Products containing caplacizumab for acquired thrombotic thrombocytopenic purpura (aTTP) are classified here. Products containing apadamtase alfa in combination with cinaxadamtase alfa for congenital thrombotic thrombocytopenic purpura (cTTP) are classified here.</p>	r2025
------------	--	-------

<b>B2</b>	<b>BLOOD COAGULATION SYSTEM PRODUCTS</b>	r2023
<b>B2A</b>	<b>ANTIFIBRINOLYTICS</b>	
B2A1	<b>Synthetic antifibrinolytics</b>  Includes inhibitors of fibrinolytic activity such as epsilon - aminocaproic acid (EACA), para-aminomethylbenzoic acid (PAMBA) and tranexamic acid (AMCHA).	
B2A2	<b>Proteinase</b>	
B2A9	<b>Other antifibrinolytics</b>	
<b>B2B</b>	<b>ANTAGONISTS (ANTIDOTES TO ANTICOAGULANTS)</b>	
B2B1	<b>Vitamin K</b>  Essential for the formulation of prothrombin complex factors in the liver.	
B2B2	<b>Protamin sulphate</b>  Neutralises the effect of heparin.	
B2B9	<b>Antidotes to anticoagulants, other</b>  Includes idarucizumab, andexanet alfa.	I2016
<b>B2C</b>	<b>PROTEINASE INHIBITORS</b>	
B2C1	<b>Coagulation inhibitors</b>  Includes coagulation inhibitors eg antithrombin III.	
B2C2	<b>Inhibitors of the Kallikrein-kinin-system</b>  Includes products containing eg camostat, gabexate, nafamostat. Products for hereditary angioedema are classified in B6D.	R2015
B2C3	<b>Inhibitors of fibrinolysis</b>  Includes aprotinin.	
B2C9	<b>Other proteinase inhibitors</b>  Products containing alpha-1-proteinase inhibitor are classified in R3X2.	r2013

<b>B2D</b>	<b>BLOOD COAGULATION PRODUCTS</b>	r2024
	Products used to treat haemophilia are classified in the appropriate fourth level according to the blood factors or blood fractions whose dysfunction they correct, eg by replacement, substitution, gene therapies etc.	
<b>B2D1</b>	<b>Factor VIII, including substitutes</b>	r2024
	Products for haemophilia A containing factors, substitutes or gene therapies, eg valoctocogene roxaparvovec, are classified here. Includes antihaemophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9.	
<b>B2D2</b>	<b>Factors II, VII, IX and X</b>	r2024
	Products for haemophilia B containing factors, substitutes or gene therapies, eg etranacogene dezaparvovec, fidanacogene elaparvovec etc, are classified here. Includes antihaemophilic globulin B and prothrombin complex.	
<b>B2D3</b>	<b>Haemophilia anti-inhibitor products</b>	r2025
	Products for haemophilia A and/or haemophilia B, when inhibitors are present or are not present, are classified here. Includes activated FVII (FVIIa), aPCC (activated prothrombin complex concentrate), concizumab, eptacog alfa, marstacimab etc.	
<b>B2D4</b>	<b>Factor XIII</b>	
<b>B2D5</b>	<b>Fibrinogen</b>	
<b>B2D6</b>	<b>Fresh frozen plasma and antihaemophilic plasma</b>	
<b>B2D7</b>	<b>Cohn-Fraction I</b>	
<b>B2D8</b>	<b>Platelet concentrates</b>	
<b>B2D9</b>	<b>Blood coagulation products, other</b>	r2025
	Includes products containing von Willebrand factor (single ingredient).	
	Products containing fitusiran for haemophilia are classified here.	
<b>B2E</b>	<b>PLATELET-ENHANCING PRODUCTS</b>	R2023
<b>B2E1</b>	<b>Thrombopoietin agonists</b>	I2023
	Includes products containing thrombopoietin agonists for thrombocytopenia, eg avatrombopag, eltrombopag, hetrombopag olamine, lusutrombopag, romiplostim, thrombopoietin, etc.	

<b>B2E9</b>	<b>Platelet-enhancing products, other</b>  Includes products for thrombocytopenia containing fostamatinib, oprelvekin, etc.	I2023
<b>B2F</b>	<b>TISSUE SEALING PREPARATIONS</b>  Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.	r2016
<b>B2G</b>	<b>SYSTEMIC HAEMOSTATICS</b>  Tissue extracts with haemostatic activity, and including snake venoms causing blood clotting, and hormone products exclusively promoted as haemostatics. Includes products containing parenteral conjugated oestrogens for control of uterine bleeding.	r2019

<b>B3</b>	<b>ANTI-ANAEMIC PREPARATIONS</b>	
<b>B3A</b>	<b>HAEMATINICS, IRON AND ALL COMBINATIONS</b>	
	Any products which contain iron, irrespective of other ingredients (for example, folic acid, vitamin B12, etc.) are classified in B3A.	
<b>B3A1</b>	<b>Plain iron</b>	
	This class also includes preparations containing ingredients for better absorption and/or reducing agents, such as ascorbic acid, as well as combinations with cobalt.	
<b>B3A2</b>	<b>Iron combination products</b>	R1993
	Includes all other iron combinations including those containing liver extract and/or folic acid.	
<b>B3B</b>	<b>LIVER EXTRACTS AND COMBINATIONS WITH B12</b>	
	Includes liver extracts, excluding all preparations not used for anaemia. Oral B12 with intrinsic factor allocated is classified in B3B.	
<b>B3C</b>	<b>ERYTHROPOIETIN PRODUCTS</b>	R1995
<b>B3D</b>	<b>HIF-PH INHIBITORS</b>	I2020
	Includes products containing HIF-PH (hypoxia-inducible factor prolyl hydroxylase) inhibitors (for example, daprodustat, enarodustat, molidustat, roxadustat, vadadustat, etc) for the treatment of anaemia in chronic kidney disease.	
<b>B3X</b>	<b>OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID</b>	r2025
	Folinic acid products with more than one indication are classified in V3D.	
	Includes products containing betibeglogene autotemcel for beta thalassaemia, luspatercept for anaemia associated with beta thalassaemia, sutimlimab for inhibition of haemolysis in cold agglutinin disease.	
	Products containing mitapivat for pyruvate kinase deficiency (PKD) are classified here.	
	Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD, eg voxelotor, are classified in B6X.	



<b>B4</b>	Out of use; can be reused from 2000. The B4 class was transferred to C10.	D1997
-----------	---	-------

<b>B5</b>	Out of use; can be reused. Group B5 discontinued. See group K.	
-----------	--	--

<b>B6</b>	<b>ALL OTHER HAEMATOLOGICAL AGENTS</b>	R1996
<b>B6A</b>	Out of use; can be reused from 1999.	D1996
<b>B6B</b>	<b>HYALURONIDASE</b>	
<b>B6C</b>	Out of use	D2020
<b>B6D</b>	<b>HEREDITARY ANGIOEDEMA PRODUCTS</b>  Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema.	I2015
<b>B6X</b>	<b>OTHER HAEMATOLOGICAL AGENTS</b>  Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A).  Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD (eg voxelotor), and those for transfusion-dependent $\beta$ -thalassaemia and SCD (eg exagamglogene autotemcel) are classified here.  Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) and/or atypical haemolytic uraemic syndrome (aHUS) only are classified here; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified in L4X.  Products containing fostamatinib or oprelvekin for the prevention of severe thrombocytopenia are classified in B2E9.  Products for haemolysis in cold agglutinin disease, and pyruvate kinase deficiency (PKD) are classified in B3X.	r2026

<b>C</b>	<b>CARDIOVASCULAR SYSTEM</b>	
<b>C1</b>	<b>CARDIAC THERAPY</b>	
<b>C1A</b>	<b>CARDIAC GLYCOSIDES AND COMBINATIONS</b>	
<b>C1A1</b>	<b>Plain cardiac glycosides</b>  This group includes all plain cardiac glycosides, either clearly defined chemical entities or standardised plant extracts and combinations of all the aforementioned. Non-standardised plant extracts are classified in C6X.	r2017
<b>C1A2</b>	<b>Cardiac glycoside combinations</b>  Excludes combinations with beta-blocking agents (C7B2), calcium antagonists (C8B3), ACE inhibitors (C9B9) and angiotensin-II antagonists (C9D9).	r2008
<b>C1B</b>	<b>ANTI-ARRHYTHMICS</b>  This group includes all products which are recommended for use in arrhythmia, disorders of cardiac rhythm and tachycardia, eg ajmaline, quinine, quinidine, procainamide, sparteine, amiodarone or similar, but only when specified as anti-arrhythmics alone. Excludes beta-blocking agents (C7) and calcium antagonists (C8).  Products containing mexiletine for cardiac arrhythmias are classified here; products containing mexiletine for non-dystrophic myotonic disorders are classified in M5X.	r2020
<b>C1C</b>	<b>CARDIAC STIMULANTS EXCLUDING CARDIAC GLYCOSIDES</b>  This group includes products for the indication hypotension, chiefly sympathomimetic agents eg amezinium methylsulphate used in the treatment of hypotension, but excluding sympathomimetics with predominant bronchodilatory effects used in the treatment of asthma and similar conditions (see R3).	R1994
<b>C1C1</b>	<b>Cardiac stimulants excluding dopaminergic agents</b>  Includes plain caffeine. Includes adrenaline/epinephrine products used for anaphylactic shock. Adrenaline combinations with antihistamines are classified here.	R2003
<b>C1C2</b>	<b>Cardiac dopaminergic agents</b>  Includes dobutamine, docarpamine, dopamine and ibopamine.	R1997

<b>C1D</b>	<b>CORONARY THERAPY EXCLUDING CALCIUM ANTAGONISTS AND NITRITES</b> <p>This group includes all other products indicated for coronary insufficiency and angina pectoris. It includes benziodarone, capobenic acid, carbocromen, cinepazet, cinepazic acid, cloridarol, dilazep, dipyridamole, efloxate, etafenone, fenalcomine, flosequinan, hexobendine, imolamine, ivabradine, medibazine, molsidomine, oxyfedrin, trimetazidine, visnadine. Combinations with nitrites are included in C1E and with beta-blockers are included in C7B.</p>	R2007
<b>C1E</b>	<b>NITRITES AND NITRATES</b> <p>This group includes all nitrites and analogous products and combinations if they are indicated for angina pectoris. Combinations of nitrites with cardiac glycosides are classified in C1A2 and combinations with beta-blockers in C7B.</p>	
<b>C1F</b>	<b>POSITIVE INOTROPIC AGENTS</b> <p>This group includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.</p>	R1994
<b>C1X</b>	<b>ALL OTHER CARDIAC PREPARATIONS</b> <p>This group includes substances such as alprostadil, crateagus glycosides, creatinolphosphate, phosphocreatinine, levocarnitine and ubidecarenone. Combination products are only classified in this group if they contain a substance which is not in the C group.</p> <p>Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified here.</p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified in N7X. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified here. Products containing tafamidis for both TAP and TAC are classified in N7X.</p> <p>Products containing mavacamten for hypertrophic cardiomyopathy are classified here.</p> <p>Products used to treat pericardial disease (eg goflikicept for idiopathic recurrent pericarditis) are classified here.</p>	r2026

C2	ANTIHYPERTENSIVES	r2014																																																																		
<p>Note: Beta-blocking agents, whether plain or in combination, are classified in group C7. Calcium antagonists with antihypertensive, and/or anti-angina action are classified in group C8. ACE inhibitors and angiotensin II antagonists are classified in group C9.</p>																																																																				
<table><tr><td><u>Alkaloids</u></td><td><u>Peripherally acting</u></td></tr><tr><td>Ajmalicine</td><td>betanidine</td></tr><tr><td>Alkavervir</td><td>bufenoide</td></tr><tr><td>Bietaserpine</td><td>bunazosin</td></tr><tr><td>Cryptenamine</td><td>cicletanine</td></tr><tr><td>Deserpidine</td><td>debrisoquine</td></tr><tr><td>Methoserpidine</td><td>diazoxide</td></tr><tr><td>Protoveratrine A</td><td>dihydralazine</td></tr><tr><td>Protoveratrine B</td><td>ecarazine</td></tr><tr><td>Rauwolfia serpentina</td><td>endralazine</td></tr><tr><td>Rauwolfia vomitoria</td><td>guabenxan</td></tr><tr><td>Rescinnamine</td><td>guanadrel</td></tr><tr><td>Reserpiline</td><td>guanethidine</td></tr><tr><td>Reserpine</td><td>guanoxan</td></tr><tr><td>Sarpagine</td><td>hexamethonium hydroxide</td></tr><tr><td>Serpentine</td><td>hydracarbazine</td></tr><tr><td>Spirgentine</td><td>hydralazine</td></tr><tr><td>Syrosingopine</td><td>indoramin</td></tr><tr><td>White veratrum</td><td>ketanserin</td></tr><tr><td></td><td>mecamylamine</td></tr><tr><td></td><td>metirosine</td></tr><tr><td></td><td>minoxidil</td></tr><tr><td><u>Centrally acting</u></td><td>nitroprusside</td></tr><tr><td>Clonidine</td><td>pargyline</td></tr><tr><td>Guanabenz</td><td>pempidine</td></tr><tr><td>Guanfacine</td><td>pentamethonium hydroxide</td></tr><tr><td>Guanoxabenz</td><td>pentolonium</td></tr><tr><td>Lofexidine</td><td>picodralazine</td></tr><tr><td>Mebutamate</td><td>prazosin</td></tr><tr><td>Methyldopa</td><td>primaperone</td></tr><tr><td>Moxonidine</td><td>todralazine</td></tr><tr><td>Tolonidine</td><td>trimethaphan</td></tr><tr><td></td><td>urapidil</td></tr></table>			<u>Alkaloids</u>	<u>Peripherally acting</u>	Ajmalicine	betanidine	Alkavervir	bufenoide	Bietaserpine	bunazosin	Cryptenamine	cicletanine	Deserpidine	debrisoquine	Methoserpidine	diazoxide	Protoveratrine A	dihydralazine	Protoveratrine B	ecarazine	Rauwolfia serpentina	endralazine	Rauwolfia vomitoria	guabenxan	Rescinnamine	guanadrel	Reserpiline	guanethidine	Reserpine	guanoxan	Sarpagine	hexamethonium hydroxide	Serpentine	hydracarbazine	Spirgentine	hydralazine	Syrosingopine	indoramin	White veratrum	ketanserin		mecamylamine		metirosine		minoxidil	<u>Centrally acting</u>	nitroprusside	Clonidine	pargyline	Guanabenz	pempidine	Guanfacine	pentamethonium hydroxide	Guanoxabenz	pentolonium	Lofexidine	picodralazine	Mebutamate	prazosin	Methyldopa	primaperone	Moxonidine	todralazine	Tolonidine	trimethaphan		urapidil
<u>Alkaloids</u>	<u>Peripherally acting</u>																																																																			
Ajmalicine	betanidine																																																																			
Alkavervir	bufenoide																																																																			
Bietaserpine	bunazosin																																																																			
Cryptenamine	cicletanine																																																																			
Deserpidine	debrisoquine																																																																			
Methoserpidine	diazoxide																																																																			
Protoveratrine A	dihydralazine																																																																			
Protoveratrine B	ecarazine																																																																			
Rauwolfia serpentina	endralazine																																																																			
Rauwolfia vomitoria	guabenxan																																																																			
Rescinnamine	guanadrel																																																																			
Reserpiline	guanethidine																																																																			
Reserpine	guanoxan																																																																			
Sarpagine	hexamethonium hydroxide																																																																			
Serpentine	hydracarbazine																																																																			
Spirgentine	hydralazine																																																																			
Syrosingopine	indoramin																																																																			
White veratrum	ketanserin																																																																			
	mecamylamine																																																																			
	metirosine																																																																			
	minoxidil																																																																			
<u>Centrally acting</u>	nitroprusside																																																																			
Clonidine	pargyline																																																																			
Guanabenz	pempidine																																																																			
Guanfacine	pentamethonium hydroxide																																																																			
Guanoxabenz	pentolonium																																																																			
Lofexidine	picodralazine																																																																			
Mebutamate	prazosin																																																																			
Methyldopa	primaperone																																																																			
Moxonidine	todralazine																																																																			
Tolonidine	trimethaphan																																																																			
	urapidil																																																																			
<p>Products containing terazosin, for BPH or hypertension, are classified in G4C2.</p>																																																																				

<b>C2A</b>	<b>ANTIHYPERTENSIVES (OF NON-HERBAL ORIGIN) PLAIN</b>  It includes plain antihypertensives and combinations other than those with diuretics, eg combinations of two synthetic antihypertensives or combinations of one synthetic antihypertensive with reserpine.	
C2A1	<b>Antihypertensives plain, mainly centrally acting</b>	
C2A2	<b>Antihypertensives plain, mainly peripherally acting</b>  Includes products containing doxazosin. Products containing indoramin alone are classified here unless the indication is migraine in which case they are classified in N2C9.	r2015
C2A3	<b>Antihypertensives plain, others</b>  Includes products containing aprocitentan.	r2025
<b>C2B</b>	<b>ANTIHYPERTENSIVES (OF NON-HERBAL ORIGIN), COMBINATION WITH DIURETICS</b>	
C2B1	<b>Antihypertensive-diuretic combinations, mainly centrally acting</b>	
C2B2	<b>Antihypertensive-diuretic combinations, mainly peripherally acting</b>	
C2B3	<b>Antihypertensive-diuretic combinations, others</b>	
<b>C2C</b>	<b>RAUWOLFIA ALKALOIDS AND OTHER ANTIHYPERTENSIVES OF HERBAL ORIGIN</b>	
<b>C2D</b>	<b>RAUWOLFIA ALKALOIDS AND OTHER ANTIHYPERTENSIVES OF HERBAL ORIGIN IN COMBINATION WITH DIURETICS</b>	

<b>C3</b>	<b>DIURETICS</b>	
<b>C3A</b>	<b>DIURETICS</b>	
	Combinations with potassium belong to C3A1, C3A2 or C3A3.	
<b>C3A1</b>	<b>Potassium-sparing agents plain</b>	r2025
	This group includes all products containing amiloride and triamterene, plain.	
	Products containing anticorticosteroids for diuresis, eg eplerenone, spironolactone (canrenoic acid) etc, are classified here.	
<b>C3A2</b>	<b>Loop diuretics plain</b>	r2008
	This group includes all products containing bumetanide, etacrynic acid, etozolin, furosemide, muzolimine, piretanide plain.	
<b>C3A3</b>	<b>Thiazides and analogues plain</b>	r2008
	This group includes all products containing thiazides, eg altizide, bendroflumethiazide, benzylhydrochlorothiazide, butizide, chlorothiazide, cyclopenthiazide, flumethiazide, hydrochlorothiazide, mebutizide, paraflutizide, teclothiazide, trichlormethiazide and analogues (which act similar to thiazides) eg chlortalidone, clopamide, indapamide, mefruside, tienilic acid, xipamide, tripamide, metolazone, quinethazone, clorexolone and meticrane.	
<b>C3A4</b>	<b>Potassium-sparing agents with loop diuretic combinations</b>	
<b>C3A5</b>	<b>Potassium-sparing agents with thiazides and/or analogue combinations</b>	
<b>C3A6</b>	Out of use; can be reused from 2014.	D2011
<b>C3A7</b>	<b>Vasopressin receptor antagonist diuretics</b>	I2011
	Includes products containing vasopressin receptor antagonists such as conivaptan, mozavaptan and tolvaptan.	
<b>C3A9</b>	<b>Other diuretics</b>	r2021
	Includes eg carboanhydrase inhibitors such as clofenamide and diclofenamide (when not used for the treatment of glaucoma or primary periodic paralysis), diuretics of vegetable origin etc, ethoxazolamide, isosorbide, mannitol, chlorazanol; mercury salts are also included in this group.	
	Products containing diclofenamide for primary periodic paralysis are classified in M5X. Products containing diclofenamide for glaucoma are classified in S1E1.	

<b>C4</b>	<b>CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS</b>	
<b>C4A</b>	<b>CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS</b>  This group includes all products (including citicoline) which are mainly recommended for cerebral vascular diseases or peripheral circulatory disorders excluding venous diseases. Combination products are only classified in this group if they do not belong to group C1-C3, C7-C11.	R2005
<b>C4A1</b>	<b>Cerebral and peripheral vasotherapeutics excluding calcium antagonists with cerebral activity</b>  Products containing phenoxybenzamine alone, and indicated either for hypertension or BPH are classified here. Products containing cinepazide alone and for vasodilation are classified here. Products containing beperminogene perplasmid for improvement of limb ischaemia are classified here. Products containing alprostadil for peripheral arterial occlusive disease only are classified here. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X.  Products containing clazosentan for cerebral haemorrhage are classified here.	r2024
<b>C4A2</b>	<b>Calcium antagonists with cerebral activity</b>  Includes, bencyclane, cinnarizine, cyclandelate, flunarizine and nimodipine.	R1993

<b>C5</b>	<b>ANTIVARICOSIS/ANTI-HAEMORRHOIDAL PREPARATIONS</b>	r2014
<b>C5A</b>	<b>TOPICAL ANTI-HAEMORRHOIDALS</b>  Topical products to treat anal fissures are classified here.	
<b>C5A1</b>	<b>Topical anti-haemorrhoids with corticosteroids</b>  This group includes all products which are used mainly for the topical treatment of haemorrhoids and which contain corticosteroids.	
<b>C5A2</b>	<b>Topical anti-haemorrhoids without corticosteroids</b>  This group includes all products which are used mainly for the topical treatment of haemorrhoids (excluding C5A1). Products designed to shrink haemorrhoids are also classified in this group.	
<b>C5B</b>	<b>VARICOSE THERAPY, TOPICAL</b>  This group includes all products which are predominantly used for the topical treatment of varicose veins. Products designed to shrink varicose veins are also classified here.	
<b>C5C</b>	<b>VARICOSE THERAPY, SYSTEMIC</b>  This group includes all products which are used for the systemic treatment of varicose veins and recommended for the treatment of diseases of the veins. Systemic anti-haemorrhoids are also classified in this group.	



<b>C6</b>	<b>OTHER CARDIOVASCULAR PRODUCTS</b>	R2017
<b>C6A</b>	Out of use; can be reused from 2020.	D2017
<b>C6B</b>	<b>PULMONARY ARTERIAL HYPERTENSION (PAH) PRODUCTS</b>	I2017
<b>C6B1</b>	<b>Endothelin receptor antagonist PAH products</b>  Includes products for pulmonary arterial hypertension (PAH) containing endothelin receptor antagonists such as ambrisentan, bosentan, macitentan, sitaxentan, etc.	I2017
<b>C6B2</b>	<b>PDE5 inhibitor PAH products</b>  Products containing PDE5 inhibitors and indicated only for pulmonary arterial hypertension (PAH) are classified here. Products containing PDE5 inhibitors and indicated for both erectile dysfunction and PAH are classified in G4E1.	I2017
<b>C6B3</b>	<b>Prostacyclin agonist PAH products</b>  Products containing prostacyclin agonists (eg iloprost, selexipag, treprostinil) and indicated for pulmonary hypertension only, are classified here. Products containing epoprostenol are all classified here. Products containing prostacyclin agonists and indicated for platelet aggregation inhibition are classified in B1C4. Products containing prostacyclin agonists for PAH and other conditions are classified in B1C4.	I2017
<b>C6B9</b>	<b>Pulmonary arterial hypertension (PAH) products, other</b>  Includes other products for PAH, eg those containing soluble guanylate synthase stimulators such as riociguat.  Includes products containing two or more substances from different PAH product classes. For example, an endothelin receptor antagonist in combination with a PDE5 inhibitor.	r2025

<b>C6X</b>	<p data-bbox="312 170 932 203"><b>OTHER CARDIOVASCULAR PRODUCTS</b></p> <p data-bbox="312 248 1390 315">This group includes all other products that are mainly recommended for diseases of the cardiovascular system and that cannot be classified in groups C1-C6B or C7-11.</p> <p data-bbox="312 360 1390 461">Potassium and magnesium aspartate are usually classified here. In certain cases when these compounds are indicated as mineral supplements, they are classified in A12.</p> <p data-bbox="312 506 1321 539">Products containing icatibant for hereditary angioedema are classified in B6D.</p> <p data-bbox="312 584 1390 651">Products containing SGLT2 inhibitors for diabetes and/or cardiovascular risk are classified in A10P1.</p> <p data-bbox="312 696 1390 763">Products containing avacopan for vasculitic conditions, eg granulomatosis with polyangiitis, microscopic polyangiitis etc, are classified here.</p>	r2025
------------	---	-------

<b>C7</b>	<b>BETA-BLOCKING AGENTS</b>	
<b>C7A</b>	<b>BETA-BLOCKING AGENTS, PLAIN</b>  Includes, eg acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bunitrolol, bupranolol, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cloranolol, dilevalol, esmolol, indenolol, labetolol, levobunolol, mepindolol, metipranolol, metoprolol, nadolol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, practolol, propranolol, sotalol, tertatolol, tilisolol, timolol, toliprolol.  Also includes substances which partly block the beta-receptors (eg labetalol). Oral propranolol for infantile haemangioma is classified here.	r2014
<b>C7B</b>	<b>BETA-BLOCKING AGENTS, COMBINATIONS</b>  Combinations of beta-blockers with calcium antagonists are classified in C8B2 and combinations with ACE inhibitors are classified in C9B2.	
<b>C7B1</b>	<b>Combinations with antihypertensives and/or diuretics</b>  Includes beta-blockers combined with drugs in group C2 (antihypertensives) or C3 (diuretics).	r2008
<b>C7B2</b>	<b>Combinations with other drugs of group C</b>  Includes beta-blockers combined with all other drugs in group C, excluding C2 (antihypertensives), C3 (diuretics), C8 (calcium antagonists) and C9 (ACE inhibitors and angiotensin II antagonists). For combinations with C10 substances, see C11.	r2008
<b>C7B3</b>	<b>Combinations with all other drugs except those of group C</b>  For combinations with substances in A10 (diabetes) see A10X1.	r2010

<b>C8</b>	<b>CALCIUM ANTAGONISTS</b>  Note: Calcium antagonists with cerebral activity (calcium overload blockers) are classified in group C4A2.  This group C8 includes eg amlodipine, aranidipine, benidipine, bepridil, diltiazem, felodipine, fendiline, gallopamil, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, nicardipine, nifedipine, nilvadipine, nisoldipine, nitrendipine, perhexiline, prenylamine, verapamil.	R1997
<b>C8A</b>	<b>CALCIUM ANTAGONISTS, PLAIN</b>	
<b>C8B</b>	<b>CALCIUM ANTAGONISTS, COMBINATIONS</b>	
<b>C8B1</b>	<b>Calcium antagonist combinations with antihypertensives (C2) and/or diuretics (C3)</b>	
<b>C8B2</b>	<b>Calcium antagonist/beta-blocker combinations</b>  In addition, the product can contain a diuretic.	r2008
<b>C8B3</b>	<b>Calcium antagonist combinations with all other drugs of group C except C2, C3, C7 and C9.</b>  For combinations with C10 substances, see C11.	r2008
<b>C8B4</b>	<b>Calcium antagonist combinations with all other drugs except those of group C</b>  For combinations with substances in A10 (diabetes) see A10X1.	r2010

<b>C9</b>	<b>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</b>	R1996
<b>C9A</b>	<b>ACE INHIBITORS, PLAIN</b>  Angiotensin-Converting-Enzyme inhibitors. It includes eg alacepril, benazepril, captopril, cilazapril, delapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril.	R1996
<b>C9B</b>	<b>ACE INHIBITORS, COMBINATIONS</b>	
C9B1	<b>ACE inhibitor combinations with antihypertensives (C2) and/or diuretics (C3)</b>	R1996
C9B2	<b>ACE inhibitor/beta-blocker combinations</b>  In addition, the product can contain a diuretic.	r2008
C9B3	<b>ACE inhibitor combinations with calcium antagonists (C8)</b>  In addition, the product can contain a diuretic.	r2008
C9B9	<b>ACE inhibitor combinations with all other drugs</b>  For combinations with C10 substances, see C11. For combinations with substances in A10 (diabetes), see A10X1.	r2010
<b>C9C</b>	<b>ANGIOTENSIN-II ANTAGONISTS, PLAIN</b>	I1996
<b>C9D</b>	<b>ANGIOTENSIN-II ANTAGONISTS, COMBINATIONS</b>  For combinations with C10 substances, see C11. Products in C9D2, C9D3 and C9D4 can also contain a diuretic substance. For example, an angiotensin-II antagonist plus an ACE inhibitor plus a diuretic is classified in C9D4.	r2010
C9D1	<b>Angiotensin-II antagonist combinations with antihypertensives (C2) and/or diuretics</b>  Includes products containing an angiotensin-II antagonist in combination with an antihypertensive substance (C2). In addition, the product can contain a diuretic.	I2008
C9D2	<b>Angiotensin-II antagonist combinations with beta-blockers</b>  Includes products containing an angiotensin-II antagonist in combination with a beta blocker. In addition, the product can contain a diuretic.	I2008

C9D3	<b>Angiotensin-II antagonist combinations with calcium antagonists</b>  Includes products containing an angiotensin-II antagonist in combination with a calcium antagonist. In addition, the product can contain a diuretic.	I2008
C9D4	<b>Angiotensin-II antagonist combinations with ACE inhibitors</b>  Includes products containing an angiotensin-II antagonist in combination with an ACE inhibitor. In addition, the product can contain a diuretic.	I2008
C9D9	<b>Angiotensin-II antagonist combinations with other drugs</b>  Includes products containing an angiotensin-II antagonist in combination with other drugs not specified in the other C9D combination classes or in the C9D guideline. For combinations with substances in A10 (diabetes) see A10X1.  Products containing angiotensin-II antagonists in combination with neprilysin inhibitors (eg sacubitril) are classified here.	r2016
C9X	<b>OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</b>	I1996

<b>C10</b>	<b>LIPID-REGULATING/ANTI-ATHEROMA PRODUCTS</b>  Excludes products intended for weight reduction.	r2025
<b>C10A</b>	<b>LIPID-REGULATING PRODUCTS</b>  Includes all products regulating cholesterol and triglycerides. Combinations with products of group C4 should be classified here. Combinations with oral antidiabetic substances are classified in A10X1.	r2025
C10A1	<b>Statins (HMG-CoA reductase inhibitors)</b>  Includes atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin.  Combinations of statins with ezetimibe are classified in C10C.	R2006
C10A2	<b>Fibrates</b>  Includes beclobrate, bezafibrate, ciprofibrate, clofibrate, clofibrade, etofibrate, fenofibrate, gemfibrozil, simfibrate.	I1997
C10A3	<b>Ion-exchange resins</b>  Includes cholestyramine, colestipol, polidexide.	I1997
C10A4	<b>PCSK9 inhibitors</b>  Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, eg alirocumab, evolocumab.	I2016
C10A9	<b>Lipid-regulating products, other</b>  Includes ezetimibe, probucol, tiadenol, pyridinolcarbamate and all other products excluding those in C10B.  Combinations of ezetimibe with statins or with bempedoic acid are classified in C10C.  Nicotinic acid derivatives if indicated in this area are classified here, eg acipimox.  Products containing volanesorsen for familial chylomicronaemia syndrome (FCS) are classified here.  Products containing evinacumab for homozygous familial hypercholesterolaemia are classified here.	r2025

<b>C10B</b>	<b>ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN</b> <p>This class includes products of natural origin used for the prevention and treatment of arteriosclerosis, eg omega-3 fatty acids, garlic preparations, lecithin.</p> <p>Products containing omega-3 fatty acids for the reduction of triglycerides and/or for the prevention and treatment of arteriosclerosis are classified here. Products containing omega-3 fatty acids for other conditions or for multiple uses are classified in V3X.</p>	r2021
<b>C10C</b>	<b>LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS</b> <p>Includes products containing two or more substances, all of which are lipid regulators. These are combinations of different types of lipid regulator in C10A. For example, products containing a statin in combination with nicotinic acid, or products containing a statin in combination with ezetimibe, are classified here.</p> <p>Products containing ezetimibe with bempedoic acid are classified here.</p> <p>Combinations of a statin with another statin are classified in C10A1. Combinations of a fibrate with another fibrate are classified in C10A2.</p> <p>Combinations of lipid regulators of natural origin with other lipid regulators of natural origin are classified in C10B.</p> <p>Combinations of a lipid regulating substance from C10A together with a substance from C10B (anti-atheroma preparations of natural origin) are also classified in C10C.</p> <p>Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class (C) are classified in A10X1. For example, a combination product containing pioglitazone with simvastatin is classified in A10X1.</p>	r2021



<b>C11</b>	<b>CARDIOVASCULAR MULTITHERAPY COMBINATION PRODUCTS</b>  Products containing cardiovascular substances in combination with oral antidiabetics where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1.	r2010
<b>C11A</b>	<b>LIPID-REGULATING CARDIOVASCULAR MULTITHERAPY COMBINATION PRODUCTS</b>  Includes products which are indicated for cardiovascular lipid disorders together with at least one other cardiovascular condition, eg hypertension.	R2006
<b>C11A1</b>	<b>Lipid-regulating cardiovascular multitherapy fixed combination products</b>  These products contain two or more substances together in a single dosage form, eg a single tablet, capsule etc.	I2006
<b>C11A2</b>	<b>Lipid-regulating cardiovascular multitherapy combi-pack combination products</b>  These products contain two or more active substances which are in separate dosage forms eg separate tablets, capsules, etc in one 'packaged' unit.	I2006

<b>D</b>	<b>DERMATOLOGICALS</b>	
<b>D1</b>	<b>ANTIFUNGALS, DERMATOLOGICAL</b>	
<b>D1A</b>	<b>ANTIFUNGALS, DERMATOLOGICAL</b>	
D1A1	<b>Topical dermatological antifungals</b>  Includes topical forms of preparations for fungal infections of the skin, whether in the form of plain antifungal preparations or in the form of combinations of antifungal compounds with antibacterial compounds. Excludes topical corticosteroid combinations (see D7B) and topical scalp antifungals which are in D1A3.	r2009
D1A2	<b>Systemic dermatological antifungals</b>  Includes only griseofulvin-type products which are used for the treatment of dermatological conditions. All other systemic forms of antifungals which are used for dermatological purposes are classified in J2A.	R1999
D1A3	<b>Topical scalp antifungals</b>  Includes shampoos, lotions, creams, gels etc containing antifungal substances eg ketoconazole.	I1998

<b>D2</b>	<b>EMOLLIENTS, PROTECTIVES</b>	
<b>D2A</b>	<b>EMOLLIENTS, PROTECTIVES</b>  Includes skincare products and emollients (with or without active therapeutic agents), protectives, suntan irradiation preparations, etc. Products containing afamelanotide for erythropoietic protoporphyria (EPP) are classified here.  Products containing sofipironium bromide for hyperhidrosis are classified here. Drying powders for hyperhidrosis are also classified here.  This class also includes wound coverings containing emollients. Other wound coverings are classified according to any ingredients they contain eg D3A, D6A, D8A.	r2026

<b>D3</b>	<b>WOUND HEALING AGENTS</b>	
<b>D3A</b>	<b>WOUND HEALING AGENTS</b>	R2002
D3A1	<b>Skin/dermal/epidermal/equivalents</b>	R2006
	Includes bioengineered and living human skin equivalents, and also skin growth factors	
D3A9	<b>All other wound healing agents</b>	r2026
	Includes topical preparations for open wounds, ulcers, etc. Wound healing topical vitamins and topical anabolic steroids should be included in this group when they cannot be classified satisfactorily elsewhere. Combinations of enzymes with anti-infectives used for wound healing are classified here. This group also includes skin regeneratives and stimulants, topical extracts, eg of camomile, unspecified suspensions and topical preparations for prophylaxis and therapy of mastitis. Topical oestrogens when used for gynaecological purposes are classified in G2F. Topical haemostyptics including those for dental use are classified here. Antibiotic-containing collagen implants (eg sponges) are classified here.	
	Products containing diperoxochloric acid for the treatment of diabetic foot ulcer are classified here.	
	Products containing beremagene geperpavec for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) are classified here.	

<b>D4</b>	<b>ANTI-PRURITICS, INCLUDING TOPICAL ANTIHISTAMINES, ANAESTHETICS, ETC</b>	
<b>D4A</b>	<b>ANTI-PRURITICS, INCLUDING TOPICAL ANTIHISTAMINES, ANAESTHETICS, ETC</b>	r2023
	Included in this group are topical preparations for the relief of itching, insect bites, etc which may contain antihistamines, anaesthetics, etc but excluding corticosteroid combinations (see D7B). Systemic anti-pruritics are classified in R6A if they contain antihistamines. Oral nalfurafine is classified here. Products containing nemolizumab for pruritus associated with atopic dermatitis are classified in D5X.	
	Local anaesthetics for use in surgical or medical procedures are in N1B.	

<b>D5</b>	<b>NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b> <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p>	r2019
<b>D5A</b>	<b>TOPICAL ANTIPSORIASIS PRODUCTS</b> <p>Includes products containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, salicylic acid for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar or salicylic acid for psoriasis are classified here. These products may also be for other inflammatory skin conditions.</p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p>	r2019
<b>D5B</b>	<b>SYSTEMIC ANTIPSORIASIS PRODUCTS</b> <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for psoriasis and also other non-skin conditions, eg arthritis, are classified in L4C. Psoriatic arthritis is defined as a skin condition.</p> <p>Apremilast is classified here if only for psoriatic skin conditions. Products containing apremilast for multiple conditions are classified in L4X.</p> <p>Products containing deucravacitinib for psoriasis are classified here.</p> <p>Products containing bimekizumab for psoriatic skin conditions only are classified here. Products containing bimekizumab for both skin conditions and non-skin conditions, eg axial spondyloarthritis, ankylosing spondylitis etc, are classified in L4C.</p>	r2025

<b>D5X</b>	<p><b>OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p>Products containing nemolizumab for pruritus associated with atopic dermatitis are classified here.</p> <p>Products containing remibrutinib for chronic spontaneous urticaria (CSU) are classified here.</p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. Products containing topical fluorouracil for actinic keratosis are classified in L1B. Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8.</p> <p>Products containing dupilumab for atopic dermatitis only are classified here. Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</p> <p>Products containing JAK inhibitors, eg ruxolitinib, for atopic dermatitis and/or other inflammatory skin disorders, eg alopecia areata, vitiligo, etc, are classified here. Products containing JAK inhibitors for inflammatory skin disorders and other non-dermatological conditions are classified in L4D.</p>	r2026
------------	--	-------

<b>D6</b>	<b>TOPICAL ANTIBACTERIALS AND ANTIVIRALS</b>	r2009
<b>D6A</b>	<b>TOPICAL ANTIBACTERIALS</b>  Includes all topical antibacterials and antibacterial combinations except those classified in D1A1, D1A3, D3A, D7B1, or D10A. Topical antibacterials when in combination with wound healing agents, are classified in D3A9. Antiseptics and disinfectants are classified in D8A.	r2009
<b>D6B</b>	Out of use; can be reused.	
<b>D6C</b>	Out of use; can be reused.	
<b>D6D</b>	<b>TOPICAL VIRAL INFECTION PRODUCTS</b>  For systemic treatment of viral conditions, see J5.	r2008
D6D1	<b>Topical antivirals</b>  Includes topical forms of antivirals eg acyclovir, idoxuridine and podophyllotoxin.	I1998
D6D9	<b>Other topical products used in viral infections</b>  Includes products, eg those containing carbenoxolone, used for the symptomatic treatment of viral infections such as herpes simplex. Other products not containing podophyllotoxin used to treat external condylomata acuminata (genital warts) are classified here, eg fluorouracil injectable gel.  Products containing topical imiquimod for actinic keratosis, genital warts and basal cell carcinoma are classified here.	r2016

<b>D7</b>	<b>TOPICAL CORTICOSTEROIDS</b>	
<b>D7A</b>	<b>PLAIN TOPICAL CORTICOSTEROIDS</b>  Includes all dermatological products containing one or more corticosteroids and no other active ingredient. Topical anabolic steroids are classified in D3A.	
<b>D7B</b>	<b>TOPICAL CORTICOSTEROID COMBINATIONS</b>  Includes all dermatological products containing corticosteroids in combination with one or more active ingredients, except those classified in D5A or D10A. It should be noted that, in the classification, the term antibacterial includes antibiotics, sulphonamides and antiseptics.  Also the basic criterion which determines the classification for products of this nature is the type of anti-infective product (antibacterial, antifungal or combination of the two) which is in combination with the corticosteroid. If the product in combination with the corticosteroid is not an anti-infective the product should be classified in D7B4.	r2019
D7B1	<b>Combinations of corticosteroids with antibacterials</b>  If, in addition to corticosteroid and antibacterial or bacteriostatic (including antiseptic) agents (eg hexachlorophene) the product also contains non-anti-infective ingredients such as an antihistamine, local anaesthetic, oestrogen, urea, etc then it should still be classified in D7B1.	r2019
D7B2	<b>Combinations of corticosteroids with antifungals</b>  If, in addition to corticosteroids and antifungal agents, the product also contains non-anti-infective ingredients such as an antihistamine, local anaesthetic, urea, etc then it should still be classified in D7B2.	
D7B3	<b>Combinations of corticosteroids with antibacterials and antifungals</b>  It should be noted that if a product contains not only corticosteroid + antibacterial + antifungal but also additional ingredients such as urea, an antihistamine, etc it should still be classified in D7B3.	
D7B4	<b>Other corticosteroid combinations</b>  Includes combinations of corticosteroids with all other types of products including, for example, antihistamines, local anaesthetics, etc. Combinations of corticosteroids with coal tar or salicylic acid and for psoriasis are classified in D5A; these products may also be for other inflammatory skin conditions as well as psoriasis.	r2019

<b>D8</b>	<b>ANTISEPTICS AND DISINFECTANTS</b>	
<b>D8A</b>	<b>ANTISEPTICS AND DISINFECTANTS</b>  This group includes all dermatological antiseptic preparations for human use not classified in any of the following:  D3A - Wound healing agents D6A - Topical antibacterials D6D - Topical viral infection products D7B – Combinations of corticosteroids with antibacterials D10A - Anti-acne preparations P3 – Ectoparasitocides  This class also includes soaps and shampoos with antiseptic and/or disinfectant properties.  Antiseptics for non-human use are classified in V5A  Products used for both human and non-human use are classified here.  In the German hospital market only, the D8A class is split to the fourth level.	r2009
D8A1	<b>Antiseptics and disinfectants, excluding hand products</b>	I2000
D8A2	<b>Hand antiseptics and disinfectants</b>	I2000

<b>D9</b>	Out of use; can be reused. Discontinued in 1991, and products classified according to their indication.	
-----------	---	--



<b>D10</b>	<b>ANTI-ACNE PREPARATIONS</b>	
<b>D10A</b>	<b>TOPICAL ANTI-ACNE PREPARATIONS</b>  Includes all topical dermatological preparations indicated for the treatment of acne or rosacea which may contain corticosteroids, antibacterials, etc.  Also includes soaps and shampoos which are specifically indicated for the treatment of acne.  Products used to physically remove blackheads, eg adhesive strips etc, are classified in D11A.	r2025
<b>D10B</b>	<b>ORAL ANTI-ACNE PREPARATIONS</b>  Includes special hormonal preparations indicated exclusively for the treatment of acne, and also antibacterials and other products indicated for the exclusive treatment of acne. Products that are indicated for both oral contraception and acne are classified in G3A.	r2017

<b>D11</b>	<b>OTHER DERMATOLOGICAL PREPARATIONS</b>	
<b>D11A</b>	<b>OTHER DERMATOLOGICAL PREPARATIONS</b>  Includes medicated shampoos, medicated soaps, scalp lotions (other than in D5A, D1A3, D7B, D8A, D10A). Products for pigmentation disorders, androgenetic alopecia, systemic products for the treatment of dermatological conditions, anti-corn agents (plasters, tinctures, including products with salicylic acid especially formulated for warts, corns and calluses etc), products to reduce and improve the appearance of scars, and hair-restorers are classified in this group.  Products containing finasteride 1mg and for androgenetic alopecia are classified here. Products containing finasteride 5mg and for BPH are classified in G4C3.  Products containing JAK inhibitors, eg ruxolitinib, for atopic dermatitis and/or other inflammatory skin disorders, eg alopecia areata, vitiligo, etc, are classified in D5X.  Products containing extracts of chamomile are classified in D3A.  Psoralens, when used for inflammatory conditions, are classified in D5.  Products containing sirolimus gel for tuberous sclerosis are classified here.  Products used to physically remove blackheads, eg adhesive strips etc, are classified here.	r2025

<b>G</b>	<b>GENITO-URINARY SYSTEM AND SEX HORMONES</b>	
<b>G1</b>	<b>GYNAECOLOGICAL ANTI-INFECTIVES</b>	
	The need for a systematic approach to classifying combination products (ie those containing two or more different gynaecological anti-infectives) has led to the adoption of a hierarchical system with a G1A (trichomonacide) ingredient taking precedence over a G1B (antifungal), G1B over G1C, etc.	
<b>G1A</b>	<b>TRICHOMONACIDES</b>	r2020
	Includes metronidazole, nifuratel, nimorazole, ornidazole, secnidazole, tinidazole. Products for both trichomoniasis and amoebiasis are classified here.	
<b>G1A1</b>	<b>Systemic trichomonacides</b>	R2004
	Includes all oral solid, suspension and oral liquid forms of metronidazole and other trichomonacides.	
<b>G1A2</b>	<b>Topical trichomonacides</b>	
	Includes vaginal tablets and vaginal suppositories of metronidazole and other trichomonacides. Rectal suppositories to be classified in J8.	
<b>G1A3</b>	<b>Combined forms of trichomonacides</b>	
	Includes those packs of metronidazole and other trichomonacides which contain both systemic and topical forms for the treatment of gynaecological conditions eg Flagyl Compak.	
<b>G1B</b>	<b>GYNAECOLOGICAL ANTIFUNGALS</b>	R1999
	Includes antifungal products indicated only for gynaecological conditions. These can be specific gynaecological forms, eg ovules, or systemic forms. Excluded are antifungals for dermatological use which are classified in D1A or J2A and antifungals for systemic infections which are classified in J2A. If a product is indicated for both systemic and gynaecological infections, then it is classified in J2A.	
<b>G1C</b>	<b>GYNAECOLOGICAL ANTIBACTERIALS</b>	r2009
	Includes those products indicated for gynaecological conditions. Excluded are antibacterials for dermatological use which are classified in D6A, and general systemic antibacterials which are classified in J1 and J3.	

<b>G1D</b>	<b>GYNAECOLOGICAL ANTISEPTICS</b> <p>Includes those products indicated for gynaecological conditions. Excluded are antiseptics for dermatological use which are classified in D8A and antiseptics for non-human use, which are classified in V5A.</p> <p>Products containing dapivirine (vaginal ring) for the prevention of HIV transmission are classified here.</p>	r2021
------------	--	-------

<b>G2</b>	<b>OTHER GYNAECOLOGICALS</b>	
<b>G2A</b>	<b>UTEROTONIC PRODUCTS</b>  Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage. Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	r2019
<b>G2B</b>	<b>TOPICAL CONTRACEPTIVES</b>	
<b>G2C</b>	Out of use; can be reused from 2000.	D1997
<b>G2D</b>	<b>PROLACTIN INHIBITORS</b>  This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc.  Products containing bromocriptine: for multiple conditions are classified here: for diabetes mellitus only are classified in A10X9: for acromegaly only are classified in H1C2: for Parkinson's disease only are classified in N4A.	r2026
<b>G2E</b>	<b>LABOUR INHIBITORS</b>  This group includes products acting as labour inhibitors eg ritodrine.	I1997
<b>G2F</b>	<b>TOPICAL SEX HORMONES</b>  This group includes all topical hormones and/or steroids indicated for gynaecological conditions. Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C.  Products containing progesterone in topical form (such as gel) for relief of breast pain are classified here.	r2021
<b>G2X</b>	<b>OTHER GYNAECOLOGICAL PRODUCTS</b>	I1997
<b>G2X1</b>	<b>Gynaecological antispasmodics</b>  This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	I1997

G2X9	<p><b>Other gynaecologicals</b></p> <p>Specific products included in this class are non-hormonal anti-inflammatories (eg benzydamine) which are indicated specifically to treat gynaecological conditions. Includes lubricants for intimate vaginal use only. Includes products (lactogogues) for the promotion of milk production.</p> <p>Products containing paroxetine (7.5mg daily) or fezolinetant, and indicated for menopausal vasomotor symptoms are classified here.</p> <p>Products containing bremelanotide or flibanserin and indicated for hypoactive sexual desire disorder (HSDD) in women are classified here.</p> <p>Products containing omega-3 fatty acids for use as supplements during pregnancy and when breastfeeding are classified in V3X.</p>	r2024
------	---	-------

<b>G3</b>	<b>SEX HORMONES AND PRODUCTS WITH SIMILAR DESIRED EFFECTS, SYSTEMIC ACTION ONLY</b>  Sex hormones used as cytostatics must be classified in L2.	
<b>G3A</b>	<b>HORMONAL CONTRACEPTIVES, SYSTEMIC</b>  Contraceptive transdermal patches are classified in G3A9.  Products that are indicated for both oral contraception and acne are classified in G3A.	r2017
G3A1	<b>Monophasic preparations with &lt; 50 mcg oestrogen</b>	I1994
G3A2	<b>Monophasic preparations with ≥ 50 mcg oestrogen</b>	I1994
G3A3	<b>Biphasic preparations</b>	I1994
G3A4	<b>Triphasic preparations</b>  Quadriphasic products are included in G3A4.	r2011
G3A5	<b>Progestogen-only preparations, oral</b>  Includes packs indicated for hormonal contraception only.	I1994
G3A6	<b>Emergency contraceptives, systemic</b>  Includes products containing eg levonorgestrel, mifepristone (10-25mg), ulipristal, when indicated for post-coital emergency contraception only.  Products containing mifepristone and indicated as abortifacients alone, or with other indications, are classified in G3X. Products containing ulipristal and indicated for uterine fibroids are classified in G3X.	I2015
G3A9	<b>Other hormonal contraceptives, systemic</b>  Includes injectable products (eg Depo Provera when used as a contraceptive), implants (eg Norplant), vaginal rings containing hormones, and IUDs containing hormones. Contraceptive transdermal patches are classified here.  Products for emergency contraception only are classified in G3A6. Products containing mifepristone are classified in G3A6 if indicated for emergency contraception and in G3X if indicated as abortifacients alone or with other indications.  Quadriphasic products are included in G3A4.	r2015

<b>G3B</b>	<b>ANDROGENS, EXCLUDING G3E, G3F</b>	R1997
<b>G3C</b>	<b>OESTROGENS, EXCLUDING G3A, G3E, G3F</b>  Oestrogens in combination with non-hormonal substances are classified here.  Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified here.  Includes transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect.  Products containing parenteral conjugated oestrogens for uterine bleeding are classified in B2G.	r2019
<b>G3D</b>	<b>PROGESTOGENS, EXCLUDING G3A, G3F</b>  Products containing progesterone in topical form (such as gel) for the relief of breast pain are classified in G2F.	r2021
<b>G3E</b>	<b>ANDROGEN WITH FEMALE HORMONE COMBINATIONS</b>	
<b>G3F</b>	<b>OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A</b>	
<b>G3G</b>	<b>GONADOTROPHINS, INCLUDING OTHER OVULATION STIMULANTS</b>	
<b>G3H</b>	Out of use; can be reused from 2009.	D2006
<b>G3J</b>	<b>SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS)</b>  Included in this class are products that contain selective oestrogen receptor modulators, eg lasofoxifene, raloxifene. When primarily indicated for cancer, SERMs are classified in L2.  Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified in G3C.	r2015

<b>G3X</b>	<p data-bbox="312 170 1110 203"><b>OTHER SEX HORMONES AND SIMILAR PRODUCTS</b></p> <p data-bbox="312 248 1401 394">Includes mammary extracts and other hormonal preparations for sexual disorders eg placenta extracts. Cyproterone acetate (tab 10mg) is classified here; higher doses (50 mg) and injectable forms are in L2B2 when used as cytostatics. Includes products containing tibolone.</p> <p data-bbox="312 432 1401 539">Products containing mifepristone are classified here if indicated as abortifacients alone, or with other indications, or in G3A6 if indicated for emergency contraception.</p> <p data-bbox="312 577 1401 651">Products containing ulipristal are classified here if indicated for uterine fibroids, or in G3A6 if indicated for emergency contraception.</p> <p data-bbox="312 689 1401 835">Products containing relugolix or elagolix in combination with oestrogens and progestogens for uterine fibroids are classified here. Products containing relugolix or elagolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix for cancer are classified in L2B9.</p>	r2022
------------	--	-------



<b>G4</b>	<b>UROLOGICALS</b>	
<b>G4A</b>	<b>URINARY ANTI-INFECTIVES AND ANTISEPTICS</b>	
G4A1	<b>Urinary antibacterials</b> <p>This group includes those products containing an antibacterial where the only indication is for urinary tract infections. Sulphonamides are generally classified in J3 and other antibacterials in J1. All trimethoprim formulations are classified in J1E. Combinations with halogenated or non-halogenated quinolones are classified in G4A2.</p>	r2009
G4A2	<b>Urinary non-halogenated quinolones</b> <p>Includes products containing non-halogenated quinolones which are only indicated for urinary tract infections. Systemic products containing halogenated quinolones (plain) are classified in J1G. Combinations of halogenated or non-halogenated quinolones with other substances (including antibacterials) and indicated for urinary tract infections are classified in G4A2.</p>	R2009
G4A3	Out of use; can be reused from 2010.	D2007
G4A9	<b>Other urinary antiseptics</b> <p>Includes such products as nitrofurantoin and methenamine. Irrigating solutions are classified in Group K.</p>	I2007
<b>G4B</b>	Out of use; can be reused from 2010.	D2007
<b>G4C</b>	<b>BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS</b>	R2007
G4C1	Out of use	D2012
G4C2	<b>BPH alpha-adrenergic antagonists, plain</b> <p>Includes products containing alpha-adrenergic antagonists, such as alfuzosin, tamsulosin. Products containing terazosin, for BPH or hypertension, are classified here. Products containing doxazosin are classified in C2A2. Products containing indoramin, for BPH or hypertension, are classified in C2A2, or in N2C9 if indicated for migraine.</p>	r2015
G4C3	<b>BPH 5-alpha testosterone reductase inhibitors (5-ARI), plain</b> <p>Includes products containing 5-alpha testosterone reductase inhibitors (5-ARI), such as dutasteride and finasteride.</p> <p>Products containing finasteride 5mg and for BPH are classified here. Products containing finasteride 1mg and for androgenetic alopecia are classified in D11A.</p>	r2024

G4C4	<b>BPH alpha-antagonists and 5-ARIs, combinations</b>  Includes products containing an alpha-adrenergic antagonist and a 5-alpha testosterone reductase inhibitor. If one or more additional substances are included, then the product is classified in G4C7.	I2012
G4C7	<b>BPH 5-ARIs and/or alpha-antagonists in combination with other substances</b>  Includes products containing eg tamsulosin with tolterodine, tamsulosin with a substance of natural origin, or tamsulosin with corticosteroids.	r2020
G4C8	Out of use	D2012
G4C9	<b>BPH products, other</b>  Includes products of herbal or animal origin, as well as homeopathic products, for BPH. Products containing mepartricine, <i>Serenoa repens</i> , or <i>Pygeum africanum</i> are classified in G4C9 if indicated for BPH. This class also includes herbal products for improving prostatic health.  Products containing PDE5 inhibitors for BPH only are classified here.	r2021
<b>G4D</b>	<b>URINARY INCONTINENCE PRODUCTS</b>	I2007
G4D4	<b>Urinary incontinence products</b>  This group includes preparations for urinary incontinence eg those containing duloxetine, flavoxate, oxybutynin, tolterodine. Products of natural origin and homeopathic products are classified in G4D8.	I2007
G4D8	<b>Urinary incontinence products of natural origin</b>  Includes products of herbal or animal origin, as well as homeopathic products, for urinary incontinence. Also includes collagen injections for incontinence.	I2007

<b>G4E</b>	<b>ERECTILE DYSFUNCTION PRODUCTS</b>  Includes products for the treatment of male impotence.	r2015
G4E1	<b>Erectile dysfunction products, PDE5 inhibitors</b>  Includes products containing PDE5 inhibitors, eg avanafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, etc, when indicated for the treatment of erectile dysfunction.  Products containing sildenafil (oral 20mg) or tadalafil and indicated for pulmonary arterial hypertension (PAH) only are classified in C6B2. Products containing tadalafil and indicated for both erectile dysfunction and PAH are classified here.  Products indicated for erectile dysfunction that contain a PDE5 inhibitor in combination with other substances are classified here.  Products containing a PDE5 inhibitor in combination with other substances, and indicated for erectile dysfunction as well as other conditions, are classified here.  Products containing PDE5 inhibitors for BPH only are classified in G4C9.	r2021
G4E9	<b>Erectile dysfunction products, others</b>  Includes products containing eg alprostadil, apomorphine, etc when indicated for the treatment of erectile dysfunction. Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified here. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X.  In addition, includes products that contain substances of natural origin for erectile dysfunction.  Products that do not contain a PDE5 inhibitor and are indicated for erectile dysfunction, together with other urological conditions, are classified here.	r2021

<b>G4X</b>	<b>ALL OTHER UROLOGICAL PRODUCTS</b> <p>Includes products containing local anaesthetics used specifically for premature ejaculation.</p> <p>Products for erectile dysfunction are classified in G4E. Products for both erectile dysfunction and other urological conditions are also classified in G4E. Products for improving general sexual performance (not specifically erectile dysfunction) are classified here.</p> <p>Products containing sibeprenlimab or sparsentan for kidney conditions, eg IgA nephropathy, are classified here.</p> <p>Products containing oral budesonide for treatment of IgA nephropathy only are classified here.</p> <p>Products containing complement inhibitors: for kidney conditions only, eg IgA nephropathy, are classified here; for paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for multiple conditions are classified in L4X.</p> <p>Products containing lumasiran for primary hyperoxaluria type 1 are classified here.</p> <p>Products containing voclosporin for lupus nephritis are classified here.</p>	r2026
------------	---	-------

<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES)</b>	
<b>H1</b>	<b>PITUITARY AND HYPOTHALAMIC HORMONES</b>	R1995
<b>H1A</b>	<b>ACTH</b>  ACTH and synthetic analogues.	
<b>H1B</b>	Out of use; can be reused.	
<b>H1C</b>	<b>HYPOTHALAMIC HORMONES</b>	R2003
H1C1	<b>Gonadotrophin-releasing hormones</b>  Includes eg buserelin, deslorelin, gonadorelin, goserelin, nafarelin, leuprorelin, triptorelin, when not used as cytostatics. When these substances are used as cytostatics, they are classified in L2A3. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions, are classified in L2A3.	r2020
H1C2	<b>Antigrowth hormones</b>  Products for acromegaly are classified here. Lanreotide, octreotide and somatostatin are classified here. Somatostatin, when used as a haemostyptic, is classified in B2G. Growth hormone antagonists, such as pegvisomant, are classified here.	r2020
H1C3	<b>Antigonadotrophin-releasing hormones</b>  Cetrorelix and ganirelix are classified here. Products containing relugolix or elagolix (single ingredient) for uterine fibroids or endometriosis are classified here. Products containing relugolix or elagolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X. Products containing relugolix for cancer are classified in L2B9.	r2022

<b>H2</b>	<b>SYSTEMIC CORTICOSTEROIDS</b>	
<b>H2A</b>	<b>SYSTEMIC CORTICOSTEROIDS, PLAIN</b>	
	Includes all systemic products containing one or more corticosteroid(s) and no other active ingredient, with or without lignocaine.	
H2A1	<b>Injectable corticosteroids, plain</b>	R1993
H2A2	<b>Oral corticosteroids, plain</b>	r2025
	Products containing corticosteroids for eosinophilic oesophagitis are classified in A7E2.	
	Products containing oral budesonide for treatment of IgA nephropathy only are classified in G4X.	
H2A3	<b>Other systemic corticosteroids, plain</b>	r2017
	Includes suppositories. Corticosteroids to treat inflammatory intestinal disorders are classified in A7E2.	
<b>H2B</b>	<b>SYSTEMIC CORTICOSTEROID COMBINATIONS</b>	r2020
	Systemic products containing one or more corticosteroid(s) and one or more other active ingredient(s) (eg antihistamine). Also includes extracts containing natural corticosteroids, but excluding products classified in the following groups:	
	A7E2 – Intestinal anti-inflammatory agents	
	H4X – Liver extracts with small doses of corticosteroids (mainly in Italy).	
	G3X - Gland extracts (mammary, placenta, etc) and corticoid extracts mainly indicated for sexual disorders.	
	G4C7 – Corticosteroids with alpha-adrenergic antagonists.	
	M1B - Corticosteroids with anti-inflammatory agents, analgesics, muscle relaxants, etc.	
	R1B – Systemic nasal preparations	
	R3D, R3F, R3L3 - Anti-asthmatic inhalants acting topically on the bronchioles.	

<b>H3</b>	<b>THYROID THERAPY</b>	
<b>H3A</b>	<b>THYROID PREPARATIONS</b>  Includes all natural thyroid extracts and synthetic analogues for the treatment of hypothyroidism.	
<b>H3B</b>	<b>ANTI-THYROID PREPARATIONS</b>  Products for treatment of hyperthyroidism and similar disorders.	
<b>H3C</b>	<b>IODINE THERAPY</b>  Includes all systemic iodine preparations with multiple indications. This group does not include dermatologicals or drug combinations with specific indications (eg rheumatism).	

<b>H4</b>	<b>OTHER HORMONES</b>	
<b>H4A</b>	<b>CALCITONINS</b>  This group includes all calcitonin products (pork, salmon, eel and synthetic).	
<b>H4B</b>	<b>GLUCAGON</b>	
<b>H4C</b>	<b>GROWTH HORMONES</b>  Includes products for growth conditions and also for AIDS wasting conditions. Products containing anamorelin for cachexia are classified here. Products containing lonapegsomatropin or somatogon are classified here.	r2023
<b>H4D</b>	<b>ANTIDIURETIC HORMONES</b>  This group includes argipressin, desmopressin, lypressin, ornipressin, vasopressin.	
<b>H4E</b>	<b>PARATHYROID HORMONES AND ANALOGUES</b>  Includes parathyroid hormone analogues, teriparatide.	I2008
<b>H4F</b>	<b>ANTIPARATHYROID PRODUCTS</b>  Includes products containing eg cinacalcet, doxercalciferol, falecalcitriol, maxacalcitol, paricalcitol, when they are indicated for secondary hyperparathyroidism. Products containing vitamin D or its analogues with multiple indications are classified in A11C2.	r2014
<b>H4G</b>	<b>ANTICORTICOSTEROID PRODUCTS</b>  Products containing anticorticosteroids, eg ketoconazole, levoketoconazole, mifepristone, osilodrostat, trilostane etc for Cushing's syndrome only are classified here.  Products containing ketoconazole for other conditions are classified elsewhere.  Products containing mifepristone for contraception or gynaecological conditions are classified in G3A6 or G3X.  Products containing pasireotide for both Cushing's syndrome and acromegaly are classified in H1C2. Products containing metyrapone for both treatment and diagnosis of Cushing's syndrome are classified in T2X9. Products containing anticorticosteroids for diuresis, for example eplerenone, spironolactone etc, are classified in C3A.	I2025
<b>H4V</b>	Out of use; can be reused from 2011.	D2008



<b>H4X</b>	<b>OTHER HORMONES AND PREPARATIONS WITH SIMILAR ACTIONS</b>  Products containing melatonin only and indicated for sleep rhythm disturbances are classified here. Prolonged-release melatonin indicated for primary insomnia is classified in N5B1. Products for insomnia that contain a sedative/hypnotic plus melatonin are classified in N5B in the appropriate subclass (N5B2, N5B4 or N5B5).	r2009
------------	--	-------

<b>J</b>	<b>GENERAL ANTI-INFECTIVES SYSTEMIC</b>  Systemic anti-infectives for the treatment of stomatological conditions are classified in J.	R2006
<b>J1</b>	<b>SYSTEMIC ANTIBACTERIALS</b>  The need for a systematic approach to classifying combination products (ie those containing two or more different antibacterials) has led to the adoption of a hierarchical system with a J1A (tetracycline) ingredient taking precedence over a J1B (chloramphenicol), J1B over J1C, etc, with the exception of combinations of products in J1K-P, J1X with other antibacterials, in which case the products in J1K-P, J1X should take precedence. Within J1K-P, J1X the same hierarchical system is used, ie a J1K ingredient takes precedence over J1L, J1L over J1M, etc.  Antibacterials indicated only for bacterial intestinal infections are classified in A7A.	r2017
<b>J1A</b>	<b>TETRACYCLINES AND COMBINATIONS</b>  Includes all systemic preparations with a tetracycline, plain or in combination with other anti-infectives, except in combination with a product in J1K-P, J1X or a sulphonamide (J3A).	R1997
<b>J1B</b>	<b>CHLORAMPHENICOL AND COMBINATIONS</b>  Includes all systemic preparations with chloramphenicol, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), products in J1K-P, J1X and sulphonamides (J3A).	R1997
<b>J1C</b>	<b>BROAD SPECTRUM PENICILLINS</b>  Includes all systemic penicillin derivatives which are used as broad spectrum antibacterials, plain or in combination with other anti-infectives except in combination with tetracyclines (J1A), chloramphenicols (J1B), products in J1K-P, J1X and sulphonamides (J3A). Combinations with fosfomycin should, however, be included in this class. Thus J1C includes amoxycillin, ampicillin, esters and derivatives of ampicillin such as azlocillin, epicillin, hetacillin, metampicillin, pivampicillin, talampicillin, bacampicillin and ciclacillin. Azidocillin should be classified in J1H and carbenicillin and similar in J1L.	r2009
J1C1	<b>Oral broad spectrum penicillins</b>  Also included are suppository presentations.	
J1C2	<b>Injectable broad spectrum penicillins</b>	

<b>J1D</b>	<b>CEPHALOSPORINS</b>  Includes all systemic cephalosporins, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), products in J1K-P, J1X and sulphonamides (J3A). Combinations with phosphonomycin should, however, be included in this class.	R1997
J1D1	<b>Oral cephalosporins</b>  Also included are suppository presentations.	
J1D2	<b>Injectable cephalosporins</b>	
<b>J1E</b>	<b>TRIMETHOPRIM AND SIMILAR FORMULATIONS</b>  Includes systemic trimethoprim formulations, eg Bactrim/Septrin, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D) and products in J1K-P, J1X. Trimethoprim combinations specifically formulated for respiratory infections, eg in combination with expectorants, are classified in R5B.	r2025
<b>J1F</b>	<b>MACROLIDES AND SIMILAR TYPES</b>  Includes all systemic macrolides, including erythromycin, spiramycin, oleandomycin, triacetyloleandomycin, kitasamycin, lincomycin and clindamycin, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D), trimethoprim combinations (J1E), products in J1K-P, J1X and sulphonamides (J3A). Also includes streptogramins.	R2003
<b>J1G</b>	<b>FLUOROQUINOLONES</b>  This group includes norfloxacin and similar quinolone antibacterials such as fleroxacin, gatifloxacin, grepafloxacin, ofloxacin, pefloxacin and sparfloxacin. Rosoxacin is also included. Excluded are combinations with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D), trimethoprim formulations (J1E), macrolides (J1F), aminoglycosides (J1K), carbenicillin and similar (J1L), rifampicin/rifamycin (J1M), other beta-lactam antibacterials (J1P), and the miscellaneous antibacterials of J1X. Includes all systemic products containing halogenated quinolones even if only indicated for urinary tract infections. Combinations of halogenated quinolones with other substances and indicated for urinary tract infections are classified in G4A2.	R2009
J1G1	<b>Oral fluoroquinolones</b>  Also included are suppository presentations.	r2018
J1G2	<b>Injectable fluoroquinolones</b>	I1997

J1G9	<b>Other fluoroquinolones</b>  Includes inhaled forms of levofloxacin. Suppository forms of fluoroquinolones are classified in J1G1.	I2018
J1H	<b>MEDIUM AND NARROW SPECTRUM PENICILLINS</b>	
J1H1	<b>Plain medium and narrow spectrum penicillins</b>  Includes all penicillins (natural and semi-synthetic) except broad spectrum penicillins in J1C, carbenicillin, carindacillin and similar in J1L, or combinations in J1A-J1F, J1K-P, J1X and J3A. Azidocillin is included in this group.	R1997
J1H2	<b>Penicillin/streptomycin combinations</b>	
J1J	Out of use; can be reused.	
J1K	<b>AMINOGLYCOSIDES</b>  Includes all systemic aminoglycosides, plain or in combination with other anti-infectives, except in combination with sulphonamides (J3A). Includes bone cements containing aminoglycosides.	R2006
J1L	<b>CARBENICILLIN AND SIMILAR TYPES</b>  Includes carbenicillin, carindacillin and similar types, plain or in combination with other anti-infectives, except in combination with aminoglycosides (J1K) and sulphonamides (J3A).	R2007
J1M	<b>RIFAMPICIN/RIFAMYCIN</b>  Includes all rifampicins/rifamycins except where used primarily as tuberculostatics (J4A) and except when combined with products in J1K, J1L and J3A.	
J1N	Out of use; can be re-used from 1997	D1994
J1P	<b>OTHER BETA-LACTAM ANTIBACTERIALS, EXCLUDING PENICILLINS, CEPHALOSPORINS</b>	I1997
J1P1	<b>Monobactams</b>  Includes aztreonam.	I1997
J1P2	<b>Penems and carbapenems</b>  Includes imipenem and combinations of imipenem with cilastatin. Also includes ertapenem, meropenem.	r2008

J1P3	<b>Carbacephems</b>  Includes loracarbef.	I1997
J1P9	<b>All other beta-lactam antibacterials</b>	I1997
J1X	<b>OTHER ANTIBACTERIALS</b>  Includes all other systemic antibacterials which do not fit into J1A-J1P or J3A. Combinations with products in J1K, J1L, J1M, J1P, and J3A are classified in these groups respectively.	R2006
J1X1	<b>Glycopeptide antibacterials</b>  Includes teicoplanin, vancomycin. Products containing vancomycin (oral forms) for intestinal infections are classified in A7A.	r2017
J1X2	<b>Polymyxins</b>  Includes colistin, polymyxin. These substances, if mainly indicated as antidiarrhoeals, are classified in A7A.	I1994
J1X9	<b>All other antibacterials</b>  Includes all systemic antibacterials which do not fit into J1A-J1X2, eg daptomycin, fosfomycin, fusidic acid, linezolid, novobiocin, plain sulbactam, pristinamycin, spectinomycin, and tigecycline. Formulations of fosfomycin with broad spectrum penicillins are in J1C and formulations with cephalosporins are in J1D.	r2020

<b>J2</b>	<b>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</b>	
<b>J2A</b>	<b>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</b>  Includes all systemic forms of antifungal products which are used for systemic and/or dermatological conditions. However griseofulvin-type products are classified in D1A2.  All gynaecological forms, eg vaginal tablets, of antifungal products are in G1B. Oral systemic forms of products, eg oral tablets, which are exclusively indicated for gynaecological use are in G1B. If a product in its oral systemic form is indicated for both gynaecological and systemic fungal infections then it is classified in J2A.  Topical oral forms of products, eg oral gels, which are exclusively indicated for fungal infections of the mouth are in A1B.	R2007

<b>J3</b>	<b>SYSTEMIC SULPHONAMIDES</b>	
<b>J3A</b>	<p><b>SYSTEMIC SULPHONAMIDES</b></p> <p>This group includes plain sulphonamides and sulphonamide/antibacterial combinations but excludes trimethoprim/sulphonamides which are classified in J1E, and specific respiratory formulation, eg in combination with expectorants, which are classified in R5B.</p> <p>Sulphonamides indicated primarily as antidiarrhoeals are classified in A7A and those indicated for the treatment of urinary tract infections only are classified in G4A1. In combination products, including other antibacterials, the importance, weight or amount of sulphonamide is unimportant as products containing, say tetracycline, chloramphenicol, oleandomycin and a sulphonamide would be classified in J3A as would a penicillin and three sulphonamides.</p>	r2025

<b>J4</b>	<b>ANTIMYCOBACTERIALS</b>	R1993
<b>J4A</b>	<b>ANTITUBERCULAR PRODUCTS</b> <p>Includes all specific tubercular preparations as well as streptomycin and dihydrostreptomycin. Other antibacterials such as viomycin and cycloserine which are indicated specifically for tuberculosis are included as well as rifampicin and rifamycin where they are used mostly as tuberculostatics. Where rifampicin and rifamycin are indicated for several conditions, then they are classified in J1M.</p> <p>The definition of ‘single ingredient’ means that only one specific antitubercular drug is present in the product. For example, if a product contains an antitubercular substance and also pyridoxine, this is a single ingredient product and will be classified in J4A1.</p> <p>Kits include various different tablets or forms with different ingredients. Fixed dose products contain the ingredients in one dosage form.</p>	r2009
J4A1	<b>Antituberculars, single ingredient</b>	I2000
J4A2	<b>Antituberculars, kits, four or more ingredients</b>	I2000
J4A3	<b>Antituberculars, kits, three ingredients</b>	I2000
J4A4	<b>Antituberculars, kits, two ingredients</b>	I2000
J4A5	<b>Antituberculars, fixed dose, four or more ingredients</b>	I2000
J4A6	<b>Antituberculars, fixed dose, three ingredients</b>	I2000
J4A7	<b>Antituberculars, fixed dose, two ingredients</b>	I2000
J4A9	<b>Antituberculars, others</b>	I2000
<b>J4B</b>	<b>DRUGS FOR THE TREATMENT OF LEPROSY</b> <p>Includes preparations used for the treatment of leprosy (eg aldesulphone, clofazimine, dapsone). Products containing thalidomide for cancer are classified in L1K and for erythema nodosum leprosum (ENL) in L4X. Products for both cancer and ENL are classified in L1K.</p>	r2022

<b>J5</b>	<b>ANTIVIRALS FOR SYSTEMIC USE</b>	R2018
<b>J5A</b>	Out of use	D1998
<b>J5B</b>	<b>ANTIVIRALS, OTHER</b>	r2022
	Includes systemic antivirals for herpes, influenza, coronavirus, other viral respiratory conditions, etc. Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), HIV antivirals (J5C), and hepatitis antivirals (J5D).	
J5B1	Out of use	D2018
J5B2	Out of use	
J5B3	<b>Herpes antivirals</b>	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	<b>Influenza antivirals</b>	r2025
	Includes products indicated specifically for influenza. Products containing favipiravir for influenza only, or for both influenza and severe fever with thrombocytopenia syndrome (SFTS), are classified here. Products containing favipiravir for COVID-19 only are classified in J5B6. Products containing favipiravir for both influenza and COVID-19 are classified in J5B6.	
J5B5	<b>Respiratory antivirals, other</b>	r2025
	Includes products indicated specifically for treatment of respiratory syncytial virus (RSV) infections. Products containing palivizumab for the prevention of RSV infections are classified in J6H6.	
	Also includes inhalation forms of ribavirin where no indication has been specified.	



J5B6	<p><b>Coronavirus antivirals</b></p> <p>Includes products containing bamlanivimab, casirivimab, etesevimab, favipiravir, imdevimab, molnupiravir, sotrovimab, regdanvimab, remdesivir, etc, for treatment of COVID-19.</p> <p>Products containing favipiravir for both influenza and COVID-19 are classified here. Products containing favipiravir for influenza only are classified in J5B4 (influenza antivirals).</p> <p>Monoclonal antibodies for prevention/post-exposure prophylaxis, and for both prevention/post-exposure prophylaxis and treatment of COVID-19 are classified in J6H7.</p> <p>Vaccines for coronavirus are classified in J7E6.</p> <p>Products containing immunosuppressants that have been used in COVID-19 are classified elsewhere, for example, levilimab is in L4C. Dexamethasone (has been used in COVID-19) is also classified elsewhere in the appropriate hormone class.</p>	r2026
J5B9	<p><b>Antivirals, others</b></p> <p>Includes products containing lysozyme for viral infections.</p> <p>Products containing favipiravir for both influenza and severe fever with thrombocytopenia syndrome (SFTS) are classified in J5B4.</p>	r2025

<b>J5C</b>	<b>HIV ANTIVIRALS</b>  Includes antiviral products specifically used to treat HIV (human immunodeficiency virus).  Combinations of different classes of HIV antivirals are classified in J5C8. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only two nucleoside reverse transcriptase inhibitors is classified in J5C1.  Pentamidine isethionate which is used to treat <i>Pneumocystis carinii</i> in AIDS is classified in P1G.  Products containing dapivirine (vaginal ring) for the prevention of HIV transmission are classified in G1D.	r2023
<b>J5C1</b>	<b>Nucleoside and nucleotide reverse transcriptase inhibitors</b>  Includes abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, zalcitabine, zidovudine. Single-ingredient products containing tenofovir disoproxil and indicated for either HIV and/or hepatitis are classified here.  Products containing single-ingredient lamivudine or tenofovir alafenamide and for hepatitis B only are classified in J5D2.	r2018
<b>J5C2</b>	<b>Protease inhibitors</b>  Includes amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir.	r2011
<b>J5C3</b>	<b>Non-nucleoside reverse transcriptase inhibitors</b>  Includes delavirdine, efavirenz, etravirine, nevirapine.	r2011
<b>J5C4</b>	<b>HIV antivirals, entry inhibitors</b>  Includes products containing entry inhibitors such as enfuvirtide, maraviroc.	I2011
<b>J5C5</b>	<b>HIV antivirals, integrase inhibitors</b>  Includes products containing integrase inhibitors eg dolutegravir, elvitegravir, raltegravir.	I2015

J5C8	<p><b>HIV antivirals, multiclass combination products</b></p> <p>Includes products containing two or more substances from different HIV subclasses. For example, an integrase inhibitor in combination with a nucleoside reverse transcriptase inhibitor.</p> <p>Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only nucleoside reverse transcriptase inhibitors is classified in J5C1.</p>	I2023
J5C9	<p><b>HIV antivirals, other</b></p> <p>Combinations of different classes of HIV antivirals are classified in J5C8. For example, an integrase inhibitor in combination with a nucleoside reverse transcriptase inhibitor. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only nucleoside reverse transcriptase inhibitors is classified in J5C1.</p> <p>Products containing cobicistat as a single ingredient are classified here. Products containing cobicistat in combination with HIV antivirals are classified in the appropriate class for the antivirals.</p>	R2023

<b>J5D</b>	<b>HEPATITIS ANTIVIRALS</b>	I2018
J5D1	<p><b>Hepatitis antivirals, interferon and ribavirin</b></p> <p>Products for hepatitis only containing interferons and/or ribavirin. The products can be for hepatitis B and/or hepatitis C.</p> <p>Products containing interferons and/or ribavirin in combination with a substance from J5D2 are classified in J5D2. Products containing interferons and/or ribavirin in combination with a substance from J5D3 are classified in J5D3. Products containing interferons (with or without ribavirin) that are for multiple indications are classified in L3B.</p>	I2018
J5D2	<p><b>Hepatitis B antivirals</b></p> <p>Includes products containing adefovir dipivoxil, clevudine, entecavir, telbivudine, etc.</p> <p>Products containing lamivudine or tenofovir alafenamide for hepatitis B are classified here; products containing lamivudine or tenofovir alafenamide for HIV are classified in J5C1 or J5C8.</p> <p>Combinations of these substances with interferons and/or ribavirin are classified here. Products containing interferons and/or ribavirin for hepatitis B are classified in J5D1.</p> <p>Products containing tenofovir disoproxil only, and indicated for hepatitis, HIV, or for both conditions, are classified in J5C1.</p>	r2025
J5D3	<p><b>Hepatitis C antivirals</b></p> <p>Includes products containing asunaprevir, beclabuvir, boceprevir, daclatasvir, dasabuvir, elbasvir, glecaprevir, grazoprevir, ledipasvir, narlaprevir, ombitasvir, paritaprevir, pibrentasvir, simeprevir, sofosbuvir, telaprevir, vaniprevir, velpatasvir, voxilaprevir, etc.</p> <p>Combinations of these substances with each other are also classified here.</p> <p>Combinations of these substances with ritonavir are classified here.</p> <p>Combinations of these substances with interferons and/or ribavirin are classified here. Products containing interferons and/or ribavirin for hepatitis C are classified in J5D1.</p>	I2018
J5D9	<p><b>Hepatitis antivirals, other</b></p> <p>Includes other products for viral hepatitis.</p>	I2018

<b>J6</b>	<b>SERA AND GAMMA-GLOBULIN</b>	
<b>J6A</b>	<b>ANTITOXIC SERA</b>	
	Includes heterologous sera derived from animals such as the horse and the sheep.	
J6A1	<b>Snake-bite sera</b>	
J6A2	<b>Botulism sera</b>	
J6A3	<b>Gas gangrene sera</b>	
J6A4	<b>Tetanus sera</b>	
J6A5	<b>Diphtheria sera</b>	
J6A6	<b>Rabies sera</b>	
J6A9	<b>Other antitoxic sera</b>	
<b>J6B</b>	Out of use; can be reused from 1998.	D1995
J6B1	Out of use; can be reused from 1998.	D1995
J6B9	Out of use; can be reused from 1998.	D1995
<b>J6C</b>	<b>POLYVALENT IMMUNO-GLOBULINS - INTRAVENOUS</b>	
	The action of these homologous substances is mainly based on the IgG fraction.	
<b>J6D</b>	<b>HOMOLOGOUS IMMUNOLOGICALLY ACTIVE GLOBULINS – INTRAVENOUS</b>	
	The action of these homologous substances is not (or not solely) based on the action of the IgG fraction.	
J6D1	<b>Humoral globulins</b>	
	Substances principally associated with the humoral immune response.	
J6D2	<b>Cellular globulins</b>	
	Substances principally associated with the cellular immune response.	

<b>J6E</b>	<b>POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR</b>  The action of these homologous substances is based on a wide spectrum of antibodies mainly belonging to the IgG fraction. Includes subcutaneous as well as intramuscular forms.	R2006
<b>J6F</b>	<b>POLYVALENT IMMUNOGLOBULINS - COMBINATION MODULATION - MAINLY INTRAMUSCULAR</b>  These homologous immunoglobulins include: - those whose action is not exclusively based on the IgG fraction. - those which exist in combination with other substances. - those which cause a modulation of the immune response.	
<b>J6G</b>	<b>SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL</b>  These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here.	r2022
J6G1	<b>Tetanus immunoglobulin</b>	
J6G2	<b>Pertussis immunoglobulin</b>	
J6G9	<b>Other antibacterial immunoglobulins</b>  This group includes diphtheria, streptococci, staphylococci and pseudomonas immunoglobulins.	
<b>J6H</b>	<b>SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL</b>  These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for prevention/post-exposure prophylaxis are classified here. Products for both prevention/post-exposure prophylaxis and for treatment are classified here. Products for treatment only are classified in J5.	r2025
J6H1	<b>Mumps immunoglobulin</b>	
J6H2	<b>Measles immunoglobulin</b>	
J6H3	<b>Rubella immunoglobulin</b>	
J6H4	<b>Hepatitis immunoglobulin</b>	
J6H5	<b>Rabies immunoglobulin</b>	
J6H6	<b>RSV (respiratory syncytial virus) immunoglobulin</b>	I2025

<b>J6H7</b>	<b>Coronavirus immunoglobulin</b>  Monoclonal antibodies for prevention/post-exposure prophylaxis, and for both prevention/post-exposure prophylaxis and treatment of COVID-19 are classified here. Monoclonal antibodies for treatment only of COVID-19 are classified in J5B6.	I2025
<b>J6H9</b>	<b>Other antiviral immunoglobulins</b>  This group includes varicella-zoster, tick-borne meningo-encephalitis, poliomyelitis, cytomegaly, and herpes immunoglobulins.	r2025
<b>J6J</b>	<b>OTHER SPECIFIC IMMUNOGLOBULINS</b>  These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen which is not of bacterial or viral origin.  Products containing anti-D (Rho) immunoglobulin are classified here.	r2014

<b>J7</b>	<b>VACCINES</b>	
<b>J7A</b>	Out of use	D2014
<b>J7B</b>	<b>COMBINATIONS OF VACCINES</b>	r2018
	Included are combinations of vaccines for protection against more than one virus and/or bacteria and/or protozoa.	
J7B1	<b>Combinations with a tetanus component</b>	
J7B2	<b>Combinations with measles and/or mumps</b>	R2007
	MMR vaccine is classified here.	
J7B3	<b>All other combinations</b>	
<b>J7C</b>	Out of use	D2014
<b>J7D</b>	<b>BACTERIAL VACCINES</b>	r2018
	Includes separate classes for vaccines against only one bacterial group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7D1	<b>Pneumococcal vaccines</b>	I2014
J7D2	<b>Meningococcal vaccines</b>	I2014
J7D3	<b>Haemophilus B vaccines</b>	I2014
J7D4	<b>Typhoid vaccines</b>	I2014
	Includes vaccines against typhoid and paratyphoid. Vaccines against typhus are classified in J7D9.	
J7D5	<b>Tetanus vaccines</b>	I2014
J7D6	<b>Tuberculosis vaccines</b>	r2020
	Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified in L3A9.	
J7D7	<b>Cholera vaccines</b>	I2014
J7D9	<b>All other bacterial vaccines</b>	I2014
	Includes all other vaccines against one bacterial group, eg diphtheria, pertussis, typhus.	



<b>J7E</b>	<b>VIRAL VACCINES</b>  Includes separate classes for vaccines against only one viral group. For vaccines against a combination of bacteria or viruses, see J7B.	r2018
J7E1	<b>Influenza vaccines</b>	I2014
J7E2	<b>Varicella vaccines</b>	I2014
J7E3	<b>HPV (human papillomavirus) vaccines</b>	I2014
J7E4	<b>Hepatitis vaccines</b>	I2014
J7E5	<b>Rotavirus vaccines</b>	I2014
J7E6	<b>Coronavirus vaccines</b>  Includes vaccines against COVID-19.	I2021
J7E7	<b>RSV (respiratory syncytial virus) vaccines</b>	I2025
J7E9	<b>All other viral vaccines</b>  Includes all other vaccines against one viral group, eg Japanese encephalitis, measles, mumps, polio, rubella, rabies, smallpox, tick-borne encephalitis, yellow fever etc.	r2025
<b>J7F</b>	<b>PROTOZOAL VACCINES</b>  Includes separate classes for vaccines against only one protozoal group. For vaccines against a combination of a protozoal group and/or other organisms, see J7B.	I2018
J7F1	<b>Malaria vaccines</b>	I2018
J7F9	<b>All other protozoal vaccines</b>	I2018
<b>J7X</b>	<b>ALL OTHER VACCINE-LIKE PRODUCTS</b>  Includes products containing infectious agents and/or their derivatives, eg lysates and extracts of bacteria, that are not strictly considered vaccines.	r2018

<b>J8</b>	<b>OTHER ANTI-INFECTIVES</b>	R1993
<b>J8A</b>	Out of use; can be reused.	
<b>J8B</b>	<b>ANAEROBICIDES</b>  Includes infusions, ampoules and rectal suppositories of metronidazole and other anaerobicides. Topical forms can be classified here. Oral forms of these compounds to be classified in G1A1 and vaginal tablets/suppositories in G1A2. Products for both trichomoniasis and amoebiasis are classified in G1A1.	R2006
<b>J8X</b>	<b>ALL OTHER ANTI-INFECTIVES</b>  Includes other anti-infectives not classified in J1-J7. Anaerobicides such as metronidazole to be classified in J8B.	I1993

<b>K</b>	<b>HOSPITAL SOLUTIONS</b>  This class includes all intravenous solutions, injection solutions/infusion additives, irrigating solutions, dialysis solutions and perfusion solutions.	
<b>K1</b>	<b>INTRAVENOUS SOLUTIONS</b>  This group includes all intravenous solutions, infusion bottles $\geq 100$ ml.	
<b>K1A</b>	<b>ELECTROLYTE SOLUTIONS (<math>\geq 100</math> ml)</b>  Electrolyte solutions in all concentrations up to and including 10% carbohydrates ( $\leq 10\%$ ). Includes also arginine, malic acid and darrow (potassium substitution therapy).  Exceptions: <ol style="list-style-type: none"> <li>1. Sodium chloride solutions and aqua/aqua bidest are classified in K1B.</li> <li>2. Combinations with fat emulsions are classified in K1D2.</li> <li>3. Combinations with amino-acids are classified in K1E.</li> <li>4. Combinations with osmotic solutions are classified in K1F.</li> </ol>	R2004
K1A1	<b>1/1 – Electrolyte solutions</b>  $\text{Na}^+ > 120$ mmol/l	
K1A2	<b>2/3 – Electrolyte solutions</b>  $\text{Na}^+ 91\text{-}120$ mmol/l	
K1A3	<b>1/2 – Electrolyte solutions</b>  $\text{Na}^+ 61\text{-}90$ mmol/l	
K1A4	<b>1/3 – Electrolyte solutions</b>  $\text{Na}^+ \leq 60$ mmol/l	
K1A5	<b>Adapting electrolyte solutions (including sodium)</b>  Includes sodium bicarbonate and forced diuresis (FD) solutions.	
K1A6	<b>Paediatric electrolyte solutions</b>  Includes all paediatric solutions but excludes paediatric combinations with amino-acids which are classified in K1E5.	

K1A7	<b>Ringer's and Ringer's lactate solutions</b>  Modified Ringer's and Ringer's lactate solution is classified in K1A9.	r2011
K1A9	<b>Other electrolyte solutions</b>  Includes Coma Diabeticum (CD) solutions. Includes Hartmann's solution. Modified Ringer's and Ringer's lactate solution is classified here.	r2011
K1B	<b>STANDARD SOLUTIONS</b>  Includes sodium chloride solutions in all concentrations, both plain and combined with carbohydrates (up to and including 10% carbohydrates ( $\leq 10\%$ )), carbohydrate solutions ( $\leq 10\%$ ) and water for use with injectables (aqua/aqua bidest $\geq 100$ ml). All carbohydrate solutions with more than 10% are classified in K1C.	R2006
K1B1	<b>Sodium chloride solutions</b>  Includes pure sodium chloride solutions in all concentrations.	R2006
K1B2	<b>Sodium chloride solutions with carbohydrates</b>  Includes sodium chloride solutions in all concentrations combined with carbohydrates ( $\leq 10\%$ ). Solutions with carbohydrate $>10\%$ or carbohydrate combinations with electrolytes other than sodium chloride are classified in K1A (carbohydrates $\leq 10\%$ ) and K1C3 (carbohydrates $>10\%$ ).	
K1B3	<b>Carbohydrate solutions (<math>\leq 10\%</math>)</b>  The types of products contained in this sub-group are sugar solutions ( $\leq 10\%$ ) such as glucose (dextrose, grape sugar) and fructose (laevulose, fruit sugar). Also includes polyalcohols such as xylitol and sorbitol.  The products classified in this group are solutions with one carbohydrate ( $\leq 10\%$ ) and carbohydrate combination solutions ( $\leq 10\%$ ).  Carbohydrate solutions ( $>10\%$ ) are classified in K1C1.	
K1B4	<b>Aqua/Aqua bidest</b>  Infusion bottles $\geq 100$ ml.	
K1C	<b>CALORIC SOLUTIONS (<math>&gt;10\%</math>)</b>  Includes carbohydrate solutions ( $>10\%$ ) and carbohydrate combination solutions ( $>10\%$ ).	

K1C1	<p><b>Solutions with one carbohydrate (&gt;10%)</b></p> <p>The types of products contained in this sub-group are sugar solutions (&gt;10%) such as glucose (dextrose, grape sugar) and fructose (laevulose, fruit sugar). Also included are polyalcohols such as xylitol and sorbitol.</p> <p>Carbohydrate solutions (&lt;=10%) are classified in K1B3.</p>	
K1C2	<p><b>Carbohydrate combination solutions (&gt;10%)</b></p> <p>Includes only combinations of two or more carbohydrates eg fructose, glucose, xylitol (FGX) and invert sugar solutions (&gt;10%).</p> <p>Carbohydrate combination solutions (&lt;=10%) are classified in K1B3.</p>	
K1C3	<p><b>Carbohydrate electrolyte combination solutions (&gt;10%)</b></p> <p>The group includes single or combined carbohydrates (&gt;10%) eg glucose, fructose, sorbitol and xylitol with electrolytes.</p> <p>The group excludes carbohydrate solutions (single or combined) with electrolytes (carbohydrates &lt;=10%) which are classified in K1A.</p>	
K1D	<b>FAT EMULSIONS, INCLUDING TOTAL PARENTERAL NUTRITION PRODUCTS</b>	R1997
K1D1	<p><b>Fat emulsions, plain</b></p> <p>This group includes plain fat emulsions for parenteral applications eg fractions of soybean oil and safflower oil, or mixtures of different oils.</p>	I1997
K1D2	<p><b>Fat emulsions, combinations</b></p> <p>This group includes fat emulsions with other substances such as amino acids, glucose, electrolytes. In particular, products for total parenteral nutrition are classified in this class. Multicomponent solutions for total parenteral nutrition with no fat emulsion content, are classified in K1E.</p>	R2006
K1E	<p><b>AMINO ACID SOLUTIONS</b></p> <p>This group contains all amino-acid solutions including combinations, except those including fats.</p>	R2006
K1E1	<p><b>Amino acid standard solutions</b></p> <p>Includes solutions containing at least all the following amino acids: isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Products may additionally contain histidine, other non-essential amino-acids, electrolytes, etc.</p>	r2025

K1E2	<b>Multi-litre concept solutions</b>  Includes multicomponent solutions for total parenteral nutrition containing amino-acids and carbohydrates. Electrolytes may also be included. Multicomponent solutions for total parenteral nutrition which additionally contain fat are classified in K1D2. Includes products which have a volume of 2 litres or more.	R2005
K1E3	<b>Nephro solutions</b>	
K1E4	<b>Hepatic solutions</b>	
K1E5	<b>Paediatric amino-acid solutions</b>	
K1E9	<b>Other amino acid solutions</b>  Includes amino-acid solutions not classified in K1E or K1D2.	R2005
K1F	<b>SOLUTIONS FOR OSMOTIC THERAPY</b>	
K1F1	<b>Osmotic therapy</b>  Includes glycerin solutions, mannitol and mannitol combinations with carbohydrates in all concentrations and sorbitol ( $\geq 40\%$ ).	
K1F2	<b>Osmotic/oncology therapy</b>  Includes solutions (eg dextran) with sorbitol (20%).	
K1G	<b>SPECIAL INFUSION SOLUTIONS</b>	R2004
K1G1	<b>Solutions for liver therapy</b>	
K1G9	<b>Other infusion solutions</b>	

<b>K2</b>	<b>PLASMA EXPANDERS</b>  Plasma expanders are colloid substances used as plasma substitutes with qualities which are to a high degree commensurate with those of human plasma. Includes dextrans, starches and gelatin solutions.	
<b>K2A</b>	<b>DEXTRANS</b>  Dextrans are high-polymeric glucose compounds which are always a mixture of all molecular weights. Dextrans with a molecular weight under 50.000 are subject to renal elimination whilst dextrans with a molecular weight over 50.000 are subject to enzymatic degradation.	
<b>K2A1</b>	<b>Low dextrans</b>  Dextrans $\leq 50,000$ Daltons. The main indication is disturbed micro-circulation. Excludes monovalent dextrans, see K4D.	R2005
<b>K2A2</b>	<b>High dextrans</b>  Dextrans $> 50,000$ Daltons. The main indication is volume substitution.	R2005
<b>K2B</b>	<b>STARCHES</b>  Includes Haes solutions.	
<b>K2C</b>	<b>GELATIN SOLUTIONS</b>  Includes modified gelatin.	

<b>K3</b>	<b>WHOLE BLOOD AND PLASMA SUBSTITUTE SOLUTIONS</b>	
<b>K3A</b>	<b>WHOLE BLOOD AND PLASMA FRACTIONS</b>  <p>This group includes whole blood (eg citrate-whole blood, citrate-fresh-blood etc) as well as fluid blood constituents (fresh fluid plasma, dehydrated plasma) and corpuscular blood constituents (eg erythrocytes etc), provided they are not allocated to other systems.</p> <ul style="list-style-type: none"> <li>- The albumin fraction is classified in groups K3B and K3C.</li> <li>- The blood constituents acting in the immunological system are classified in group J6.</li> <li>- The blood constituents acting in the coagulation system are classified in group B2.</li> </ul>	
<b>K3B</b>	<b>PROTEIN SOLUTIONS</b>  <p>This group includes all plasma protein solutions and albumin solutions with an albumin concentration <math>\geq 80\%</math>. Subdivision as to total protein concentration is effected on the 4th level.</p>	
K3B1	<b>Protein solutions <math>&lt;5,0\%</math></b>	
K3B2	<b>Protein solutions <math>5,0\%</math></b>	
K3B3	<b>Protein solutions <math>&gt;5,0\%</math></b>	
<b>K3C</b>	<b>PRESERVED HUMAN SERUM</b>  <p>This group includes all plasma protein solutions (albumin concentration <math>&lt;80\%</math>) containing gammaglobulins but no coagulation factors.</p>	



<b>K4</b>	<b>INJECTION SOLUTIONS/INFUSION ADDITIVES (&lt;100ML)</b>  Includes injection solutions and infusion additives <100ml.	
<b>K4A</b>	<b>ELECTROLYTE SOLUTIONS (&lt;100ml)</b>  Includes electrolyte solutions in all concentrations up to and including ≤10% carbohydrates (1/1, 2/3, 1/2 and 1/3; adapting and paediatric electrolyte solutions), Ringer's and Ringer's lactate solutions.	
K4A1	<b>Electrolyte solutions (≤20ml)</b>	R1993
K4A2	<b>Electrolyte solutions (&gt;20ml and &lt;100ml)</b>	R1993
<b>K4B</b>	<b>STANDARD SOLUTIONS (&lt;100ml)</b>  Includes sodium chloride solutions in all concentrations, sodium chloride solutions with carbohydrates (≤10%) and carbohydrate solutions (≤10%). Also included are polyalcohols such as xylitol and sorbitol.	
K4B1	<b>Standard solutions (≤20ml)</b>	R1993
K4B2	<b>Standard solutions (&gt;20ml and &lt;100ml)</b>	R1993
<b>K4C</b>	<b>CALORIC SOLUTIONS (&lt;100ml)</b>  Includes solutions with one carbohydrate (>10%), carbohydrate combination solutions (>10%) and carbohydrate electrolyte combination solutions (>10%). Also includes polyalcohols such as xylitol and sorbitol.	
<b>K4D</b>	<b>OTHER INJECTION SOLUTIONS/INFUSION ADDITIVES (&lt;100ml)</b>  Includes aqua/aqua bidest, arginine, arginine/malic acid solutions, monovalent dextrans and buffer solutions. Multivitamin products used for parenteral infusion are classified here.	R2005

<b>K5</b>	<b>IRRIGATING SOLUTIONS</b>  Irrigating solutions are not to be given intravenously or to be injected. This group includes all solutions which are specified as irrigating solutions.	
<b>K5A</b>	<b>IRRIGATING SOLUTIONS</b>	R2004
K5A1	<b>Water</b>	
K5A2	<b>Saline</b>	
K5A3	<b>Citrates</b>	
K5A4	<b>Glycine</b>	
K5A9	<b>Other irrigating solutions</b>	R1993

<b>K6</b>	<b>DIALYSIS SOLUTIONS</b>  This group includes all solutions for haemodialysis, peritoneal dialysis and haemofiltration (systemic lavage).	
<b>K6A</b>	<b>HAEMODIALYSIS SOLUTIONS</b>	
<b>K6B</b>	<b>PERITONEAL DIALYSIS SOLUTIONS</b>	
<b>K6C</b>	<b>HAEMOFILTRATION</b>	

<b>K7</b>	<b>PERFUSION SOLUTIONS</b>  Perfusion solutions are not to be given intravenously or to be injected. This group includes all solutions which are used for the storage of donor organs and gravity perfusion. Also included are anticoagulant solutions for blood samples. Also products used to arrest the heart are classified here.	R2006
<b>K7A</b>	<b>PERFUSION SOLUTIONS</b>  Catheter lock solution products without heparin are classified here. Catheter lock solution products that contain heparin are classified in B1B3.	r2025

<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	R1994
<b>L1</b>	<b>ANTINEOPLASTICS</b>  Includes all preparations mainly indicated for the treatment of cancers and all packs specifically produced for use in anticancer therapy eg special anticancer packs of antibiotics. The definition of neoplasms includes both malignant and benign conditions.  Immunosuppressants used to treat cancer are classified in the appropriate antineoplastic class. For example, nogapendekin alfa inbakcept for bladder cancer is classified in L1X9.	r2026
<b>L1A</b>	<b>ALKYLATING AGENTS</b>  Includes nitrogen mustard analogues (eg chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine, trofosfamide), ethylene imines (eg altretamine (hexamethylmelamine), carboquone, thiotepa, triaziquone), nitrosoureas (eg bendamustine, carmustine, fotemustine, lomustine, semustine, streptozocin), alkyl sulfonates (eg busulfan, mannosulfan, mitolactol, treosulfan), triazenes and analogues. Dacarbazine is classified in this group.	R2003
<b>L1B</b>	<b>ANTIMETABOLITES</b>  Includes folic acid analogues (eg methotrexate), pyrimidine analogues (eg capecitabine, carmofur, cytarabine, fluorouracil, tegafur) and purine analogues (eg fludarabine, mercaptopurine, tioguanine).  Methotrexate can also be classified in M1C for rheumatic conditions or in D for dermatological conditions.  Products containing topical fluorouracil for actinic keratosis are classified here.	r2016
<b>L1C</b>	<b>PLANT-BASED ANTINEOPLASTICS</b>  Includes products that contain plant-derived alkaloids, terpenes, lignans etc, or their derivatives/analogues.  Combination products containing substances from two fourth level classes of L1C are classified in the higher level class, eg a combination of a camptothecin with a podophyllotoxin is classified in L1C3.	R2016
<b>L1C1</b>	<b>Vinca alkaloid antineoplastics</b>  Includes products containing alkaloids (or their derivatives/analogues) that are derived from <i>Cantharanthus roseus</i> (Madagascan periwinkle), eg vinblastine, vincristine, vindesine, vinflunine, vinorelbine, etc.	I2016

L1C2	<b>Taxane antineoplastics</b>  Includes products containing diterpenes (or their derivatives/analogues) that are derived from species of <i>Taxus</i> (yew), eg cabazitaxel, docetaxel, paclitaxel, etc.	I2016
L1C3	<b>Camptothecin antineoplastics</b>  Includes products containing alkaloids (or their derivatives/analogues) derived from <i>Camptotheca acuminata</i> (happy tree), eg hydroxycamptothecin, irinotecan, topotecan, etc.	I2016
L1C4	<b>Podophyllotoxin antineoplastics</b>  Includes products containing lignans (or their derivatives/analogues) derived from <i>Podophyllum</i> (May apple) species, eg etoposide, mitopodozide, teniposide, etc.	I2106
L1C9	<b>Plant-based antineoplastics, other</b>  Includes antineoplastic products containing other plant chemicals (or their derivatives/analogues), eg colchicine derivatives such as demecolcine.  Products for cancer containing omacetaxine mepisuccinate are classified here. Products for cancer containing <i>Brucea javanica</i> are classified here.  Antineoplastic products that contain dried plant material or unrefined plant extracts are classified in L1X9.  Antineoplastic products that are derived from natural sources other than plants, eg from bacteria or fungi, are classified elsewhere.	I2016
L1D	<b>ANTINEOPLASTIC ANTIBIOTICS</b>  Includes eg aclarubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mithramycin, mitoxantrone, plicamycin, zorubicin.  Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified here.  Products containing gemtuzumab ozogamicin and inotuzumab ozogamicin are classified in L1G9.	r2019
L1F	<b>PLATINUM ANTINEOPLASTICS</b>  Includes products containing eg carboplatin, cisplatin, oxaliplatin.	I2014

<b>L1G</b>	<b>MONOCLONAL ANTIBODY ANTINEOPLASTICS</b> <p>Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.</p> <p>Products containing antibody drug conjugates (ADCs) are classified in the appropriate fourth level, according to the antibody target. If there is not a class for the target, the product is classified in L1G9.</p> <p>Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified in L1G9. If there is a separate class for each target, the product is classified in L1G9.</p>	r2024
L1G1	<b>Monoclonal antibody antineoplastics, CD20</b> <p>Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc. Products containing ofatumumab for multiple sclerosis only are classified in N7A.</p>	r2022
L1G2	<b>Monoclonal antibody antineoplastics, VEGF/VEGFR</b> <p>Includes products containing bevacizumab, ramucirumab, etc.</p>	I2019
L1G3	<b>Monoclonal antibody antineoplastics, HER-2</b> <p>Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, etc.</p>	r2021
L1G4	<b>Monoclonal antibody antineoplastics, EGFR</b> <p>Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.</p>	I2019
L1G5	<b>Monoclonal antibody antineoplastics, PD-1/PD-L1</b> <p>Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc. Products containing a combination of nurulimab with prolgolimab are classified here. Products containing a combination of nivolumab with relatlimab are classified in L1G9. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified here.</p>	r2025

L1G9	<p><b>Monoclonal antibody antineoplastics, other</b></p> <p>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified in L1G5. Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified here. If there is a separate class for each target, the product is classified here.</p> <p>Includes antibody drug conjugates (ADCs) if not classified with the target class (brentuximab vedotin, datopotamab deruxtecan, gemtuzumab ozogamicin, inotuzumab ozogamicin).</p> <p>Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).</p> <p>Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, sabatolimab, siltuximab, tositumomab, tositumomab iodine-131, etc.</p> <p>Includes products containing a combination of nivolumab with relatlimab. Products containing nivolumab alone are classified in L1G5. Products containing a combination of nurulimab with prolgolimab are classified in L1G5.</p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p>	r2026
L1H	<p><b>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</b></p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.</p>	R2019
L1H1	<p><b>Protein kinase inhibitor antineoplastics, BCR-ABL</b></p> <p>Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.</p>	I2019
L1H2	<p><b>Protein kinase inhibitor antineoplastics, EGFR</b></p> <p>Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.</p>	I2019

L1H3	<b>Protein kinase inhibitor antineoplastics, ALK</b>  Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.	I2019
L1H4	<b>Protein kinase inhibitor antineoplastics, BRAF/MEK</b>  Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc.  Products containing avutometinib in combination with defactinib are classified here.	r2026
L1H5	<b>Protein kinase inhibitor antineoplastics, CDK 4/6</b>  Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.	I2019
L1H6	<b>Protein kinase inhibitor antineoplastics, BTK</b>  Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.	I2021
L1H7	<b>Protein kinase inhibitor antineoplastics, JAK</b>  Includes products containing fedratinib, momelotinib, pacritinib, ruxolitinib, etc that are primarily for cancer.  Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.  Products containing JAK inhibitors to treat multiple immune conditions are classified in L4D.	I2024

L1H9	<p><b>Protein kinase inhibitor antineoplastics, other</b></p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2 etc. Pi3K inhibitors are included even though they are lipid kinase inhibitors and not strictly protein kinase inhibitors.</p> <p>Includes axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, pazopanib, regorafenib, rivoceranib (apatinib), sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, vimseltinib, zongertinib etc.</p> <p>Products containing multi-kinase inhibitors, eg umbralisib etc, are classified here.</p> <p>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</p> <p>Products containing alpelisib for PIK3CA-related overgrowth spectrum (PROS) are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified in L1X9.</p>	r2026
L1J	<p><b>PROTEASOME INHIBITOR ANTINEOPLASTICS</b></p> <p>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc</p>	I2018
L1K	<p><b>LIDOMIDE ANTINEOPLASTICS</b></p> <p>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</p> <p>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</p>	I2022
L1L	<p><b>PARP INHIBITOR ANTINEOPLASTICS</b></p> <p>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</p> <p>Products containing combinations of niraparib with abiraterone are classified here</p>	r2024



<b>L1X</b>	<b>ALL OTHER ANTINEOPLASTICS</b>	R2018
L1X1	<b>Alternative preparations for cancer therapy</b>  Includes products derived from Viscum (mistletoe).	r2018
L1X2	Out of use	D2022
L1X3	<b>HDAC inhibitor antineoplastics</b>  Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.	I2018
L1X4	Out of use	D2022
L1X5	<b>CAR T-cell therapy antineoplastics</b>  Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.	I2019
L1X6	<b>Hedgehog pathway inhibitor antineoplastics</b>  Includes products containing glasdegib, sonidegib, vismodegib, etc.	I2022
L1X8	<b>Photosensitisers for cancer therapy</b>  Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.  Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.  Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.  Products containing verteporfin for macular degeneration are classified in S1P.	r2023

L1X9	<p><b>All other antineoplastics</b></p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, pentostatin, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Includes products containing cancer gene therapies eg nadofaragene firadenovec, talimogene laherparepvec, etc.</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p> <p>Products containing miltefosine for skin metastases of breast cancer are classified here. Products containing miltefosine for leishmaniasis are classified in P1G.</p> <p>Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified here.</p> <p>Products containing tabellecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD) are classified here.</p> <p>Products containing antineoplastic, non-transformed cell therapies, eg lifileucel, are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified here.</p> <p>Products containing zopapogene imadenovac for recurrent respiratory papillomatosis (RRP) are classified here.</p> <p>Products containing nogapendekin alfa inbakicept for bladder cancer are classified here.</p>	r2026
------	---	-------

<b>L2</b>	<b>CYTOSTATIC HORMONE THERAPY</b>  Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens.	I1994
<b>L2A</b>	<b>CYTOSTATIC HORMONES</b>	I1994
L2A1	<b>Cytostatic oestrogens</b>	I1994
L2A2	<b>Cytostatic progestogens</b>	I1994
L2A3	<b>Cytostatic gonadotrophin-releasing hormone analogues</b>  Buserelin, deslorelin, goserelin, nafarelin, leuprorelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions are classified here.	r2020
L2A9	<b>Other cytostatic hormones</b>  Includes substances such as drostanolone, testolactone.	I1994
<b>L2B</b>	<b>CYTOSTATIC HORMONE ANTAGONISTS</b>	I1994
L2B1	<b>Cytostatic anti-oestrogens</b>  Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene. Products containing selective oestrogen receptor degraders (SERDs), eg elacestrant, fulvestrant, etc, for cancer are classified here.	r2024
L2B2	<b>Cytostatic anti-androgens</b>  Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here. Products containing combinations of niraparib with abiraterone are classified in L1L.	r2024
L2B3	<b>Cytostatic aromatase inhibitors</b>  Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole.  Products containing both ribociclib and letrozole are classified in L1H5.	r2019
L2B9	<b>Other cytostatic hormone antagonists</b>  Products containing relugolix for cancer are classified here. Products containing relugolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X.	r2024

<b>L3</b>	<b>IMMUNOSTIMULATING AGENTS</b>	I1994
<b>L3A</b>	<b>IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS</b>	R2004
L3A1	<b>Colony-stimulating factors</b>  Includes ancestim, empegfilgrastim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim.  Products containing inhaled sargramostim for autoimmune pulmonary alveolar proteinosis (aPAP) are classified in R7X.	r2025
L3A9	<b>All other immunostimulating agents excluding interferons</b>  Includes cridanimod, glatiramer acetate, interleukin-2, picibanil.  <i>Corynebacterium parvum</i> and levamisole are classified here when used as immunostimulants.  Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified here. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.  Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified here.	r2021
<b>L3B</b>	<b>INTERFERONS</b>  Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1. Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified in L1X9.	r2024
L3B1	<b>Interferons, alpha</b>	I1994
L3B2	<b>Interferons, beta</b>  Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here.	R2017
L3B3	<b>Interferons, gamma</b>	I1994
L3B9	<b>Interferons, non-specified</b>	I1994

<b>L4</b>	<b>IMMUNOSUPPRESSANTS</b>  Immunosuppressants used to treat cancer are classified in the appropriate antineoplastic class. For example, nogapendekin alfa+inbakicept for bladder cancer is classified in L1X9	r2026
<b>L4A</b>	Out of use; can be reused from 2013.	D2010
<b>L4B</b>	<b>ANTI-TNF PRODUCTS</b>  Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis.  Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X.	r2020
<b>L4C</b>	<b>INTERLEUKIN INHIBITORS</b>  Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants (eg basiliximab, daclizumab etc) and for auto-inflammatory diseases such as cryopyrin-associated periodic syndromes (eg canakinumab, rilonacept etc). Products containing daclizumab and indicated for multiple sclerosis (MS) only, or both MS and other conditions, are classified in N7A  Products containing levilimab for use in COVID-19 are classified here.  Products containing bimekizumab, brodalumab, ixekizumab, secukinumab or ustekinumab; for psoriatic skin conditions only are classified in D5B; for both psoriatic and also non-skin conditions, eg axial spondyloarthritis are classified here. Psoriatic arthritis is defined as a skin condition.  Products containing dupilumab for both atopic dermatitis and asthma are classified here. Products containing dupilumab for atopic dermatitis only are classified in D5X.  Products containing tocilizumab or anakinra and indicated for arthritic conditions only, or both arthritic and other conditions, are classified in M1C.  Products containing interleukin inhibitors for asthma only, or for asthma and any of the following conditions, EGPA (eosinophilic granulomatosis with polyangiitis), chronic rhinosinusitis with nasal polyposis, nasal polyps, hypereosinophilic syndrome are classified in R3M.	r2026

<b>L4D</b>	<p><b>JAK INHIBITORS</b></p> <p>Includes products containing JAK inhibitors, eg baricitinib, filgotinib, tofacitinib, upadacitinib, etc. These products are indicated for multiple conditions, eg rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, etc.</p> <p>Products containing JAK inhibitors primarily for cancer are classified in L1H7.</p> <p>Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.</p>	I2024
<b>L4E</b>	<p><b>COMPLEMENT INHIBITORS</b></p> <p>Includes products containing complement inhibitors, eg eculizumab, iptacopan, pozelimab, ravulizumab, etc. These products are indicated for multiple conditions, eg atypical haemolytic uraemic syndrome (aHUS), CHAPLE disease, generalised myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), paroxysmal nocturnal haemoglobinuria (PNH), etc.</p> <p>Products containing vilobelimab for use in COVID-19 are classified here.</p> <p>Products containing complement inhibitors: for haemolysis in cold agglutinin disease only are classified in B3X; for hereditary angioedema only are classified in B6D; for atypical haemolytic uraemic syndrome (aHUS) and/or paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for vasculitic conditions only, eg granulomatosis with polyangiitis, are classified in C6X; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for generalised myasthenia gravis (gMG) only are classified in M5X; for geographic atrophy only are classified in S1X.</p>	I2026
<b>L4F</b>	<p><b>CALCINEURIN INHIBITORS</b></p> <p>Includes products containing calcineurin inhibitors, eg ciclosporin, tacrolimus, etc. for the prevention and treatment of organ transplant rejection, graft versus host disease etc.</p> <p>Products containing calcineurin inhibitors are classified in D5 if only for skin conditions (eg topical forms of tacrolimus for atopic dermatitis), or in S1 if only for ophthalmological conditions. Products containing voclosporin are classified in G4X.</p>	I2026

<b>L4X</b>	<p data-bbox="312 170 829 206"><b>OTHER IMMUNOSUPPRESSANTS</b></p> <p data-bbox="312 246 1388 318">Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p data-bbox="312 356 1388 427">Products containing antilymphocyte or antithymocyte immunoglobulins are classified here.</p> <p data-bbox="312 465 1388 573">Products containing apremilast for multiple conditions are classified here. Products containing apremilast for psoriatic skin conditions only are classified in D5B. Psoriatic arthritis is defined as a skin condition.</p> <p data-bbox="312 611 1388 719">Products containing thalidomide or its analogues for erythema nodosum leprosum (ENL) only are classified here, but for cancer, or for both cancer and ENL, are classified in L1K</p> <p data-bbox="312 757 1388 900">Products containing leflunomide for multiple conditions are classified here but for rheumatoid arthritis only are classified in M1C. Products containing efgartigimod alfa for multiple conditions are classified here, but for myasthenia gravis only are classified in M5X.</p> <p data-bbox="312 938 1388 1010">Products containing immunosuppressants and indicated for multiple sclerosis (MS) only, or both MS and other conditions are classified in N7A.</p> <p data-bbox="312 1048 807 1084">Corticosteroids are not classified here.</p>	r2026
------------	--	-------

<b>M</b>	<b>MUSCULO-SKELETAL SYSTEM</b>	
<b>M1</b>	<b>ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS</b>	
<b>M1A</b>	<b>ANTI-RHEUMATICS, NON-STEROIDAL</b>	r2009
	Includes all non-hormonal anti-inflammatory products for systemic treatment of musculoskeletal inflammation. Products for analgesia only are classified in N2B.	
<b>M1A1</b>	<b>Anti-rheumatics, non-steroidal plain</b>	r2020
	Includes products containing an additional non-therapeutic ingredient or an ingredient to minimise the side-effects of the main active substance. Examples include alkalizing agents, local anaesthetics or cytoprotectants. For example, combinations of non-steroidals with antiulcerants, where the antiulcerant is for gastric protection, are classified here.	
<b>M1A2</b>	<b>Anti-rheumatics, non-steroidal combination</b>	R2007
	Combination products containing colchicine, or minerals, vitamins, rutin should be classified here. Combinations of anti-inflammatory substances with analgesics for musculoskeletal conditions are classified here. Includes coxib combinations.	
<b>M1A3</b>	<b>Coxibs, plain</b>	R2007
	Includes products that are highly specific to the COX-2 enzyme. At therapeutic doses, they specifically inhibit cyclo-oxygenase-2 (COX-2) but do not inhibit the cyclo-oxygenase-1 (COX-1) isoenzyme. Products in this class include celecoxib, etoricoxib, parecoxib, rofecoxib and valdecoxib.	
<b>M1B</b>	<b>ANTI-RHEUMATIC CORTICOSTEROID COMBINATIONS</b>	
	Includes all systemic steroid combinations specifically or primarily indicated in rheumatic disorders. Examples include corticosteroids with one or more of the following ingredients:  non-hormonal anti-inflammatory agents Analgesics Vitamins muscle relaxants.	



<b>M1C</b>	<p data-bbox="312 170 906 203"><b>SPECIFIC ANTI-RHEUMATIC AGENTS</b></p> <p data-bbox="312 248 1401 427">This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, seniprutug and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosaliclates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p data-bbox="312 472 1401 539">Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in D or L1B</p> <p data-bbox="312 584 1401 719">Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here. Products containing tocilizumab or anakinra and indicated for both arthritic and other conditions are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p data-bbox="312 763 1401 898">Products containing baricitinib, filgotinib, tofacitinib or upadacitinib (JAK inhibitors), and indicated for rheumatic conditions only, are classified here. Products containing baricitinib, filgotinib, tofacitinib or upadacitinib for multiple conditions are classified in L4D.</p> <p data-bbox="312 943 1401 1055">Products containing leflunomide, and indicated for rheumatic conditions only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X. Products containing anti-TNF substances are classified in L4B.</p> <p data-bbox="312 1099 1023 1133">Products containing azathioprine are classified in L4X.</p> <p data-bbox="312 1178 927 1211">Psoriatic arthritis is defined as a skin condition.</p>	r2026
------------	--	-------

<b>M2</b>	<b>TOPICAL ANTI-RHEUMATICS</b>	
<b>M2A</b>	<b>TOPICAL ANTI-RHEUMATICS AND ANALGESICS</b>  Includes rubefacients for topical treatment of muscular disorders (excluding products for the treatment of dermatological conditions, antivaricose products, etc). Products in this group may also contain suprarenal cortex (small amount of corticosteroid). Topical formulations of products in M1A and M5X are classified here, for example topical products containing chondroitin and glucosamine.	r2009

<b>M3</b>	<b>MUSCLE RELAXANTS</b>  All products containing muscle relaxants, irrespective of formulation, are classified here. Combinations of muscle relaxants with other substances are classified here (except systemic corticosteroids, see M1B).	R2006
<b>M3A</b>	<b>MUSCLE RELAXANTS, PERIPHERALLY ACTING</b>  Includes eg alcuronium, atracurium, botulinum toxin, dantrolene (directly-acting), dimethyltubocurarine, doxacurium, gallamine, hexafluronium, pancuronium, pipecuronium bromide, suxamethonium, tubocurarine, vecuronium.	R1994
<b>M3B</b>	<b>MUSCLE RELAXANTS, CENTRALLY ACTING</b>  Includes eg afloqualone, baclofen, carisoprodol, chlormezanone, chlorphenazine, chlorzoxazone, cyclobenzaprine, eperisone, febarbamate, mephenesin, mephenoxalone, methocarbamol, orphenadrine citrate, phenprobamate, phenylamidol, pridinol mesylate, styramate, thiocolchicoside, tizanidine, tolperisone.	R2006

<b>M4</b>	<b>ANTI-GOUT PREPARATIONS</b>	
<b>M4A</b>	<b>ANTI-GOUT PREPARATIONS</b>  Includes anti-gout preparations containing probenecid, colchicine, etc for the treatment of hyperuricaemia.  Combinations of colchicine with antirheumatic non-steroidals are classified in M1A2.	

<b>M5</b>	<b>OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</b>	
<b>M5A</b>	Out of use; can be reused from 1996.	D1993
<b>M5B</b>	<b>BONE CALCIUM REGULATORS</b>	R2002
	Calcitonin products are classified in H4A. Products containing calcium only are classified in A12A and fluoride products are classified in A12C2.	
M5B1	Out of use; can be reused from 2010.	D2007
M5B2	Out of use; can be reused from 2010.	D2007
M5B3	<b>Bisphosphonates for osteoporosis and related disorders</b>	r2024
	Includes products indicated and used mainly for osteoporosis and Paget's disease of bone, eg those containing alendronic acid, etidronic acid, ibandronic acid, risedronic acid, zoledronic acid, when indicated for these conditions. Combinations of bisphosphonates with calcium, calcitriol or colecalciferol are also classified here.	
M5B4	<b>Bisphosphonates for tumour-related calcium disorders</b>	I2007
	Includes products indicated and used mainly for tumour-related calcium disorders (eg hypercalcaemia of malignancy) eg those containing clodronic acid, etidronic acid, ibandronic acid, pamidronic acid, zoledronic acid when indicated for these conditions.	
M5B9	<b>Other bone calcium regulators</b>	r2026
	Includes other specific products which are used for osteoporosis (eg ipriflavone).  Products containing denosumab for giant cell tumour of bone, with or without other indications related to bone loss (osteoporosis, malignancy-related bone loss etc.), are classified here.	

<b>M5X</b>	<p><b>ALL OTHER MUSCULOSKELETAL PRODUCTS</b></p> <p>Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.</p> <p>Includes hydroquinine indicated for restless leg syndrome.</p> <p>Includes herbal products used for musculoskeletal pain.</p> <p>Products containing amifampridine for Lambert-Eaton myasthenic syndrome are classified here.</p> <p>Products containing burosumab for X-linked hypophosphataemia are classified here.</p> <p>Products containing nusinersen, onasemnogene abeparvovec or risdiplam for spinal muscle atrophy (SMA) are classified here.</p> <p>Products containing vamorolone for Duchenne muscular dystrophy (DMD) are classified here.</p> <p>Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are classified in C1B .</p> <p>Products containing diclofenamide for primary periodic paralysis are classified here. Products containing diclofenamide for diuretic use are classified in C3A9. Products containing diclofenamide for glaucoma are classified in S1E1.</p> <p>Products containing efgartigimod alfa, nipocalimab, rozanolixizumab, or zilucoplan for myasthenia gravis only are classified here. Products containing efgartigimod alfa for both myasthenia gravis and immune thrombocytopenia, or both myasthenia gravis and chronic demyelinating immune polyneuropathy (CIDP) are classified in L4X.</p>	r2026
------------	---	-------

<b>M6</b>	Out of use; can be reused from 2009.	D2006
<b>M6A</b>	Out of use; can be reused from 2009.	D2006

<b>N</b>	<b>NERVOUS SYSTEM</b>	R2007
<b>N1</b>	<b>ANAESTHETICS</b>	
<b>N1A</b>	<b>ANAESTHETICS, GENERAL</b>	
<b>N1A1</b>	<b>Inhalation general anaesthetics</b>  Gas cylinders for hospital use are classified here.	r2010
<b>N1A2</b>	<b>Injectable general anaesthetics</b>  Also includes injectable sedatives, eg midazolam, given for the induction and maintenance of anaesthesia, for the sedation of ventilator - dependent patients (intubation) and as sedative/premedication for surgical procedures.  Products containing esketamine for general anaesthesia are classified here; products containing esketamine for depression are classified in N6A9.	r2020
<b>N1B</b>	<b>ANAESTHETICS, LOCAL</b>  Includes local injectable and topical anaesthetics intended for surgery, surgical and medical procedures, and associated pain relief. Included are eg articaine, bupivacaine, chloroprocaine, dibucaine, etidocaine, lidocaine, mepivacaine, mesocaine, prilocaine, procaine, ropivacaine, tetracaine.  Only single active ingredient products or combinations of different local anaesthetics are classified under N1B. Specific single-ingredient ophthalmological local anaesthetics are classified in S1H. Combinations of local anaesthetics with vasoconstrictors eg adrenaline, are classified here. Products containing either local anaesthetics only or other substances in combination with local anaesthetics and intended for indications other than surgery or associated pain relief are classified under eg A1A, D4A, R2A or S1H according to the indication. Products containing local anaesthetics used specifically for premature ejaculation are classified in G4X.	R2007
<b>N1B1</b>	<b>Anaesthetics local, medical injectables</b>  Injectable local anaesthetic products intended for local, regional or central nerve block except for products intended for nerve block in dental practice which should be classified in N1B2.	I1998
<b>N1B2</b>	<b>Anaesthetics local, dental injectables</b>  Injectable local anaesthetic products intended for local, regional or central nerve block in dental practice. These products usually contain higher concentrations of vasoconstrictor or are presented in cartridges which are applicable to a dental injection system.	I1998

N1B3	<b>Anaesthetics local, topical</b>  Topical or surface local anaesthetic products intended for anaesthesia of skin and mucous membranes.	I1998
N1B9	<b>Anaesthetics local, others</b>  Local anaesthetic products not classified elsewhere, eg cooling sprays and solutions used in medical procedures, topical products containing benzocaine, etc.	R1999

<b>N2</b>	<b>ANALGESICS</b>  Only includes general purpose analgesics with multiple indications and uses. Thus products specifically used for rheumatic disorders are classified in group M, analgesic cold preparations are classified in R5, products specifically for dysmenorrhoea are classified in G2X.	R2003
<b>N2A</b>	<b>NARCOTICS</b>  Includes all analgesics classified as narcotics in accordance with the legal definition of narcotic analgesics in each country.	R1993
<b>N2B</b>	<b>NON-NARCOTICS AND ANTI-PYRETICS</b>  Includes systemic products for non-specific analgesia except those classified in N2A (narcotics), N2C (specific anti-migraine preparations), R5A (analgesic/antihistamine cold preparations) and G2X1 (specific dysmenorrhoea preparations).  Topical products for analgesia are classified in M2A. Products containing acetylsalicylic acid only are classified in N2B, not M1A. Products containing low-dose oral solid acetylsalicylic acid (162mg and below) are classified in B1C1 (platelet aggregation inhibition).  Products containing non-steroidal anti-inflammatories and for both musculoskeletal conditions and analgesia are classified in M1A.  Alka-Seltzer, when it contains an analgesic, is classified in N2B. Otherwise, it is classified in A2A1.  Products containing muscle relaxants in combination with analgesics are classified in M3.  4th level used in Austria, Finland, Hungary, Germany, South Africa, Sweden and Switzerland only.	r2025
N2B1	<b>Prescription-bound non-narcotics and anti-pyretics</b>	
N2B2	<b>Non-prescription-bound non-narcotics and anti-pyretics</b>	
<b>N2C</b>	<b>ANTI-MIGRAINE PREPARATIONS</b>	
N2C1	<b>Anti-migraine selective serotonin agonists</b>  These are selective 5HT <sub>1</sub> receptor agonists eg almotriptan, eletriptan, frovatriptan, lasmiditan, naratriptan, rizatriptan, sumatriptan, zolmitriptan. Includes triptans and ditans.	r2023

<b>N2C2</b>	<b>Anti-migraine CGRP antagonists</b>  Includes products containing CGRP (calcitonin gene-related peptide) antagonists, for example, atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, rimegepant, ubrogepant, etc.	r2023
<b>N2C9</b>	<b>All other anti-migraine preparations</b>  Includes products containing indoramin alone if indicated for migraine.	r2015
<b>N2D</b>	<b>GABAPENTINOID PRODUCTS</b>  Includes products containing gabapentinoids, eg crisugabalin, gabapentin, gabapentin enacarbil, mirogabalin, pregabalin, etc. Gabapentinoids for diabetic neuropathy, epilepsy, generalised anxiety disorder, neuropathic pain, restless leg syndrome etc are classified here.  Combinations of gabapentinoids with other substances are classified here.	I2025

<b>N3</b>	<b>ANTI-EPILEPTICS</b>	r2025
<b>N3A</b>	<b>ANTI-EPILEPTICS</b>  Also includes products for non-epileptic convulsions, eg in pregnancy.  Products containing clonazepam are classified here.  Products containing gabapentinoids, eg gabapentin, pregabalin, etc, for epilepsy only, and for epilepsy and also other conditions are classified in N2D.	

<b>N4</b>	<b>ANTI-PARKINSON DRUGS</b>	r2026
<b>N4A</b>	<b>ANTI-PARKINSON DRUGS</b>  Products containing bromocriptine: for Parkinson's disease only are classified here: for diabetes mellitus only are classified in A10X9: for multiple conditions are classified in G2D: for acromegaly only are classified in H1C2.  Products containing ropinirole or similar substances for restless leg syndrome are classified here.	



<b>N5</b>	<b>PSYCHOLEPTICS</b>	
<b>N5A</b>	<b>ANTIPSYCHOTICS</b>	R2005
	Combinations with psychoanaleptics eg antidepressants are classified in N6C.	
<b>N5A1</b>	<b>Atypical antipsychotics</b>	R2005
	Includes products containing substances such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, remoxipride, risperidone, sertindole, ziprasidone, zotepine.	
<b>N5A9</b>	<b>Conventional antipsychotics</b>	R2005
	Includes eg phenothiazines, thioxanthenes, butyrophenones. Also includes sulpiride, in all countries except Japan, Korea and Taiwan where it is classified in A2B9 (all other anti-ulcerants).	
<b>N5B</b>	<b>HYPNOTICS/SEDATIVES</b>	r2008
	Products for sleep rhythm disturbances containing melatonin only are classified in H4X. Products for insomnia that contain a hypnotic/sedative plus melatonin are classified in N5B in the appropriate subclass (N5B2, N5B4 or N5B5).	
<b>N5B1</b>	<b>Non-barbiturates, plain</b>	r2023
	Includes benzodiazepines indicated exclusively for the treatment of insomnia, eg nitrazepam, flurazepam. Includes orexin inhibitors for the treatment of insomnia, eg daridorexant, lemborexant, suvorexant. Prolonged-release melatonin is classified here when indicated for primary insomnia. Products containing melatonin only and indicated for sleep rhythm disturbances are classified in H4X.	
<b>N5B2</b>	<b>Non-barbiturates, combinations</b>	
<b>N5B3</b>	<b>Barbiturates, plain</b>	
<b>N5B4</b>	<b>Barbiturates, combinations</b>	
<b>N5B5</b>	<b>Herbal hypnotics/sedatives</b>	r2009
	Includes products containing one or more herbal substances. Products classified here can also contain other non-sedative substances. Prolonged-release melatonin indicated for primary insomnia is classified in N5B1. Melatonin (any form/strength) in combination with a hypnotic/sedative is classified in the appropriate N5B subclass. Other products in N5B containing both herbal and non-herbal substances are classified according to the non-herbal substance.	

<b>N5B6</b>	<b>Orexin Antagonists</b>  Includes products containing orexin receptor antagonists, eg daridorexant, lemborexant, suvorexant etc. for insomnia.	I2026
<b>N5C</b>	<b>TRANQUILLISERS</b>  Includes minor tranquillisers, eg benzodiazepines, hydroxyzine, meprobamate, but excludes benzodiazepines indicated exclusively for the treatment of insomnia, eg nitrazepam, flurazepam (N5B1). Combinations with psychoanaleptics are classified in N6C. Products containing clonazepam are classified in N3A.	R2004

<b>N6</b>	<b>PSYCHOANALEPTICS EXCLUDING ANTI-OBESITY PREPARATIONS</b>	
<b>N6A</b>	<b>ANTI-DEPRESSANTS AND MOOD STABILISERS</b>	R2003
	Includes substances used in the treatment of depression and mood stabilisation. Combinations with ataractics are classified in N6C.	
N6A1	Out of use; can be reused from 2009.	D2006
N6A2	<b>Antidepressants, herbal</b>	R2006
	Includes products containing herbal substances only, eg St. John's Wort. Products containing both a synthetic and a herbal substance are classified in N6A4, N6A5 or N6A9.	
N6A3	<b>Mood stabilisers</b>	R2006
	These products affect the manic phases of bipolar disorders, eg products containing lithium. Includes products containing valproate semisodium when indicated exclusively for mood stabilisation.	
N6A4	<b>SSRI antidepressants</b>	r2014
	Selective serotonin re-uptake inhibitor antidepressants. Includes eg citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline.	
	Products containing paroxetine (7.5mg daily) and indicated for menopausal vasomotor symptoms are classified in G2X9.	
N6A5	<b>SNRI antidepressants</b>	I2006
	Serotonin-noradrenaline re-uptake inhibitor antidepressants. Includes eg duloxetine when used in depression, milnacipran, venlafaxine.	
N6A9	<b>Antidepressants, all others</b>	r2020
	Includes eg amitriptyline, clomipramine, imipramine, mirtazapine, vortioxetine. Products containing esketamine for depression are classified here; products containing esketamine for general anaesthesia are classified in N1A2.	
<b>N6B</b>	<b>PSYCHOSTIMULANTS</b>	R2004
	Includes drugs which increase the psychic and physical performance and which have a fatigue depressing, stimulating effect, eg fentyllines, fencamfamine, methylphenidate, amphetamines (excluding their use in obesity, see A8A). Atomoxetine is classified in N7X.	

<b>N6C</b>	<b>PSYCHOLEPTIC-PSYCHOANALEPTIC COMBINATIONS</b>  Includes combinations of tranquillisers and/or antipsychotics with antidepressants.	r2010
<b>N6D</b>	<b>NOOTROPICS</b>  A class of psychoactive drugs which are claimed to have a selective action on integrative functions of the CNS. Their action is alleged to be particularly associated with intellectual function, learning and memory. Includes preparations containing substances such as piracetam, pyritinol, pyrisuccideanol maleate, meclofenoxate, cyprodenate and their combinations with other substances, excluding those products with a vasodilatory action (see C4A). Combinations with cardiac glycosides are classified in C1A2.	
<b>N6E</b>	<b>NEUROTONICS AND OTHER MISCELLANEOUS PRODUCTS</b>  Includes products not classified above such as single or combination products containing bisibutiamin, deanol and derivatives, GABA, GABOB, N-acetyl asparaginic acid, glutaminic acid and salts, kavain, phospholipid, succinodinitrate.	

<b>N7</b>	<b>OTHER CNS DRUGS</b>	R1996
<b>N7A</b>	<b>MULTIPLE SCLEROSIS PRODUCTS</b> <p>Products containing alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, laquinimod, teriflunomide, etc, and indicated for multiple sclerosis only, are classified here.</p> <p>Products containing daclizumab, divozilimab, natalizumab, etc, and indicated for multiple sclerosis and also for other conditions are classified here.</p> <p>Products containing alemtuzumab and indicated for cancer only, are classified in L1G9.</p> <p>Products containing daclizumab for use in kidney transplantation only are classified in L4C.</p> <p>Products containing beta interferons and indicated for multiple sclerosis only are classified here. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified in L3B2.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified in L1D.</p> <p>Products containing fampridine for improvement in walking in multiple sclerosis are classified in N7X.</p> <p>Products containing ofatumumab for cancer are classified in L1G1.</p> <p>Products containing sphingosine-1-phosphate (S1P) receptor modulators, eg etrasimod, ozanimod etc, for multiple sclerosis and also other conditions, eg inflammatory bowel disease etc, are classified here. Products containing S1P receptor modulators and indicated for inflammatory bowel disease only are classified in A7E9.</p> <p>Products containing other substances, eg corticosteroids, immunosuppressants such as azathioprine, that have multiple uses, are classified elsewhere.</p>	r2025
<b>N7B</b>	<b>ANTISMOKING PRODUCTS</b> <p>Includes products used to stop smoking.</p>	
<b>N7C</b>	<b>ANTIVERTIGO PRODUCTS</b> <p>Includes betahistine, cinnarizine and flunarizine when indicated for vertigo and Meniere's disease.</p>	I1996

<b>N7D</b>	<b>ANTI-ALZHEIMER PRODUCTS</b>	I1998
<b>N7D1</b>	<b>Anti-Alzheimer products, cholinesterase inhibitors</b>  Includes eg donepezil, galantamine, rivastigmine and tacrine.	R2003
<b>N7D9</b>	<b>All other anti-Alzheimer products</b>  Includes all other products specifically used for Alzheimer's disease.	I1998
<b>N7E</b>	<b>DRUGS USED IN ALCOHOL DEPENDENCE</b>  Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol use disorder (AUD) or both AUD and opioid use disorder (OUD) is classified here.	r2026
<b>N7F</b>	<b>DRUGS USED IN OPIOID DEPENDENCE</b>  Includes naltrexone, except when also used in alcohol use disorder (use N7E).	r2026
<b>N7X</b>	<b>ALL OTHER CNS DRUGS</b>  Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in this class. Products containing gabapentinoids, eg. crisugabalin, gabapentin, gabapentin enacarbil, mirogabalin, pregabalin, etc, plain or in combination with other substances, are classified in N2D.  Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here.  Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here.  Products indicated for amyotrophic lateral sclerosis (ALS) are classified here.  Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here.  Products containing inebilizumab or satralizumab for neuromyelitis optica spectrum disorder (NMOSD) only are classified here. Product containing inebilizumab for multiple conditions are classified in L4X.  Products containing naloxone for reversal of CNS depression in opioid overdose or intoxication are classified here.  Products containing eladocogene exuparvovec for the treatment of human aromatic L-amino acid decarboxylase (AADC) are classified here.	r2026

<b>P</b>	<b>PARASITOLOGY</b>	
<b>P1</b>	<b>ANTIPROTOZOALS AND ANTHELMINTICS</b>	R2003
<b>P1A</b>	<b>AMOEBICIDES</b>	R2006
	Includes products whose major indication is amoebiasis. Trichomonacides, eg metronidazole, will be classified in G1A or J8B, except when they are used primarily as amoebicides. Products indicated for both trichomoniasis and amoebiasis are classified in G1A1.	
<b>P1B</b>	<b>ANTHELMINTICS, EXCLUDING SCHISTOSOMICIDES</b>	
	In an anthelmintic combination product the anthelmintic component takes precedence over other components.	
<b>P1C</b>	<b>SCHISTOSOMICIDES</b>	
	Products used to treat bilharziasis.	
<b>P1D</b>	<b>ANTI-MALARIALS</b>	r2018
	If a product contains an antimalarial ingredient and also a second ingredient which is not a specific antimalarial, then this is considered a single-ingredient antimalarial.	
	Vaccines against malaria are classified in J7F1.	
<b>P1D1</b>	<b>Anti-malarials, single ingredient</b>	I2000
<b>P1D2</b>	<b>Anti-malarials, multi-ingredient</b>	I2000
<b>P1E</b>	Out of use; can be reused from 2006.	D2003
<b>P1F</b>	Out of use; can be reused	
<b>P1G</b>	<b>OTHER ANTI-PARASITIC AGENTS</b>	r2023
	Includes products for the treatment of leishmaniasis and toxoplasmosis. Pentamidine (used to treat Pneumocystis carinii) is classified here. Products containing miltefosine for leishmaniasis are classified here. Products containing miltefosine for skin metastases of breast cancer are classified in L1X9.	

<b>P3</b>	<b>ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES AND REPELLENTS</b>	I2003
<b>P3A</b>	<b>ECTOPARASITICIDES, INCLUDING SCABICIDES</b>  Includes scabicides and products for the eradication of lice and fleas	I2003
<b>P3B</b>	<b>INSECTICIDES AND REPELLENTS</b>  Includes pyrethrines.	I2003



<b>R</b>	<b>RESPIRATORY SYSTEM</b>	
<b>R1</b>	<b>NASAL PREPARATIONS</b>	
<b>R1A</b>	<b>TOPICAL NASAL PREPARATIONS</b>	R1993
R1A1	<b>Nasal corticosteroids without anti-infectives</b>  Includes all products containing corticosteroids (plain or in combination with other compounds) but excludes all those containing an anti-infective. Products indicated for both asthma and rhinitis are classified in R3D1.	R2007
R1A2	Out of use; can be reused from 1997.	D1994
R1A3	<b>Nasal corticosteroids with anti-infectives</b>  Includes all products containing both a corticosteroid and an anti-infective.	R1994
R1A4	<b>Nasal anti-infectives without corticosteroids</b>  Includes all products containing anti-infectives (plain or in combination with other compounds) but excludes all those containing a corticosteroid.	R1994
R1A5	Out of use; can be reused from 1997.	R2007
R1A6	<b>Nasal antiallergic agents</b>  Includes all nasal preparations containing an antihistamine or antiallergic compound (plain or in combination) eg azelastine, cromoglicic acid, ketotifen, levocabastine. Products containing both a nasal form and an ophthalmic form in the same pack are classified here.	R2003
R1A7	<b>Nasal decongestants</b>  Includes all products containing decongestants. Decongestants in combination with anti-allergics will be classified in R1A6. Includes specific nasal formulations.	R2005
R1A9	<b>Other topical nasal preparations</b>  Nasal products containing anticholinergics, antivirals, antifungals and antiseptics are classified here. Also included are topical nasal saline solutions. Includes specific nasal formulations.	R2005

<b>R1B</b>	<b>SYSTEMIC NASAL PREPARATIONS</b>  Includes all preparations indicated primarily for rhinitis, allergic rhinitis, sinusitis, catarrh, nasal congestion and other similar conditions. This group includes preparations containing decongestants with or without antihistamines, but excludes those containing analgesics, antitussives and vitamins together with those which are primarily indicated for colds and influenza which are classified in R5A.	R1994
------------	--	-------

<b>R2</b>	<b>THROAT PREPARATIONS</b>	r2017
<b>R2A</b>	<b>THROAT PREPARATIONS</b>  All preparations formulated for infections of the throat, nose/throat and mouth/throat, such as tablets, lozenges, pastilles, drops, sprays, gargles and suppository forms (eg with bismuth, povidone-iodine).  Lozenges with broncholytic or cough-relieving effects are classified in R5F unless they contain anti-infectives (R5B), expectorants (R5C) or antitussives (R5D).	

<b>R3</b>	<b>ANTI-ASTHMA AND COPD PRODUCTS</b> <p>This group includes all preparations indicated for bronchial asthma and chronic obstructive pulmonary disease (COPD). It consists of preparations with bronchodilatory, broncho-spasmolytic or anti-asthmatic activity.</p> <p>Bronchodilators combined with expectorants or mucolytics are generally classified in R5C.</p> <p>The need to classify combination products has led to the adoption of a hierarchical system with R3A ingredients taking precedence over R3B etc. Due to the importance of specific combinations, there are some exceptions included in R3C, R3E, R3F, and R3L.</p>	r2016
<b>R3A</b>	<b>B2-AGONISTS</b> <p>This class includes the following substances - bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, isoetarine, isoprenaline, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, tulobuterol.</p> <p>Excluded are combinations of B2-agonists with non-steroidal respiratory anti-inflammatories (R3E) and combinations of B2-agonists with corticoids (R3F) and combinations of B2-agonists with anticholinergics (with or without corticosteroids) (R3L).</p>	r2016
R3A1	Out of use; can be reused in 2005.	D2002
R3A2	<b>B2-agonists, systemic</b>	r2016
R3A3	<b>Long-acting B2-agonists, inhalant</b> <p>Includes formoterol, salmeterol and procaterol. Includes liquids and capsules to be used as inhalants.</p>	r2022
R3A4	<b>Short-acting B2-agonists, inhalant</b> <p>Includes liquids and capsules to be used as inhalants.</p>	r2016
<b>R3B</b>	<b>XANTHINES</b> <p>This group includes substances such as theophylline, aminophylline, diprophylline etc.</p>	
R3B1	<b>Xanthines, inhalant</b>	
R3B2	<b>Xanthines, systemic</b>	R1993

<b>R3C</b>	<b>NON-STEROIDAL RESPIRATORY ANTI-INFLAMMATORIES</b>  This group contains respiratory antihistamines and non-steroidal respiratory anti-inflammatory products. It includes azelastine, cromoglycic acid, ketotifen, levocabastine, and tranilast. In Japan only, terfenadine is included in this group. In other countries it is classified in R6A. Excluded are combinations of these compounds with B2-agonists (R3E).	r2016
R3C1	<b>Non-steroidal respiratory anti-inflammatories, inhalant</b>	
R3C2	<b>Non-steroidal respiratory anti-inflammatories, systemic</b>	
<b>R3D</b>	<b>CORTICOIDS</b>  Excluded are combinations of corticoids with B2-agonists (R3F) and LAMA/LABA combinations (R3L3).	r2019
R3D1	<b>Corticoids, inhalant</b>  Includes plain inhalant corticosteroids only. Also includes products indicated for both rhinitis and asthma.	R2007
R3D2	<b>Corticoids, systemic</b>  This subgroup includes combinations only, with the exception of those classified in R3F and R3L3.  Plain systemic corticosteroids are classified in H2A.	r2019
<b>R3E</b>	<b>B2-AGONIST AND R3C COMBINATIONS</b>	r2016
R3E1	<b>B2-agonist and R3C combinations, inhalant</b>	r2016
R3E2	<b>B2-agonist and R3C combinations, systemic</b>	r2016
<b>R3F</b>	<b>B2-AGONIST AND CORTICOID COMBINATIONS</b>  Combinations of LAMA/LABAs with corticosteroids are classified in R3L3.	r2019
R3F1	<b>B2-agonist and corticoid combinations, inhalant</b>	r2016
R3F2	<b>B2-agonist and corticoid combinations, systemic</b>	r2016
<b>R3G</b>	Out of use	D2016
R3G1	Out of use	D2002

R3G2	Out of use	D2016
R3G3	Out of use	D2016
R3G4	Out of use	D2016
<b>R3H</b>	<b>PDE4 INHIBITORS FOR ASTHMA/COPD</b>  Includes cilomilast, roflumilast.	I2005
R3H1	<b>PDE4 inhibitors for asthma/COPD, inhalant</b>	I2005
R3H2	<b>PDE4 inhibitors for asthma/COPD, systemic</b>	I2005
<b>R3I</b>	<b>DEVICES FOR ASTHMATIC CONDITIONS</b>  This excludes nebulising machines/nebulators which are classified in V7A.	R2001
<b>R3J</b>	<b>ANTILEUKOTRIENE ANTI-ASTHMATICS</b>  Includes montelukast, pranlukast, zafirlukast, and 5-lipoxygenase inhibitors such as zileuton when indicated for asthma.	R2004
R3J1	<b>Antileukotriene anti-asthmatics, inhalant</b>	R1998
R3J2	<b>Antileukotriene anti-asthmatics, systemic</b>	R1998
<b>R3K</b>	<b>ANTICHOLINERGICS, PLAIN</b>	I2016
R3K1	<b>Short-acting anticholinergics, plain, inhalant</b>  Includes products containing eg, ipratropium bromide, oxitropium bromide, etc	I2016
R3K2	<b>Long-acting anticholinergics, plain, inhalant</b>  Includes products containing eg aclidinium bromide, flutropium bromide, glycopyrronium bromide, tiotropium bromide, umeclidinium bromide, etc.	I2016
R3K3	<b>Anticholinergics, plain, systemic</b>  Includes products containing anticholinergics (short- or long-acting) for systemic use.	I2016

<b>R3L</b>	<b>ANTICHOLINERGICS IN COMBINATION WITH B2-AGONISTS</b>	I2016
R3L1	<b>Short-acting anticholinergic combinations with short-acting B2-agonists, inhalant</b>  Includes products containing eg ipratropium bromide with fenoterol, ipratropium bromide with salbutamol, etc	I2016
R3L2	<b>Long-acting anticholinergic combinations with long-acting B2-agonists, inhalant</b>  Includes products containing eg aclidinium bromide with formoterol, glycopyrronium bromide with indacaterol, tiotropium bromide with formoterol, tiotropium bromide with olodaterol, umeclidinium bromide with vilanterol, etc. These are known as LAMA/LABA combinations.	r2019
R3L3	<b>Long-acting anticholinergic combinations with both long-acting B2-agonists and with corticosteroids, inhalant</b>  Includes products containing a triple combination of a long-acting anticholinergic, a long-acting B2-agonist and a corticosteroid. Includes glycopyrronium bromide plus formoterol plus beclomethasone or budesonide, tiotropium bromide plus formoterol plus ciclesonide, umeclidinium bromide plus vilanterol plus fluticasone, etc.	I2019
R3L8	<b>Anticholinergic combinations with B2-agonists, systemic</b>  Includes products containing anticholinergics (short- or long-acting) in combination with B2-agonists (short- or long-acting) for systemic use.	I2016
R3L9	<b>Anticholinergic combinations with B2-agonists, inhalant, other</b>  Includes products containing anticholinergics in combination with B2-agonists that cannot be classified in the other R3L classes.	I2016
<b>R3M</b>	<b>INTERLEUKIN INHIBITOR ANTI-ASTHMATICS</b>  Includes products containing interleukin inhibitors for asthma, eg benralizumab, mepolizumab, reslizumab, etc.  Products containing interleukin inhibitors for asthma and any of the conditions, EGPA (eosinophilic granulomatosis with polyangiitis), chronic rhinosinusitis with nasal polyposis, nasal polyps, hypereosinophilic syndrome are classified here.  Products containing dupilumab for both asthma and atopic dermatitis are classified in L4C.	r2023

<b>R3X</b>	<b>ALL OTHER ANTI-ASTHMA AND COPD PRODUCTS</b>	R2000
<b>R3X1</b>	<b>All other anti-asthma and COPD products, inhalant</b>  This subgroup includes anti-asthmatic cigarettes.	R2003
<b>R3X2</b>	<b>All other anti-asthma and COPD products, systemic</b>  Includes products containing alpha-1-proteinase inhibitor (alpha-1-antitrypsin), omalizumab, tezepelumab, etc.	r2023

<b>R4</b>	<b>CHEST RUBS AND OTHER INHALANTS</b>	
<b>R4A</b>	<b>CHEST RUBS AND OTHER INHALANTS</b>  Includes chest rubs and other inhalants (such as nasal decongestants and baths excluding specific nasal formulations) which are not classified under R1A, R2A, R3A or R5C; also includes medical sprays for disinfecting the air in sick rooms as a prophylactic against colds, etc.	R2005

<b>R5</b>	<b>COUGH AND COLD PREPARATIONS</b>	
<b>R5A</b>	<b>COLD PREPARATIONS WITHOUT ANTI-INFECTIVES</b>  This group consists of all products indicated for colds, influenza, etc. It therefore includes combination products such as those containing antihistamines with decongestants, analgesics, antipyretics, vitamins, etc and since symptoms of colds and influenza may include a cough, an antitussive, and possibly an expectorant may also be included (see also R5D2 and R5C).	R1994
<b>R5B</b>	<b>COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES</b>  Includes combinations with anti-infectives (including antivirals) indicated specifically for coughs, colds, influenza and other respiratory conditions. Combinations of antiseptics with expectorants are classified in R5C and with antitussives are classified in R5D2.	r2016
<b>R5C</b>	<b>EXPECTORANTS</b>  'Expectorants' mean substances with secretolytic or secretomotoric activity, so that mucolytics are classified in this group.  The group includes all cough preparations with an expectorant as the main ingredient (eg guaiacol, saponin, ammonium chloride). These may also include antihistamines and bronchodilators but excluded are combinations of expectorants with antitussives (R5D2), with analgesics and antipyretics (R5A), and with anti-infectives (R5B). Lozenges indicated for cough and containing expectorants are classified here. Products containing dornase alfa for cystic fibrosis are classified here.	r2021
<b>R5D</b>	<b>ANTITUSSIVES</b>	
<b>R5D1</b>	<b>Plain antitussives</b>  Includes all plain antitussives. Products containing gefapixant are classified here.	r2023
<b>R5D2</b>	<b>Antitussives in combinations</b>  Includes combinations with expectorants, antihistamines, ephedrine, herbal tinctures, etc. Excluded are combinations with analgesics and antipyretics (R5A) and combinations with anti-infectives (R5B).	R1994
<b>R5E</b>	Out of use; can be reused.	



<b>R5F</b>	<b>OTHER COUGH AND COLD PREPARATIONS</b>  This group includes: <ul style="list-style-type: none"> <li>- combinations without a clearly expectorating or antitussive effect;</li> <li>- lozenges indicated for cough unless they contain anti-infectives, R5B or antitussives, R5D, or expectorants, R5C);</li> <li>- expectorant teas.</li> </ul>	r2009
------------	---	-------

<b>R6</b>	<b>SYSTEMIC ANTIHISTAMINES</b>	
<b>R6A</b>	<b>SYSTEMIC ANTIHISTAMINES</b>  Includes all systemic antihistamines, plain and in combination, not classified elsewhere.  Antihistamines in combination with decongestants are classified in R1B.  Terfenadine in Japan is classified in R3C; in all other countries it is classified here.	R2003

<b>R7</b>	<b>OTHER RESPIRATORY SYSTEM PRODUCTS</b>	
<b>R7A</b>	<b>RESPIRATORY STIMULANTS</b>  Includes centrally acting respiratory stimulants such as lobeline, ethamivan, crotetiamide, croptopamide, nikethamide and doxapram (plain only).  Also includes products specifically indicated for primary apnoea in premature newborn babies.	R2006
<b>R7B</b>	<b>CYSTIC FIBROSIS PRODUCTS</b>  Products containing dornase alfa for cystic fibrosis are classified in R5C.	I2021
<b>R7B1</b>	<b>Cystic fibrosis transmembrane regulator (CFTR) modulators</b>  Includes products containing eg elexacaftor, ivacaftor, lumacaftor, tezacaftor, etc for cystic fibrosis.	I2021
<b>R7C</b>	<b>LUNG SURFACTANTS</b>  Includes substances such as colfoscaril palmitate used in neonatal respiratory distress syndrome.	I1996
<b>R7D</b>	<b>IDIOPATHIC PULMONARY FIBROSIS PRODUCTS</b>  Includes products containing eg pirfenidone, nintedanib, etc for idiopathic pulmonary fibrosis.  Products containing nerandomilast for idiopathic pulmonary fibrosis (IPF), and/or progressive pulmonary fibrosis (PPF), are classified here.  Products containing nintedanib for idiopathic pulmonary fibrosis only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified here. Products containing nintedanib for cancer only are classified in L1H9.	r2026
<b>R7X</b>	<b>ALL OTHER RESPIRATORY SYSTEM PRODUCTS</b>  Products containing inhaled sargramostim for autoimmune pulmonary alveolar proteinosis (aPAP) are classified in R7X.	r2025

<b>S</b>	<b>SENSORY ORGANS</b>	
<b>S1</b>	<b>OPHTHALMOLOGICALS</b>	
<b>S1A</b>	<b>OPHTHALMOLOGICAL ANTI-INFECTIVES</b>  Includes plain anti-infectives: antibacterials (eg sulphonamides), antifungals, and antiparasitics (eg lotilaner). Also includes all anti-infective combinations with the exception of corticosteroid/anti-infective combinations (S1C).  Excluded are antiseptics (S1G6) and antivirals (S1D).	r2025
<b>S1B</b>	<b>OPHTHALMOLOGICAL CORTICOSTEROIDS</b>  Includes plain corticosteroids and all corticosteroid combinations, with the exception of corticosteroid/anti-infective combinations (S1C).	
<b>S1C</b>	<b>OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTI-INFECTIVE COMBINATIONS</b>	R2001
S1C1	<b>Ophthalmological corticosteroid and anti-infective combinations</b>	I2001
S1C2	<b>Ophthalmological NSAIDS and anti-infective combinations</b>	I2001
S1C9	<b>Other ophthalmological anti-inflammatory and anti-infective combinations</b>	I2001
<b>S1D</b>	<b>OPHTHALMOLOGICAL ANTIVIRAL AGENTS</b>  Includes aciclovir, iododesoxycytidine, idoxuridine, 5-ethyl-2' deoxyuridine, trifluridine, tromantadine, vidarabine. Systemic forms of products for cytomegalovirus retinitis are classified in J5B3.	r2008
<b>S1E</b>	<b>MIOTICS AND ANTIGLAUCOMA PREPARATIONS</b>	
S1E1	<b>Miotics and antiglaucoma preparations, systemic</b>  Includes carboanhydrase inhibitors (acetazolamide, diclofenamide and methazolamide), only when they are specifically promoted and used for the treatment of glaucoma (see also C3A9). Products containing diclofenamide for primary periodic paralysis are classified in M5X and for diuretic use are classified in C3A9.	r2021

S1E2	<b>Miotics and antiglaucoma preparations, topical</b>  Includes parasympathomimetics (acelidine, acetylcholine, clonidine, pilocarpine); anticholinesterases or cholinesterase inhibitors (carbachol, demecarium bromide, distigmine, ecothiopate iodide, isoflurophate (DFP), neostigmine, paraoxon, physostigmine); sympathicolytics (guanethidine); beta-blockers (bupranolol, timolol); sympathomimetics (adrenaline/epinephrine); prostaglandin analogues; carbo-anhydrase inhibitors.	R2007
S1F	<b>MYDRIATICS AND CYCLOPLEGICS</b>  Includes parasympathicolytics (atropine, cyclopentolate, homatropine, scopolamine, tropicamide) and sympathomimetics (phenylephrine, tyramine) in concentration of 2% or more.	
S1G	<b>OCULAR ANTI-ALLERGICS, DECONGESTANTS, ANTISEPTICS</b>  Combination products containing substances from more than one subgroup of S1G are classified according to the hierarchical principle. For example, a product containing an antihistamine together with a sympathomimetic, is classified in S1G1, rather than S1G5.  Combination products containing substances from one or more of the subgroups of S1G, together with eye vitamins or similar substances, are classified in the appropriate S1G subclass.  Ophthalmic non-steroidal anti-inflammatories are classified in S1R. Products containing non-steroidal anti-inflammatories in combination with anti-allergics and/or antihistamines are classified in the appropriate S1G subclass.	r2017
S1G1	<b>Ocular anti-allergics, antihistamines</b>  Includes antazoline, chlorphenamine, emedastine, epinastine, levocabastine.	R2005
S1G2	<b>Ocular anti-allergics, mast cell stabilisers</b>  Includes acitazanolast, cromoglicic acid, ibudilast, nedocromil, lodoxamide, pemirolast, tranilast.	I2004
S1G3	<b>Ocular anti-allergics, multiple action</b>  Includes antihistamines which also have a mast cell stabilisation action, eg alcaftadine, azelastine, ketotifen, olopatadine.	r2014
S1G5	<b>Ocular decongestants, sympathomimetics</b>  Includes naphazoline, phenylephrine, tetryzoline.	I2004

<b>S1G6</b>	<b>Ocular antiseptics</b>  Includes benzalkonium chloride, bibrocathol, boric acid, chlorbutanol, chlorhexidine, edetic acid, ethacridine, mercury salts, povidone, salicylic acid, sodium propionate.	I2004
<b>S1G9</b>	<b>Other similar ocular products</b>  Includes salts of bismuth, silver and zinc.	I2004
<b>S1H</b>	<b>OPHTHALMOLOGICAL LOCAL ANAESTHETICS</b>  Includes cocaine, oxybuprocaine, proxymetacaine and tetracaine.	
<b>S1J</b>	Out of use; can be reused from 2009.	D2006
<b>S1K</b>	<b>DRY EYE PRODUCTS</b>	R2016
<b>S1K1</b>	<b>Artificial tears and ocular lubricants</b>  Includes products containing substances that are used to replace the moisturising action of natural tears.	I2016
<b>S1K9</b>	<b>Dry eye products, other</b>  Includes products containing eg, ciclosporin, diquafosol, rebamipide, when indicated for dry eye. These substances can act in various ways to improve the availability of tears, eg to increase tear production, or to manage inflammation arising from dry eye.  Products containing rebamipide for gastric mucosal protection are classified in A2B9.	I2016
<b>S1L</b>	<b>PREPARATIONS FOR USE WITH CONTACT LENSES</b>  Includes products for cleaning, disinfecting and deproteinising contact lenses.	R2001
<b>S1M</b>	<b>EYE TONICS AND EYE VITAMINS</b>  Preparations which claim to improve asthenopia and weakness of accommodation or which are for 'tired eyes'. Vitamin products specifically for eye conditions are classified here.  Combination products containing substances from one or more of the subgroups of S1G, together with eye vitamins or similar substances, are classified in the appropriate S1G subclass.  Ocular forms of products containing only vitamin A are classified here.	r2011

<b>S1N</b>	<b>PREPARATIONS TO PREVENT CATARACT AND ANTICATARACTOGENICS</b>  Preparations which claim to prevent cataracts or improve vision in early cataract formation.	R2003
<b>S1N1</b>	<b>Preparations to prevent cataract and anticataractogenics, systemic</b>	R1993
<b>S1N2</b>	<b>Preparations to prevent cataract and anticataractogenics, topical</b>	R1993
<b>S1P</b>	<b>OCULAR ANTINEOVASCULARISATION PRODUCTS</b>  Includes products indicated specifically for the treatment of wet age-related macular degeneration (AMD) and other ocular conditions where neovascularisation is believed to play a role. Includes aflibercept, anecortave, pegaptanib, ranibizumab, rostoporfin, and verteporfin. Vitamins promoted to prevent AMD are classified in S1M. Products containing aflibercept for cancer are classified in L1X9.	r2018
<b>S1Q</b>	Out of use; can be reused.	
<b>S1R</b>	<b>OPHTHALMIC NON-STEROIDAL ANTI-INFLAMMATORIES</b>  Includes non-steroidal anti-inflammatory products for specific ophthalmological conditions. For example, bendazac, diclofenac, flurbiprofen, indomethacin, oxyphenbutazone, piroxicam, pranoprofen, suprofen.  Products containing non-steroidal anti-inflammatories in combination with anti-allergics and/or antihistamines are classified in the appropriate S1G subclass.	r2017
<b>S1S</b>	<b>OPHTHALMOLOGICAL SURGICAL AIDS</b>  This group comprises drugs used during ophthalmological surgery.	R2003
<b>S1S1</b>	<b>Viscoelastic substances</b>  Hyaluronic acid injection or other substances used during surgical procedures on the eye is classified in this group. Hyaluronic acid injection for intra-articular administration (eg 2.5 mg/ampoule) used in the treatment of arthritis is classified in M5X.	I1998
<b>S1S9</b>	<b>Other surgical aids</b>  Preparations containing eg enzymes (chymotrypsin, zonolytics) for use in eye surgery; surgical irrigation solutions, eye washes for surgical use only, are classified in this group.	I1998

<b>S1T</b>	<b>OPHTHALMOLOGICAL DIAGNOSTIC AGENTS</b>  All diagnostics as far as they do not fit into other classes, diagnostic dyes eg rose bengal, fluorescein.	I1998
<b>S1X</b>	<b>OTHER OPHTHALMOLOGICALS</b>  Includes preparations which improve regeneration (iodine); preparations which improve retinal blood flow (heparin, tolazoline); preparations which improve adaptation and all other ophthalmological preparations not mentioned in S1A-S1T. Products used for diabetic retinopathy are classified here.	r2016
S1X1	<b>Other ophthalmologicals, systemic</b>	I1993
S1X2	<b>Other ophthalmologicals, topical</b>  Products containing topical sirolimus for chronic non-infectious uveitis are classified here.  Products for geographic atrophy, such as avacincaptad pegol and ophthalmic pegcetacoplan, are classified in S1X2.	r2025

<b>S2</b>	<b>OTOLOGICALS</b>	
<b>S2A</b>	<b>OTIC ANTI-INFECTIVES</b>  Includes all ear preparations containing an anti-infective but no steroid. This, therefore, includes both plain anti-infective products, eg penicillin ointment, and those where the anti-infective is one of several ingredients.	
<b>S2B</b>	<b>OTIC CORTICOSTEROIDS</b>  Includes all ear preparations containing a steroid but no anti-infective. This, therefore, includes plain steroid products and those where a steroid is one of several ingredients.	
<b>S2C</b>	<b>OTIC CORTICOSTEROID/ANTI-INFECTIVE COMBINATIONS</b>  Includes all ear preparations containing both a steroid and an anti-infective, whether alone or with other ingredients.	
<b>S2D</b>	<b>OTHER OTOLOGICALS</b>	R2003
<b>S2D1</b>	<b>Earwax removal products</b>  Includes earwax removal products which do not contain either an antibacterial or a steroid.	r2009
<b>S2D9</b>	<b>All other otologicals</b>  Products containing acetic acid only, and for otological use, are classified in S2D9.	r2008



<b>S3</b>	<b>OPHTHALMOLOGICAL/OTOLOGICAL COMBINATIONS</b>	
<b>S3A</b>	<b>EYE/EAR ANTI-INFECTIVES</b>  All eye/ear preparations containing an anti-infective but no steroid. This, therefore, includes both plain anti-infective products eg penicillin ointment, and those where the anti-infective is one of several ingredients.  NB. Antiseptics are not classified as anti-infectives; they belong in S3D.	
<b>S3B</b>	<b>EYE/EAR CORTICOSTEROIDS</b>  Includes all eye/ear preparations containing a steroid but no anti-infective. This, therefore, includes plain steroid products and those where a steroid is one of several ingredients.	
<b>S3C</b>	<b>EYE/EAR CORTICOSTEROID/ANTI-INFECTIVE COMBINATIONS</b>  Includes all eye/ear preparations containing both a steroid and an anti-infective, whether alone or with other ingredients.	
<b>S3D</b>	<b>OTHER EYE/EAR COMBINATIONS</b>  Includes all other products not classified in S3A, S3B or S3C.	

<b>T</b>	<b>DIAGNOSTIC AGENTS</b>	I1994
<b>T1</b>	<b>DIAGNOSTIC IMAGING</b>	I1994
<b>T1A</b>	<b>LOW OSMOLAR ANGIO-UROGRAPHY</b>	I1994
<b>T1B</b>	<b>IONIC ANGIO-UROGRAPHY</b>	I1994
<b>T1C</b>	<b>GASTROENTEROGRAPHY</b>  Products containing pronase for use as a premedication in endoscopy are classified here.	r2026
<b>T1D</b>	<b>CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY</b>	I1994
<b>T1E</b>	<b>MRI AGENTS</b>  Magnetic resonance imaging agents.	I1994
<b>T1F</b>	<b>ULTRASOUND AGENTS</b>	I1994
<b>T1G</b>	<b>RADIODIAGNOSTIC AGENTS</b>  Includes radiopharmaceutical products used in diagnosis. Radiopharmaceuticals used as therapeutic agents are classified in V3C.	I2003
<b>T1X</b>	<b>OTHER IMAGING AGENTS</b>  Products containing aminolaevulinic acid for cancer therapy are classified in L1X8.  Products containing pegulicianine for fluorescence imaging during cancer surgery are classified here.	r2026

<b>T2</b>	<b>DIAGNOSTIC TESTS</b>	I1994
<b>T2A</b>	Out of use; can be reused from 2005.	<b>D2002</b>
<b>T2B</b>	Out of use; can be reused from 2005.	D2002
<b>T2C</b>	<b>PREGNANCY AND OVULATION TESTS</b>	I2002
<b>T2D</b>	<b>DIABETES TESTS</b>	I2002
T2D1	<b>Diabetes tests, urine</b>  Includes ketone tests.	r2014
T2D2	<b>Diabetes tests, blood</b>  Includes ketone tests.	r2014
T2D9	<b>Diabetes tests, other</b>  Includes glucose tolerance tests.	I2002
<b>T2X</b>	<b>ALL OTHER DIAGNOSTIC TESTS</b>  Includes tests for coronavirus.	r2022
T2X1	<b>All other diagnostic tests, urine</b>	I2002
T2X2	<b>All other diagnostic tests, blood</b>	I2002
T2X9	<b>All other diagnostic tests</b>  Includes in vivo and in vitro tests.	I2002

<b>T3</b>	<b>DIAGNOSTIC EQUIPMENT AND ACCESSORIES</b>	I2001
<b>T3A</b>	<b>DIAGNOSTIC EQUIPMENT AND ACCESSORIES</b>  Includes equipment and instruments used in diagnostic procedures. Also includes accessories needed for the correct use of diagnostic equipment, eg calibration solutions. Diagnostic strips and kits are classified in T2. However, kits including meters are classified here. Lancets are classified in V7A.	R2004

<b>V</b>	<b>VARIOUS</b>	
<b>V1</b>	<b>ALLERGENS</b>	
<b>V1A</b>	<b>ALLERGENS</b>  Includes desensitizing vaccines, histamine injections, etc.  Allergens, purely for diagnosis, are classified in T2X9.	R2003

<b>V2</b>	Out of use; can be reused from 1997. Immunomodulators transferred to L3 and L4.	D1994
-----------	---	-------

<b>V3</b>	<b>ALL OTHER THERAPEUTIC PRODUCTS</b>	
<b>V3A</b>	Out of use; can be reused from 2009.	D2006
<b>V3B</b>	<b>KANPO AND CHINESE MEDICINES</b>	
<b>V3B1</b>	<b>Kanpo medicines</b>	R2003
<b>V3B2</b>	<b>Chinese medicines</b>	R2003
<b>V3C</b>	<b>RADIOPHARMACEUTICALS</b>  This group includes medical products which are registered on the Japanese pharmacopoeia and radioactive medicament standard and also includes combination products with radioactive nucleus prescribed by standard provisions.  This group excludes products used as diagnostics (see T1).  Strontium-89 and similar substances used to treat pain of bone metastases are classified here.	R2003
<b>V3D</b>	<b>DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT</b>  Includes amifostine, calcium folinate, calcium levofolate, dexrazoxane, and mesna when indicated for adjuvant therapy in antineoplastic treatment. Products containing calcium folinate and which have multiple indications are classified here.	R2005
<b>V3E</b>	<b>ANTIDOTES</b>  Includes products containing eg dimercaprol, edetates, methionine, protamine, pralidoxime. Zinc acetate for Wilson's disease is classified here.	R2007
<b>V3F</b>	<b>IRON-CHELATING AGENTS</b>  Includes products containing eg deferiprone, deferoxamine.	I2006
<b>V3G</b>	<b>HYPERKALAEMIA/HYPERPHOSPHATAEMIA PRODUCTS</b>	R2016
<b>V3G1</b>	<b>Hyperkalaemia products</b>  Includes products used specifically for hyperkalaemia, eg those containing calcium polystyrene sulfonate, sodium polystyrene sulfonate, patiromer calcium etc.	I2016

V3G2	<p><b>Hyperphosphataemia products</b></p> <p>Includes products used specifically for hyperphosphataemia, eg those containing bixalomer, calcium acetate, calcium acetate in combination with magnesium carbonate, calcium carbonate, colestilan, ferric citrate, lanthanum carbonate, sevelamer, sucroferric oxyhydroxide, etc.</p> <p>Products containing calcium and indicated in both hyperphosphataemia and calcium deficiency are classified in V3G2.</p>	I2016
V3H	<p><b>ANTI-INFLAMMATORY ENZYMES</b></p> <p>This group includes all enzyme preparations which are indicated to treat inflammatory conditions. Includes enzyme preparations for respiratory conditions. Excluded are enzyme preparations used in digestive conditions which are classified in A9A. Also excluded are specific cholagogues - classified in A5A, enzymatic topical wound treatments - classified in D3A, enzymes for ophthalmic use - classified in S1S9.</p>	R2007
V3X	<p><b>ALL OTHER THERAPEUTIC PRODUCTS</b></p> <p>Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.</p> <p>Products containing omega-3 fatty acids for the reduction of triglycerides and/or the prevention and treatment of arteriosclerosis are classified in C10B. Products containing omega-3 fatty acids for other conditions (including supplementation in pregnancy and breastfeeding) or for multiple uses are classified here.</p> <p>Products containing lonafarnib for Hutchinson-Gilford progeria syndrome or progeroid laminopathies are classified here.</p> <p>Products containing antioxidants, eg glutathione, ubidecarenone etc, for general health and/or wellbeing are classified here.</p> <p>4<sup>th</sup> level used only in Germany and Hungary.</p>	r2025
V3X1	<p><b>Umstimmungsmittel preparations of herbal origin</b></p> <p>Products which are said to intensify the body's defence against infection.</p>	I2006
V3X4	<p><b>Cure-all preparations</b></p> <p>These products have a broad spectrum of indications for internal and external use. Includes products containing a mixture of homeopathic together with allopathic or herbal ingredients. These products can have several indications.</p>	I2006

V3X5	<b>Homeopathic preparations (1)</b>  Includes single homeopathic dilutions named after the homeopathic ingredient (eg belladonna D3) and complex series. These products can have several indications or the indication is not specified.	I2006
V3X6	<b>Homeopathic preparations (2)</b>  Includes homeopathic specialities with a brand name and containing only homeopathic ingredients. These products can have several indications or the indication is not specified.	I2006
V3X7	<b>Dried and cut plants for tea preparations</b>  These are packed for sale and have more than one indication, or they are standard registrations.	I2006
V3X9	<b>Other therapeutic preparations</b>	I2006

<b>V4</b>	Out of use; can be reused from 1997. Was incorporated in the T class.	D1994
-----------	---	-------

<b>V5</b>	<b>ANTISEPTICS FOR NON-HUMAN USE</b>	R1999
<b>V5A</b>	<b>ANTISEPTICS FOR NON-HUMAN USE</b>  Includes antiseptic preparations for non-human use only, eg instrument sterilization.  Products used for both human and non-human use are classified in D8A.	R1999

<b>V6</b>	<b>DIETETIC AGENTS</b>	R2005
<b>V6A</b>	<b>SLIMMING PREPARATIONS</b>  Includes dietary products (nutrients) used to aid weight reduction. For substances used to treat obesity, see A8. Chitosan (chitin) is classified here when used for weight reduction.	
<b>V6B</b>	<b>PROTEIN SUPPLEMENTS</b>  Includes products indicated exclusively for protein deficiency but excluding IV products (see K).	
<b>V6C</b>	<b>INFANT FORMULAS</b>	
<b>V6D</b>	<b>OTHER NUTRIENTS</b>  Includes sodium salt substitutes.	

<b>V7</b>	<b>ALL OTHER NON-THERAPEUTIC PRODUCTS</b>	
<b>V7A</b>	<b>ALL OTHER NON-THERAPEUTIC PRODUCTS</b>  Includes artificial sweetening agents.	